"The prevalence of heart failure in patients with congenital heart disease is as high as 20%, but prospective clinical studies of the medical treatment are limited.",prevalence heart failure patients congenital heart disease 20% prospective clinical studies medical treatment limited,C0033105|C0018787|C0231174|C0030705|C0009678|C0018787|C0012634|C0450371|C0023981|C0205210|C0947630|C0199168|C0039798|C0439801
"Infants  were  excluded  if  they  had  any  of  the  following conditions:  congenital  or  neurological  anomalies,  grade  III or  IV  intraventricular  hemorrhage,  surgery,  signs  of  heel tissue  breakdown  or  inammation/necrosis,  medically unstable,  required  oxygen  or  respiratory  support,  or mother  had  a  history  of  drug  abuse  during  pregnancy.",infants excluded conditions congenital neurological anomalies grade iii iv intraventricular hemorrhage surgery signs heel tissue breakdown inammation/necrosis medically unstable required oxygen respiratory support mother history drug abuse pregnancy,C0021270|C1554077|C0012634|C0009678|C0205494|C0000769|C0441800|C0439070|C0022326|C1517569|C0019080|C0038894|C0220912|C0018870|C0040300|C0443161|C0027540|G0000000|C0443343|C1514873|C0030054|C0521346|C0183683|C0026591|C0019664|C0013227|C0013146|C0032961
"Exclusion criteria were as follows: age <18 or >75 years, ejection fraction <30%, left atrial size >55 mm, absence of informed patient consent, and any condition that would make survival for 1 year unlikely.",exclusion criteria age <18 75 ejection fraction <30% left atrial size 55 mm absence informed patient consent condition survival 1,C0680251|C0243161|C0001779|C0450371|C0450371|C0302131|C1264633|C0450371|C0205091|C0018792|C0456389|C0450371|G0000000|C0332197|C1522154|C0030705|C1511481|C0012634|C0038952|G0000000
Male and female preterm infants at 3032 weeks GA and 29 days postnatal age were recruited using convenience sampling for two pilot studies from a community-based Level II NICU in a three-city metropolis in Washington state.,male female preterm infants 3032 weeks ga 29 days postnatal age recruited convenience sampling pilot studies community-based level ii nicu three-city metropolis washington,C0086582|C0015780|C0151526|C0021270|G0000000|C0439230|C0016993|C0450371|C0439228|C0443281|C0001779|G0000000|C3831015|C0441621|C0473169|C0947630|C0009462|C0441889|G0000000|C0021709|C0205449|G0000000|C0043038
"General practices in Northern Ireland and the Republic of Ireland, regions with different healthcare systems.",practices northern ireland republic ireland regions healthcare systems,C0237607|C1709269|C0022067|G0000000|C0022067|C0017446|C0086388|C0449913
"85%  of  patients  were  aged 65 years  and  older,  mean  left-ventricular  ejection fraction  was  31%,  69%  were  men,  and  79%  had  a history  of  ischaemic  heart  disease.",85% patients aged 65 left-ventricular ejection fraction 31% 69% 79% history ischaemic heart disease,C0450371|C0030705|C0001779|C0450371|C0225897|C0302131|C1264633|C0450371|C0450371|C0450371|C0019664|C0475224|C0018787|C0012634
"The National Institutes of Health is currently sponsoring a multisite clinical trial titled Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) that has 3000 as an enrollment target.29 For the first 3 months, participants exercise 3 times weekly at a participating institution and then continue their customized exercise regimen at home for up to 3 years using a treadmill or stationary bicycle.",national institutes health sponsoring multisite clinical trial titled heart failure controlled trial investigating outcomes exercise training hf-action 3000 enrollment target29 3 months participants exercise 3 times weekly participating institution continue customized exercise regimen 3 treadmill stationary bicycle,C3245503|C0021622|C0018684|C1711305|G0000000|C0205210|C0008976|C1519530|C0018787|C0231174|C2587213|C0008976|C1292732|C1274040|C0015259|C0040607|C0018488|G0000000|C1516879|G0000000|G0000000|C0439231|C0679646|C0015259|G0000000|C0040223|C0332174|C0679823|C0018704|C0549178|C1880202|C0015259|C0040808|G0000000|C0184069|C0439835|C0005375
"Female sex, diabetes, smoking, sheath to radial artery mismatch and low BMI are considered predisposing factors for radial artery spasm (20).",female sex diabetes smoking sheath radial artery mismatch low bmi considered predisposing factors radial artery spasm 20,C0015780|C0009253|C0011847|C0037369|C0227952|C0442038|C0003842|C1881865|C0205251|G0000000|C0750591|C0231203|C1521761|C0442038|C0003842|C0026821|C0450371
Patients were in NYHA class II (59%) and III (41%).,patients nyha class ii 59% iii 41%,C0030705|G0000000|C0456387|G0000000|C0450371|C0439070|C0450371
"least 18 years of age, were hospitalized in a cardiac intensive care unit for an ACS (unstable angina, ST-segment elevation myocardial infarction, or nonST-segment elevation myocardial infarction), and had at least 1 of the following educationmodifiable risk factors: current smoking (for 12 months), sedentary lifestyle (<3 hours of physical activity per week), or overweight or obesity (body mass index 25 for overweight or 30 for obesity, calculated as weight in kilograms divided by height in meters squared).",18 age hospitalized cardiac intensive care unit acs unstable angina st-segment elevation myocardial infarction nonst-segment elevation myocardial infarction 1 educationmodifiable risk factors current smoking 12 months sedentary lifestyle <3 hours physical activity week overweight obesity body mass 25 overweight 30 obesity calculated weight kilograms divided height meters squared,C0450371|C0001779|C0701159|C0018787|C0162425|C1947933|C0439148|G0000000|C0443343|C0002962|C0429029|C0439775|C0027061|C0021308|C0441635|C0439775|C0027061|C0021308|G0000000|G0000000|C0035647|C1521761|C0521116|C0037369|C0450371|C0439231|C0205254|C0023676|G0000000|C0439227|C0031809|C0205177|C0332174|C0497406|C0028754|C0242821|C0577559|C0450371|C0497406|C0450371|C0028754|C0444686|C0005910|C0439209|C0332849|C0489786|C0441074|C0205120
"Twenty infants with an age up to 3 months referred to our hospital between 9 / 1997 and 2 / 2000, exceeding a score of 6 points using Ross heart failure score [12], entered the trial (Fig. 1 ).",twenty infants age 3 months referred hospital 9 / 1997 2 / 2000 exceeding score 6 ross heart failure score 12 entered trial fig 1,C0724000|C0021270|C0001779|G0000000|C0439231|C0205543|C0019994|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0449820|G0000000|C0331968|C0018787|C0231174|C0449820|C0450371|C1521975|C0008976|C0349966|G0000000
"In order to be enrolled in the study, the patients had to be aged between 20 and 75 years with symptomatic HF, in NYHA class II  IV and an ejection fraction (EF) < 35% measured echocardiographically by the area  length method or Simpsons rule, or by radionuclide or angiocardiographic ventriculography.",enrolled study patients aged 20 75 symptomatic hf nyha class ii iv ejection fraction ef < 35% measured echocardiographically length method simpsons rule radionuclide angiocardiographic ventriculography,G0000000|C0557651|C0030705|C0001779|C0450371|C0450371|C0231220|C0018488|G0000000|C0456387|G0000000|C0022326|C0302131|C1264633|G0000000|G0000000|C0450371|C0444706|G0000000|C1444754|C0025663|G0000000|C0805874|C0034595|C0002971|C0007800
"In a multicenter pilot trial, 50 patients with myocardial infarction requiring either primary or rescue PCI were randomized to radial or femoral access.",multicenter pilot trial 50 patients myocardial infarction requiring primary rescue pci randomized radial femoral access,C0439743|C0473169|C0008976|C0450371|C0030705|C0027061|C0021308|G0000000|C0205225|G0000000|C4049621|C0034656|C0442038|C0015811|C0444454
Patients and Methods    &    For the cooperative treatment study COALL-92 children age 1  18  years were eligible with newly diagnosed B-Precursor ALL or TALL.,patients methods cooperative treatment study coall-92 children age 1 18 eligible newly diagnosed b-precursor tall,C0030705|C0025663|C0679729|C0039798|C0557651|C0450371|C0008059|C0001779|G0000000|C0450371|C1548635|C0750546|C0011900|C1709634|C0023493
"To be eligible, they had to have been receiving for at least two weeks a fixed-dose drug regimen that could include ACE inhibitors, diuretics, digoxin, and beta-blockers.",eligible receiving weeks fixed-dose drug regimen ace inhibitors diuretics digoxin beta-blockers,C1548635|C1514756|C0439230|C0443218|C0013227|C0040808|C1452534|C0243077|C0012798|C0012265|C0001645
We included patients with paroxysmal or persistent AF who were intolerant of antiarrhythmic drugs or in whom two or more antiarrhythmic drug regimens had failed.,included patients paroxysmal persistent af intolerant antiarrhythmic drugs antiarrhythmic drug regimens failed,C0332257|C0030705|C0205311|C0205322|C0344434|C0231200|C0003195|C0013227|C0003195|C0013227|C2945654|C0231175
All patients had to have tumour  hormone  receptors  assessed  and  to  have  at  least  one  measurable  lesion  according  to  response  evaluation  criteria  in  solid  tumours17 (with  a  minimum  indicator  lesion size of 20 mm when measured by palpation) or  in ammatory carcinoma.,patients tumour hormone receptors assessed measurable lesion response evaluation criteria solid tumours17 minimum indicator lesion size 20 mm measured palpation ammatory carcinoma,C0030705|C0027651|C0019932|C0597357|C1516048|C1513040|C0221198|C0871261|C0220825|C0243161|C0205208|G0000000|C1524031|C0021212|C0221198|C0456389|C0450371|G0000000|C0444706|C0030247|G0000000|C0007097
"Of these, 776 were excluded from the analysis on the basis of a priori criteria, which fell mainly into three categories: absence of cardiac arrest; cardiac arrest due to drug overdose, alcohol intoxication, or carbon monoxide poisoning; or no provision of advanced cardiac life support (Table 1).",776 excluded analysis basis priori criteria fell categories absence cardiac arrest cardiac arrest drug overdose alcohol intoxication carbon monoxide poisoning provision advanced cardiac life support table 1,C1442061|C1554077|C0002778|C1527178|G0000000|C0243161|C0085639|C0683312|C0332197|C0018787|C0237477|C0018787|C0237477|C0013227|C0029944|C0001962|C0728899|C0007009|G0000000|C0032343|C1549071|C0205179|C0018787|C0376558|C0183683|C0039224|G0000000
"Patients eligible for enrolment in ARCHJ were ambulatory or hospitalised men and women, 20 years of age, with symptomatic CHF due to previous myocardial infarction, hypertensive heart disease, dilated cardiomyopathy or valvular disease.",patients eligible enrolment archj ambulatory hospitalised women 20 age symptomatic chf previous myocardial infarction hypertensive heart disease dilated cardiomyopathy valvular disease,C0030705|C1548635|C1516879|G0000000|C0439841|G0000000|C0043210|C0450371|C0001779|C0231220|C0018802|C0205156|C0027061|C0021308|C0857121|C0018787|C0012634|C0700124|C0878544|C0184252|C0012634
"Infants with congenital anomalies, severe periventricular/intraventricular hemorrhage (IVH  Grade III), a history of minor or major surgery, or in whom sedatives, vasopressors, or analgesics had been used in the 24 hr prior to testing were excluded.",infants congenital anomalies severe periventricular/intraventricular hemorrhage ivh grade iii history minor major surgery sedatives vasopressors analgesics 24 hr prior testing excluded,C0021270|C0009678|C0000769|C0205082|C1517569|C0019080|G0000000|C0441800|C0439070|C0019664|C0026193|C0205082|C0038894|C0036557|C0042397|C0002771|C0450371|G0000000|C0332152|C0039593|C1554077
We enrolled 1587 men and women 18 years of age with symptomatic heart failure for at least 3 months who were in sinus rhythm and had left ventricular ejection fraction of 35%.,enrolled 1587 women 18 age symptomatic heart failure 3 months sinus rhythm left ventricular ejection fraction 35%,G0000000|G0000000|C0043210|C0450371|C0001779|C0231220|C0018787|C0231174|G0000000|C0439231|C0016169|C0871269|C0205091|C0018827|C0302131|C1264633|C0450371
"Patients with a history of malignancy other than completely excised in situ carcinoma of the cervix, basal carcinoma of the skin, inammatory breast cancer, serious cardiac disease, other serious medical illness or inability to comply with the treatment plan and follow-up visits were not eligible.",patients history malignancy completely excised situ carcinoma cervix basal carcinoma skin inammatory breast cancer cardiac disease medical illness inability comply treatment plan follow-up visits eligible,C0030705|C0019664|C0006826|C0205197|G0000000|G0000000|C0007097|C0007874|C0205112|C0007097|C0444099|G0000000|C0006141|C0006826|C0018787|C0012634|C0199168|C0221423|G0000000|C0725694|C0039798|C0270724|C0589120|C0545082|C1548635
Excluded were patients with an earlier arterial bypass graft procedure in the same leg or with the greater saphenous vein removed earlier.,excluded patients earlier arterial bypass graft procedure leg saphenous vein removed earlier,C1554077|C0030705|C1279919|C0003842|C0741847|C0181074|C0184661|C0023216|G0000000|C0042449|C0849355|C1279919
"Although coronary heart disease risk in women lags ten years behind that of men, risk increases progressively with age (Bello & Mosca, 2004).",coronary heart disease risk women lags ten risk increases progressively age bello mosca 2004,C0018787|C0018787|C0012634|C0035647|C0043210|C1416797|C0014518|C0035647|C0205217|G0000000|C0001779|G0000000|G0000000|G0000000
"gen-coated, heparin-bonded Dacron (HBD) prostheses with PTFE grafts in all patients undergoing elective AK reconstructions and those undergoing BK reconstructions for which saphenous vein was not available.13 Full details of patients, methods, preoperative assessments, randomization, follow-up, sample size, trial end points, and statistical analysis are given in that interim paper,13 and are summarized here.",gen-coated heparin-bonded dacron hbd prostheses ptfe grafts patients undergoing elective ak reconstructions undergoing bk reconstructions saphenous vein available13 details patients methods preoperative assessments randomization follow-up sample size trial statistical analysis interim paper13 summarized,C2239486|C0019134|C0947693|G0000000|C0175649|C0032611|C0332835|C0030705|G0000000|C0206058|C0001905|C0524865|G0000000|C0006036|C0524865|G0000000|C0042449|G0000000|C1522508|C0030705|C0025663|C0445204|C1261322|C0034656|C0589120|C0370003|C0456389|C0008976|C0038215|C0002778|C2827738|G0000000|G0000000
Critical limb ischemia was dened as ischemic rest pain and/or tissue loss combined with an ankle pressure < 60 mmHg with at or barely palpable pulsations at the ankle or metatarsals.,critical limb ischemia dened ischemic rest pain and/or tissue loss combined ankle pressure < 60 mmhg barely palpable pulsations ankle metatarsals,C1511545|C0015385|C0022116|G0000000|C0475224|C0035253|C0030193|G0000000|C0040300|C1517945|C0205195|C0003086|C0033095|G0000000|C0450371|C0439475|G0000000|C0522499|G0000000|C0003086|C0025584
"Thisstudyaimedtoevaluate,inarandomizedclinicaltrial, the effect of a text messagebased intervention to encourage lifestyle change on objective measures of cardiovascular risk in individuals with coronary heart disease (CHD).",thisstudyaimedtoevaluateinarandomizedclinicaltrial text messagebased intervention encourage lifestyle change objective measures cardiovascular risk individuals coronary heart disease chd,G0000000|C1527021|G0000000|C0886296|G0000000|C0023676|C0392747|C0018017|C0079809|C0007226|C0035647|C0027361|C0018787|C0018787|C0012634|C0280604
"Patients between 18 and 80 years of age were eligible for  inclusion in the study if they had had a documented myocardial infarction at least 3 months before  inclusion and had a well-demarcated region of  left ventricular dysfunction and a patent infarctrelated artery. Exclusion criteria were the presence of acutely decompensated heart failure with  a New York Heart Association (NYHA) class of  IV, a history of other severe chronic diseases or  cancer, or unwillingness to participate.",patients 18 80 age eligible inclusion study documented myocardial infarction 3 months inclusion well-demarcated region left ventricular dysfunction patent infarctrelated artery exclusion criteria presence acutely decompensated heart failure york heart association nyha class iv history severe chronic diseases cancer unwillingness participate,C0030705|C0450371|C0450371|C0001779|C1548635|C0007637|C0557651|C1301725|C0027061|C0021308|G0000000|C0439231|C0007637|C0205170|C0017446|C0205091|C0018827|C0031847|C0030650|G0000000|C0003842|C0680251|C0243161|C0150312|G0000000|C0205434|C0018787|C0231174|G0000000|C0018787|C0004083|G0000000|C0456387|C0022326|C0019664|C0205082|C0205191|C0012634|C0006826|C0558080|G0000000
"Between March 2006 and October 2007, we studied 640 term newborns, who were placed in the room with their mothers in a third-level reference maternity hospital in Belem, in the northern Brazilian state of Para .",march 2006 october 2007 studied 640 term newborns mothers third-level reference maternity hospital belem northern brazilian para,C3829202|G0000000|C3828732|G0000000|C0557651|C1442061|C0233324|C0021289|C0026591|C0563056|C1514811|C0681108|C0019994|G0000000|C1709269|C0238815|C0030563
"After blood collection was completed, or 3 minutes had elapsed from the start of collection, a Band-Aid was applied to the heel, and the infant entered into the 3-minute recovery period.",blood collection completed 3 minutes elapsed start collection band-aid applied heel infant entered 3-minute recovery period,C0005767|C1516698|C0205197|G0000000|C0439232|C1707889|C0439659|C1516698|C0175723|C4048755|C0018870|C0021270|C1521975|C0439232|C0237820|C0439531
"From 2003 to 2007, 78 patients scheduled for aortic valve replacement (75% for aortic valve stenosis, 24% for aortic valve regurgitation, and 1% for aortic valve disease) were randomized to receive minimal sternotomy access (MS) or conventional access (ST) in a 1:1 ratio according to a computer-generated randomization system with a 6-per-block design.",2003 2007 78 patients scheduled aortic valve replacement 75% aortic valve stenosis 24% aortic valve regurgitation 1% aortic valve disease randomized receive minimal sternotomy access ms conventional access st 11 ratio computer-generated randomization system 6-per-block design,G0000000|G0000000|C0450371|C0030705|C0086960|C0003483|C0184252|C0035139|C0450371|C0003483|C0184252|C0678234|C0450371|C0003483|C0184252|C0232605|G0000000|C0003483|C0184252|C0012634|C0034656|C1514756|C0547040|C0185792|C0444454|C0039676|C0439858|C0444454|C0036056|C0450371|C0456603|C0009622|C0034656|C0449913|C0028778|C1707689
"Exclusion criteria were redo, combined surgery, ASA score more than or equal to 4, acute pulmonary edema, chronic obstructive pulmonary disease(COPD), endocarditis, chronic renal failure, antiplatelet discontinuation less than 7 days before surgery, and no known hemostatic abnormality.",exclusion criteria redo combined surgery asa score equal 4 acute pulmonary edema chronic obstructive pulmonary diseasecopd endocarditis chronic renal failure antiplatelet discontinuation 7 days surgery hemostatic abnormality,C0680251|C0243161|C0439617|C0205195|C0038894|C0004057|C0449820|C0205163|G0000000|C0205178|C0024109|C0013604|C0205191|C0549186|C0024109|G0000000|C0014118|C0205191|C0022646|C0231174|G0000000|C0457454|G0000000|C0439228|C0038894|C0019116|C1704258
"Eligible patients were younger than 22 years with either intermediate-risk (IB, IIA/IIIA1 with large mediastinal adenopathy or IIIA2) or high-risk (IIB, IIIB, IV) biopsy-proven classic HL (excluding lymphocyte predominant HL).",eligible patients 22 intermediate-risk ib iia/iiia1 mediastinal adenopathy iiia2 high-risk iib iiib iv biopsy-proven classic hl excluding lymphocyte predominant hl,C1548635|C0030705|C0450371|C3640764|C2744579|G0000000|C0025066|C0497156|G0000000|C0332167|G0000000|G0000000|C0022326|C0005558|C0439658|C1453952|C0332196|C0024264|C1542147|C1453952
"Exclusion criteria were age 18 or 70 years, long-standing persistent AF (1 year of continuous AF), rst episode of AF, hyperor hypothyroidism, hypertrophic cardiomyopathy, implanted pacemaker or debrillator, moderate or severe mitral disease or mitral prosthesis, left ventricular ejection fraction 30%, left atrial diameter 50 mm, prior ablation procedure, contraindication for oral anticoagulation, left atrial thrombus, active infection or sepsis, pregnancy, unstable angina, acute myocardial infarction during previous 3 months, life expectation 12 months, current participation in another clinical trial, mental disease or inability to give informed consent, or disease contraindicating ablation or ADT.",exclusion criteria age 18 70 long-standing persistent af 1 continuous af rst episode af hyperor hypothyroidism hypertrophic cardiomyopathy implanted pacemaker debrillator moderate severe mitral disease mitral prosthesis left ventricular ejection fraction 30% left atrial diameter 50 mm prior ablation procedure contraindication oral anticoagulation left atrial thrombus active infection sepsis pregnancy unstable angina acute myocardial infarction previous 3 months life expectation 12 months current participation clinical trial mental disease inability informed consent disease contraindicating ablation adt,C0680251|C0243161|C0001779|C0450371|C0450371|C0205166|C0205322|C0344434|G0000000|C0549178|C0344434|C1425219|C0332189|C0344434|G0000000|C0020676|C0020564|C0878544|C0021102|C0030163|G0000000|C0205081|C0205082|C0746591|C0012634|C0746591|C0175649|C0205091|C0018827|C0302131|C1264633|C0450371|C0205091|C0018792|C1301886|C0450371|G0000000|C0332152|C0547070|C0184661|C0522473|C0442027|C0003281|C0205091|C0018792|C0087086|C0205177|C0009450|C0036690|C0032961|C0443343|C0002962|C0205178|C0027061|C0021308|C0205156|G0000000|C0439231|C0376558|C0679138|C0450371|C0439231|C0521116|C0679823|C0205210|C0008976|C0229992|C0012634|G0000000|C1522154|C1511481|C0012634|G0000000|C0547070|C0279492
"Major exclusion criteria included  intolerance of contrast media or of relevant anticoagulant  or antithrombotic drugs, unconsciousness or cardiogenic",major exclusion criteria included intolerance contrast media relevant anticoagulant antithrombotic drugs unconsciousness cardiogenic,C0205082|C0680251|C0243161|C0332257|C0231199|C0009924|C0009458|C2347946|C0003280|G0000000|C0013227|C0041657|C1749797
Fourteen were female.,fourteen female,C3715152|C0015780
"For patients who had ANCs  500 per microliter for  7 days, the pegylated liposomal doxorubicin dose was reduced by 25% in all subsequent cycles.",patients ancs 500 microliter 7 days pegylated liposomal doxorubicin dose reduced 25% subsequent cycles,C0030705|C0948762|C1442061|C0439243|G0000000|C0439228|G0000000|C0023828|C0013089|C0178602|C0392756|C0450371|C0332282|C1511572
"The study subjects were 30 healthy full-term newborns delivered at Boston Medical Center, Boston, Massachusetts, between March and October 1998.",study subjects 30 healthy full-term newborns delivered boston medical center boston massachusetts march october 1998,C0557651|C0681850|C0450371|C3898900|C1547236|C0021289|C1705822|C0006037|C0199168|C0205099|C0006037|C0024874|C3829202|C3828732|G0000000
"Patients with Rutherford category 1 to 5 ischemia were eligible, with symptoms of claudication, rest pain, or with supercial ulceration in the target lower extremity.",patients rutherford category 1 5 ischemia eligible symptoms claudication rest pain supercial ulceration target lower extremity,C0030705|G0000000|C0683312|G0000000|G0000000|C0022116|C1548635|C0683368|C0311395|C0035253|C0030193|G0000000|C0041582|C1521840|C0441994|C0015385
"2 Chronic conditions measured included CAD, CHF, stroke, diabetes, cancer, chronic obstructive pulmonary disease, dementia, peripheral vascular  disease, end-stage renal disease, depression, asthma, bipolar disorder, schizophrenia, coagulation disorders, sickle cell anemia, and HIV/AIDS.",2 chronic conditions measured included cad chf stroke diabetes cancer chronic obstructive pulmonary disease dementia peripheral vascular disease end-stage renal disease depression asthma bipolar disorder schizophrenia coagulation disorders sickle cell anemia hiv/aids,G0000000|C0205191|C0012634|C0444706|C0332257|C3813548|C0018802|C0038454|C0011847|C0006826|C0205191|C0549186|C0024109|C0012634|C0011265|C0205100|C0005847|C0012634|C0205088|C0022646|C0012634|C0011570|C0004096|C0443156|C0012634|C0036341|C0005778|C0012634|G0000000|C0007634|C0002871|C0497169
"Forty patients with non-Hodgkin lymphomas (NHLs) (three CLL, two MALT-lymphomas, three mantle cell lymphomas, 16 centroblastic centrocytic lymphomas, 16 high malignant NHL) of a median age of 64 years (placebo group) and 66 years (carnitine group) were randomly assigned to the L-carnitine or to the unsupplemented group (n=20 for each group).",forty patients non-hodgkin lymphomas nhls cll malt-lymphomas mantle cell lymphomas 16 centroblastic centrocytic lymphomas 16 malignant nhl median age 64 placebo 66 carnitine randomly assigned l-carnitine unsupplemented n=20,C3816449|C0030705|C0024305|C0024299|C0024305|C0023434|C0242647|C3846131|C0007634|C0024299|C0450371|G0000000|G0000000|C0024299|C0450371|C0205282|C0024305|C0549183|C0001779|C0450371|C0032042|C0450371|C0007258|G0000000|C1516050|C0087163|G0000000|C0369718
"Median age was 48 years (range, 22 to 65), 44% were postmenopausal, 40% had both negative hormone receptors.",median age 48 range 22 65 44% postmenopausal 40% negative hormone receptors,C0549183|C0001779|C0450371|C1514721|C0450371|C0450371|C0450371|C0232970|C0450371|C0205160|C0019932|C0597357
Eligibility criteria included node-positive disease  or node-negative disease if the pathological tumour size  was  larger  than  1  cm.,eligibility criteria included node-positive disease node-negative disease pathological tumour size larger 1 cm,C0013893|C0243161|C0332257|C0746319|C0012634|C0678034|C0012634|C0030664|C0027651|C0456389|C0549177|G0000000|G0000000
"Included were ambulatory patients at least 21 years of age, in sinus rhythm, with chronic moderate symptomatic heart failure (New York Heart Association class IIIII) and a left-ventricular ejection fraction of 40% or lower.",included ambulatory patients 21 age sinus rhythm chronic moderate symptomatic heart failure york heart association class iiiii left-ventricular ejection fraction 40% lower,C0332257|C0439841|C0030705|C0450371|C0001779|C0016169|C0871269|C0205191|C0205081|C0231220|C0018787|C0231174|G0000000|C0018787|C0004083|C0456387|G0000000|C0225897|C0302131|C1264633|C0450371|C0441994
Women over the age of 18 years with conrmed advanced/metastatic breast carcinoma and a history of prior anthracycline exposure were enrolled in the study provided they: had progressive disease; had been anthracycline-free for at least 6 months prior to the start of the study; and had a LVEF considered normal according to the lower limit of the normal range in use in the center.,women age 18 conrmed advanced/metastatic breast carcinoma history prior anthracycline exposure enrolled study provided progressive disease anthracycline-free 6 months prior start study lvef considered normal lower limit normal range center,C0043210|C0001779|C0450371|G0000000|C0205179|C0006141|C0007097|C0019664|C0332152|C0003234|C0274281|G0000000|C0557651|C1999230|C0205329|C0012634|C0003234|G0000000|C0439231|C0332152|C0439659|C0557651|C0428772|C0750591|C0205307|C0441994|C0439801|C0205307|C1514721|C0205099
Patients must have had histologically node-positive HER2positive primary breast cancer without evidence of metastatic disease and must have completed primary surgery and axillary dissection.,patients histologically node-positive her2positive primary breast cancer evidence metastatic disease completed primary surgery axillary dissection,C0030705|C0205462|C0746319|G0000000|C0205225|C0006141|C0006826|C3887511|C0036525|C0012634|C0205197|C0205225|C0038894|C0004454|C0012737
"Included were patients with the presence of prolonged (more than 30 minutes) chest pain, started less than 12 h before hospital arrival and ST elevation of at least 1 mm in two or more contiguous limb electrocardiographic leads or 2 mm in precordial leads.",included patients presence prolonged 30 minutes chest pain started 12 hospital arrival st elevation 1 mm contiguous limb electrocardiographic leads 2 mm precordial leads,C0332257|C0030705|C0150312|C0439590|C0450371|C0439232|C0817096|C0030193|C1272689|C0450371|C0019994|C1555577|C0036056|C0439775|G0000000|G0000000|C0205283|C0015385|C0013798|C0023175|G0000000|G0000000|C0230134|C0023175
"Women eligible for the study were  65 years of age, had a WHO performance status of  1, and had undergone mastectomy or breastconserving surgery with axillary nodal dissection for invasive breast carcinoma.",women eligible study 65 age performance status 1 undergone mastectomy breastconserving surgery axillary nodal dissection invasive breast carcinoma,C0043210|C1548635|C0557651|C0450371|C0001779|C0597198|C0449438|G0000000|G0000000|C0024881|G0000000|C0038894|C0004454|C0443268|C0012737|C0205281|C0006141|C0007097
"Other eligibility criteria included age  18 and  65 years, surgical complete resection, normal blood tests.",eligibility criteria included age 18 65 surgical complete resection normal blood tests,C0013893|C0243161|C0332257|C0001779|C0450371|C0450371|C0543467|C0205197|C0015252|C0205307|C0005767|C0022885
The groups were similar in terms of age and New York Heart Association functional class: mean age in group I was 62.6  9.5 years compared with 64  12.4 years in group II (p = 0.57); mean New York Heart Association functional class in group I was 2.7  0.9 compared with 2.5  0.7 in group II (p = 0.27).,terms age york heart association functional class age 626 95 compared 64 124 ii = 057 york heart association functional class 27 09 compared 25 07 ii = 027,C0233324|C0001779|G0000000|C0018787|C0004083|C0205245|C0456387|C0001779|C1442061|C0450371|C1707455|C0450371|C1442061|G0000000|G0000000|C1442061|G0000000|C0018787|C0004083|C0205245|C0456387|C0450371|C0450371|C1707455|C0450371|C0450371|G0000000|G0000000|C1442061
"Patients were ineligible if they had a condition that  conferred a high risk of cardiac embolism, such as  atrial fibrillation, a mechanical cardiac valve, endocarditis, or an intracardiac mobile or pedunculated thrombus.",patients ineligible condition conferred risk cardiac embolism atrial fibrillation mechanical cardiac valve endocarditis intracardiac mobile pedunculated thrombus,C0030705|C1512714|C0012634|G0000000|C0035647|C0018787|C0013922|C0018792|C0232197|C0443254|C0018787|C0184252|C0014118|C0729936|C0231435|C0205320|C0087086
"Inclusion criteria were as follows: English-speaking, aged between 18 and 80 years, HF (defined as New York Heart Association [NYHA] class II through IV) and left ventricular systolic dysfunction with a left ventricular ejection fraction 40% as documented by echocardiogram or radionuclide ventriculography within the previous 6 months, and sinus rhythm.",inclusion criteria english-speaking aged 18 80 hf defined york heart association nyha class ii iv left ventricular systolic dysfunction left ventricular ejection fraction 40% documented echocardiogram radionuclide ventriculography previous 6 months sinus rhythm,C0007637|C0243161|C0376245|C0001779|C0450371|C0450371|C0018488|C1704788|G0000000|C0018787|C0004083|G0000000|C0456387|G0000000|C0022326|C0205091|C0018827|C0039155|C0031847|C0205091|C0018827|C0302131|C1264633|C0450371|C1301725|C0013516|C0034595|C0007800|C0205156|G0000000|C0439231|C0016169|C0871269
"According to the classification of cardiomyopathy provided by the World Health Organization, dilated cardiomyopathy is defined on the basis of reduced left ventricular systolic function in the presence of symptoms, or a family history of dilated cardiomyopathy or a left ventricular fractional shortening of 20 percent or less in the absence of regional wall-motion abnormalities on echocardiography in asymptomatic patients without a family history.",classification cardiomyopathy provided health organization dilated cardiomyopathy defined basis reduced left ventricular systolic function presence symptoms family history dilated cardiomyopathy left ventricular fractional shortening 20 percent absence regional wall-motion abnormalities echocardiography asymptomatic patients family history,C0008902|C0878544|C1999230|C0018684|C0029237|C0700124|C0878544|C1704788|C1527178|C0392756|C0205091|C0018827|C0039155|C0031843|C0150312|C0683368|C0015576|C0019664|C0700124|C0878544|C0205091|C0018827|C1264633|C0441636|C0450371|C0439165|C0332197|C0205147|C1980023|C0000768|C0013516|C0231221|C0030705|C0015576|C0019664
"In the RIFLE-STEACS trial, patients with symptom duration up to 24 h were included as well as patients presenting after failed thrombolysis or in cardiogenic shock.",rifle-steacs trial patients symptom duration 24 included patients failed thrombolysis cardiogenic shock,C0035611|C0008976|C0030705|C1457887|C0449238|C0450371|C0332257|C0030705|C0231175|C0520997|C1749797|C0036974
"Five infants were delivered via cesarean section; 11 subjects were males; 16 were black, 4 white, 6 Hispanic, and 1 American Indian.",infants delivered cesarean 11 subjects males 16 black 4 white 6 hispanic 1 american indian,C0021270|C1705822|C3841297|C0450371|C0681850|C0086582|C0450371|C0005680|G0000000|C0007457|G0000000|C0086409|G0000000|C0596070|C1524069
"Reasons for noneligibility were the presence of metastatic disease at the time of randomization (12 patients), history of other cancer [6], bilateral breast cancer [7], inammatory breast cancer [4], left ventricular EF <50% [2], N0 disease [2], administration of RT before chemotherapy [1] and simple mastectomy without axillary clearance in one patient.",reasons noneligibility presence metastatic disease time randomization 12 patients history cancer 6 bilateral breast cancer 7 inammatory breast cancer 4 left ventricular ef <50% 2 n0 disease 2 administration rt chemotherapy 1 simple mastectomy axillary clearance patient,C0392360|G0000000|C0150312|C0036525|C0012634|C0040223|C0034656|C0450371|C0030705|C0019664|C0006826|G0000000|C0238767|C0006141|C0006826|G0000000|G0000000|C0006141|C0006826|G0000000|C0205091|C0018827|G0000000|C0450371|G0000000|C0445085|C0012634|G0000000|C0001554|C0230425|C0013216|G0000000|C0205352|C0024881|C0004454|C0449297|C0030705
Neonates with  neurological  abnormalities  and  major  congenital defects and those receiving sedatives or analgesics were excluded from the study.,neonates neurological abnormalities major congenital defects receiving sedatives analgesics excluded study,C0021289|C0205494|C0000768|C0205082|C0009678|C0243067|C1514756|C0036557|C0002771|C1554077|C0557651
"Between  March,  1999,  and  March,  2001,  we enrolled  2028  patients  with  symptomatic  heart  failure  and left-ventricular  ejection  fraction  40%  or  less  who  were  not receiving  ACE  inhibitors  because  of  previous  intolerance.",march 1999 march 2001 enrolled 2028 patients symptomatic heart failure left-ventricular ejection fraction 40% receiving ace inhibitors previous intolerance,C3829202|G0000000|C3829202|G0000000|G0000000|G0000000|C0030705|C0231220|C0018787|C0231174|C0225897|C0302131|C1264633|C0450371|C1514756|C1452534|C0243077|C0205156|C0231199
Patients were eligible for study enrollment if they were over 18 years of age and required isolated AVR because of aortic stenosis with or without aortic insufciency.,patients eligible study enrollment 18 age required isolated avr aortic stenosis aortic insufciency,C0030705|C1548635|C0557651|C1516879|C0450371|C0001779|C1514873|C0205409|C0449217|C0003483|C0678234|C0003483|G0000000
The sample consisted of 36 motherneonate dyads who  were randomly assigned by computerized minimization technique into two groups: SSC (n = 17) and control (n = 19).,sample consisted 36 motherneonate dyads randomly assigned computerized minimization technique ssc = 17 control = 19,C0370003|C0332529|C0450371|G0000000|C0870454|G0000000|C1516050|G0000000|G0000000|C0449851|C3897657|G0000000|C0450371|C0243148|G0000000|C0450371
"Patients could not have received more than 4 weeks of hormonal therapy or any other prior systemic therapy for breast cancer, or prior anthracycline or taxane for any malignancy.",patients received 4 weeks hormonal therapy prior systemic therapy breast cancer prior anthracycline taxane malignancy,C0030705|C1514756|G0000000|C0439230|C0458083|C0039798|C0332152|C0205373|C0039798|C0006141|C0006826|C0332152|C0003234|C0215136|C0006826
"Because there may be  some difficulties with the use of VAS among the elderly, we  excluded patients over 75 years (14).",difficulties vas elderly excluded patients 75 14,C1299586|C0042815|C0001792|C1554077|C0030705|C0450371|C0450371
"Patients with cardiogenic shock at presentation (systolic blood pressure #90 mm Hg despite drug therapy), left main coronary disease ($50% diameter stenosis), previous coronary artery bypass grafting (CABG) surgery, severe valvular heart disease and unsuccessful procedures were excluded from the study.",patients cardiogenic shock presentation systolic blood pressure #90 mm hg drug therapy left main coronary disease 50% diameter stenosis previous coronary artery bypass grafting cabg surgery severe valvular heart disease unsuccessful procedures excluded study,C0030705|C1749797|C0036974|C0449450|C0039155|C0005767|C0033095|C0450371|G0000000|C0025424|C0013227|C0039798|C0205091|C0205225|C0018787|C0012634|C0450371|C1301886|C0678234|C0205156|C0018787|C0003842|C0741847|C0332835|C0010055|C0038894|C0205082|C0184252|C0018787|C0012634|C1272705|C0025664|C1554077|C0557651
"A total of 297 (28.3%) patients, among them 195 diagnostic coronary angiograms and 102 coronary interventions, fullled the inclusion criteria and were subsequently included in the study.",total 297 283% patients 195 diagnostic coronary angiograms 102 coronary interventions fullled inclusion criteria subsequently included study,C0439175|C1442061|C1442061|C0030705|C1442061|C0011900|C0018787|C0002978|C1442061|C0018787|C0886296|G0000000|C0007637|C0243161|G0000000|C0332257|C0557651
Femoro-popliteal bypass grafting has been shown to be an for arterial occlusive disease in effective treatment patients with severe claudication or critical ischaemia.,femoro-popliteal bypass grafting arterial occlusive disease effective treatment patients severe claudication critical ischaemia,C0545765|C0741847|C0332835|C0003842|C1947917|C0012634|C1280519|C0039798|C0030705|C0205082|C0311395|C1511545|C0022116
"Candidates were ineligible if they presented with an acute arterial occlusion requiring urgent intervention, if they had undergone a prior open surgical bypass in the target extremity, or if angioplasty or stenting had been performed at the site of a planned anastomosis within the previous 30 days.",candidates ineligible acute arterial occlusion requiring urgent intervention undergone prior surgical bypass target extremity angioplasty stenting performed site planned anastomosis previous 30 days,G0000000|C1512714|C0205178|C0003842|C0011382|G0000000|C0439609|C0886296|G0000000|C0332152|C0543467|C0741847|C1521840|C0015385|C0162577|C0038257|C0884358|C0205145|C1301732|C0332853|C0205156|C0450371|C0439228
Eligible patients had either at least one positive axillary node  (regardless of the primary tumor size or its hormone-receptor  expression)  or  a  node-negative  breast-cancer mass at least 20 mm in diameter  and a negative test for progesterone receptors  (usually defined as staining of <10 percent of the  cancer cells).,eligible patients positive axillary node primary tumor size hormone-receptor expression node-negative breast-cancer mass 20 mm diameter negative test progesterone receptors defined staining <10 percent cancer cells,C1548635|C0030705|C0439178|C0004454|C0746922|C0205225|C0027651|C0456389|C0019929|C0185117|C0678034|C0006142|C0577559|C0450371|G0000000|C1301886|C0205160|C0022885|C0033308|C0597357|C1704788|C0487602|C0450371|C0439165|C0006826|C0007634
"Patients with coronary heart disease were identied from general practice computer systems, recruited and randomized (2:1) to intervention or control.",patients coronary heart disease identied practice computer systems recruited randomized 21 intervention control,C0030705|C0018787|C0018787|C0012634|G0000000|C0237607|C0009622|C0449913|G0000000|C0034656|C0450371|C0886296|C0243148
"Exclusion criteria were hemodynamically signicant valvular heart disease, uncontrolled diabetes mellitus and hypertension,",exclusion criteria hemodynamically signicant valvular heart disease uncontrolled diabetes mellitus hypertension,C0680251|C0243161|G0000000|G0000000|C0184252|C0018787|C0012634|C0205318|C0011847|G0000000|C0020538
"Among  those  enrolled through March 2006 (the first 15  months  of  program  intake),  about  30  percent  of  demonstration  enrollees  were  age  65  or  younger,  and  about  9  percent  were  age 85 or over.",enrolled march 2006 15 months program intake 30 percent demonstration enrollees age 65 9 percent age 85,G0000000|C3829202|G0000000|C0450371|C0439231|C1709697|C1512806|C0450371|C0439165|G0000000|G0000000|C0001779|C0450371|G0000000|C0439165|C0001779|C0450371
Participants:  15  VLBW  neonates  who  needed  adhesive  tape removal  for  the  first  part  and  50  VLBW  neonates  needing adhesive tape removal for the second part.,participants 15 vlbw neonates adhesive tape removal 50 vlbw neonates adhesive tape removal,C0679646|C0450371|C0282666|C0021289|C0001516|C0183828|C0015252|C0450371|C0282666|C0021289|C0001516|C0183828|C0015252
"Exclusion criteria included the following: pure aortic insufciency, planned concomitant procedures, previous surgical procedures, congenital true bicuspid (ie, Sievers type 0) aortic valve, emergency operations, ejection fraction below 25%, and recent myocardial infarction (90 days), or stroke or transient ischemic attack (6 months).",exclusion criteria included pure aortic insufciency planned concomitant procedures previous surgical procedures congenital true bicuspid sievers type 0 aortic valve emergency operations ejection fraction 25% myocardial infarction 90 days stroke transient ischemic attack 6 months,C0680251|C0243161|C0332257|C2247561|C0003483|G0000000|C1301732|C0521115|C0025664|C0205156|C0543467|C0025664|C0009678|C0205238|C0005373|G0000000|C0332307|G0000000|C0003483|C0184252|C0013956|C0038895|C0302131|C1264633|C0450371|C0027061|C0021308|C0450371|C0439228|C0038454|C0040704|C0475224|C0277793|G0000000|C0439231
Inclusion criteria were defined by acute coronary syndrome with ST segment elevation associated with sustained chest pain.,inclusion criteria defined acute coronary syndrome st segment elevation sustained chest pain,C0007637|C0243161|C1704788|C0205178|C0018787|C0039082|C0036056|C0441635|C0439775|C0443318|C0817096|C0030193
Twenty-eight stable male and female preterm infants and their mothers were enrolled.,twenty-eight stable male female preterm infants mothers enrolled,C0724000|C0205360|C0086582|C0015780|C0151526|C0021270|C0026591|G0000000
"The gestational age of the infants ranged from 29 to 36 completed weeks with an average of 32 weeks, 2 days, mean birthweight 2200 g, mean 5-min Apgar of 8.5 and 20 previous painful procedures.",gestational age infants ranged 29 36 completed weeks average 32 weeks 2 days birthweight 2200 5-min apgar 85 20 previous painful procedures,C0439671|C0001779|C0021270|C1514721|C0450371|C0450371|C0205197|C0439230|C1510992|C0450371|C0439230|G0000000|C0439228|C0005612|G0000000|C0702093|C0741195|C0450371|C0450371|C0205156|C0030193|C0025664
"This is a prospective, double-blind, placebo-controlled, multicenter trial (nine U.S. centers) conducted in 105 patients with New York Heart Association class II to III, ischemic or nonischemic chronic heart failure (CHF).",prospective double-blind placebo-controlled multicenter trial centers conducted 105 patients york heart association class ii iii ischemic nonischemic chronic heart failure chf,C0023981|C0013072|C1706408|C0439743|C0008976|C0205099|C0004927|C1442061|C0030705|G0000000|C0018787|C0004083|C0456387|G0000000|C0439070|C0475224|G0000000|C0205191|C0018787|C0231174|C0018802
"Exclusion criteria were: (1) age <18 or >80 years; (2) permanent AF (AF was the sole rhythm for the last 12 months); (3) AF secondary to a transient or correctable abnormality, including electrolyte imbalance, trauma, recent surgery, infection, toxic ingestion, and endocrinopathy; (4) persistence of AF episodes triggered by another uniform arrhythmia (i.e. atrial utter or atrial tachycardia) despite previous supraventricular tachycardia ablation; intra-atrial thrombus, tumour, or other abnormality precluding catheter insertion; (6) WolffParkinsonWhite syndrome; (7) heart failure with NYHA class III or IV or EF  35%; (7) unstable angina or acute myocardial infarction within 3 months; (8) cardiac revascularization or other cardiac surgery within 6 months or with prior atrial surgery; (9) renal failure requiring dialysis, or hepatic failure; (10) an implanted device (pacemaker or cardioverter-debrillator); (11) left atrial diameter .60 mm.",exclusion criteria 1 age <18 80 2 permanent af af sole rhythm 12 months 3 af secondary transient correctable abnormality including electrolyte imbalance trauma surgery infection toxic ingestion endocrinopathy 4 persistence af episodes triggered uniform arrhythmia atrial utter atrial tachycardia previous supraventricular tachycardia ablation intra-atrial thrombus tumour abnormality precluding catheter insertion 6 wolffparkinsonwhite syndrome 7 heart failure nyha class iii iv ef 35% 7 unstable angina acute myocardial infarction 3 months 8 cardiac revascularization cardiac surgery 6 months prior atrial surgery 9 renal failure requiring dialysis hepatic failure 10 implanted device pacemaker cardioverter-debrillator 11 left atrial diameter 60 mm,C0680251|C0243161|G0000000|C0001779|C0450371|C0450371|G0000000|C0205355|C0344434|C0344434|C0230463|C0871269|C0450371|C0439231|G0000000|C0344434|C0027627|C0040704|G0000000|C1704258|C0332257|C0013832|C1397014|C0043251|C0038894|C0009450|C0600688|C0232478|C0014130|G0000000|C0546816|C0344434|C0332189|C0032930|C0205375|C0003811|C0018792|G0000000|C0018792|C0039231|C0205156|G0000000|C0039231|C0547070|C0347985|C0087086|C0027651|C1704258|G0000000|C0085590|C0021107|G0000000|G0000000|C0039082|G0000000|C0018787|C0231174|G0000000|C0456387|C0439070|C0022326|G0000000|C0450371|G0000000|C0443343|C0002962|C0205178|C0027061|C0021308|G0000000|C0439231|G0000000|C0018787|C0581603|C0018787|C0038894|G0000000|C0439231|C0332152|C0018792|C0038894|G0000000|C0022646|C0231174|G0000000|C0011945|C0205054|C0231174|C0450371|C0021102|C0025080|C0030163|C0180307|C0450371|C0205091|C0018792|C1301886|C0450371|G0000000
"Aside from those who had received estramustine phosphate and had treatment discontinued  6 weeks before the rst infusion of liposomal doxorubicin, all patients who had previously received chemotherapy were ineligible for the current trial.",received estramustine phosphate treatment discontinued 6 weeks rst infusion liposomal doxorubicin patients received chemotherapy ineligible current trial,C1514756|C0014921|C0031603|C0039798|C1444662|G0000000|C0439230|C1425219|C0574032|C0023828|C0013089|C0030705|C1514756|C0013216|C1512714|C0521116|C0008976
"All patients were receiving standard heart failure therapy for at least 1 month at the time of randomization , including angiotenis in converting enzyme inhibitors unless contraindicated or if patients could not tolerate it.",patients receiving standard heart failure therapy 1 month time randomization including angiotenis converting enzyme inhibitors contraindicated patients tolerate,C0030705|C1514756|C1442989|C0018787|C0231174|C0039798|G0000000|C0332177|C0040223|C0034656|C0332257|G0000000|G0000000|C0014442|C0243077|C1444657|C0030705|G0000000
"Inclusion criteria were residency in the city where the CR programs were offered, prociency in the English language, written approval to participate in the CR program by the patients cardiac specialist or general practitioner, and eligibility for home-based CR (ie, low to moderate risk of an adverse event during exercise as demonstrated by lack of complex ventricular dysrhythmia, New York Heart Association32 class 1-2 classication, and left ventricular ejection fraction of >40%, or Canadian Cardiovascular Society33 class 1-2 classication).",inclusion criteria residency city cr programs offered prociency english language written approval participate cr program patients cardiac specialist practitioner eligibility home-based cr low moderate risk adverse event exercise demonstrated lack complex ventricular dysrhythmia york heart association32 class 1-2 classication left ventricular ejection fraction 40% canadian cardiovascular society33 class 1-2 classication,C0007637|C0243161|C0035182|C0008848|C0201975|C0376691|C1444648|G0000000|C0376245|C0023008|C0043266|C0205540|G0000000|C0201975|C1709697|C0030705|C0018787|C0087009|C1709627|C0013893|C0442519|C0201975|C0205251|C0205081|C0035647|G0000000|C0441471|C0015259|G0000000|C0332268|C0439855|C0018827|C0003811|G0000000|C0018787|G0000000|C0456387|G0000000|G0000000|C0205091|C0018827|C0302131|C1264633|C0450371|C0238884|C0007226|G0000000|C0456387|G0000000|G0000000
"Patients were eligible for inclusion if they presented with symptoms of disabling claudication, rest pain or tissue loss and suprageniculate femoro-popliteal bypass was feasible.",patients eligible inclusion symptoms disabling claudication rest pain tissue loss suprageniculate femoro-popliteal bypass feasible,C0030705|C1548635|C0007637|C0683368|G0000000|C0311395|C0035253|C0030193|C0040300|C1517945|G0000000|C0545765|C0741847|G0000000
"From January 16, 2008, through March 24, 2009, there were 185 infants who were determined to be eligible from 3 university-affiliated level III neonatal intensive care units.",january 16 2008 march 24 2009 185 infants determined eligible 3 university-affiliated level iii neonatal intensive care units,C3829466|C0450371|G0000000|C3829202|C0450371|G0000000|C1442061|C0021270|G0000000|C1548635|G0000000|C0041740|C0441889|C0439070|C1552240|C0162425|C1947933|C0439148
The  most  direct  evaluation  of  heart  failure  consists  of inquiring  about  symptoms  at  rest  and  during  exertion.,direct evaluation heart failure consists inquiring symptoms rest exertion,C0439851|C0220825|C0018787|C0231174|C0332529|G0000000|C0683368|C0035253|C0015264
Men and women between the ages of 30 and 70 who were an outpatient in an HF clinic in Northeast Georgia with a documented diagnosis of NYHA Class II to III heart failure and a Beck Depression Inventory II (BDI-II) [48] score of 10 or higher were asked to participate in the study.,women ages 30 70 outpatient hf clinic northeast georgia documented diagnosis nyha class ii iii heart failure beck depression inventory ii bdi-ii 48 score 10 participate study,C0043210|C0001779|C0450371|C0450371|C0029921|C0018488|C0002424|C1709272|C0017452|C1301725|C0011900|G0000000|C0456387|G0000000|C0439070|C0018787|C0231174|G0000000|C0011570|C0021941|G0000000|C0006448|C0450371|C0449820|C0450371|G0000000|C0557651
"Inclusion criteria were infants 30 through 32 weeks gestational age (GA), two through nine postnatal days old, cared-for in an incubator, and whose mothers were English speaking.",inclusion criteria infants 30 32 weeks gestational age ga postnatal days cared-for incubator mothers english speaking,C0007637|C0243161|C0021270|C0450371|C0450371|C0439230|C0439671|C0001779|C0016993|C0443281|C0439228|C1947933|C0021178|C0026591|C0376245|C0234856
There were 76 females and 140 males.,76 females 140 males,C0450371|C0015780|C1442061|C0086582
"The main objective of the present study was to compare respiratory parameters of patients scheduled for aortic valve surgery performed either by total median sternotomy or ministernotomy and secondarily to evaluate bleeding, transfusion, and pain status.",main objective study compare respiratory parameters patients scheduled aortic valve surgery performed total median sternotomy ministernotomy secondarily evaluate bleeding transfusion pain status,C0205225|C0018017|C0557651|C1707455|C0521346|C0449381|C0030705|C0086960|C0003483|C0184252|C0038894|C0884358|C0439175|C0549183|C0185792|G0000000|G0000000|C0220825|C0019080|C0005841|C0030193|C0449438
Infants with a Neonatal Skin Condition Score > 6 were excluded.,infants neonatal skin condition score 6 excluded,C0021270|C1552240|C0444099|C0012634|C0449820|G0000000|C1554077
"Four patients were withdrawn from the trial before month 1 without reaching a study end point; per the study protocol, 4 additional patients were enrolled and randomized so that the total study sample size would remain unchanged.",patients withdrawn trial month 1 reaching study study protocol 4 additional patients enrolled randomized total study sample size remain unchanged,C0030705|C0424092|C0008976|C0332177|G0000000|C2584321|C0557651|C0557651|C0442711|G0000000|C1524062|C0030705|G0000000|C0034656|C0439175|C0557651|C0370003|C0456389|G0000000|C0442739
"Potentially eligible patients were asked to provide Ethics Committeeapproved verbal assent before coronary angiography, which was undertaken via the femoral or radial artery, according to operator preference.",eligible patients provide ethics committeeapproved verbal assent coronary angiography undertaken femoral radial artery operator preference,C1548635|C0030705|C1999230|C0015000|G0000000|C0439824|C1879749|C0018787|C0002978|G0000000|C0015811|C0442038|C0003842|C1705273|C0558295
"This study involving 570 women aged 60 years or older with heart disease, assessed the effects of a disease",study involving 570 women aged 60 heart disease assessed effects disease,C0557651|C1314939|C1442061|C0043210|C0001779|C0450371|C0018787|C0012634|C1516048|C1280500|C0012634
"Following review and approval of the study protocol by the Institutional Review Boards at all the participating institutions, we enrolled 3,522 patients with diagnosed ischemic heart disease into a randomized controlled trial known as PROMOTION (Patient Response tO Myocardial Infarction following a Teaching Intervention Offered by Nurses) from 2002 to 2004 and were followed for two years following their enrollment.",review approval study protocol institutional review boards participating institutions enrolled 3522 patients diagnosed ischemic heart disease randomized controlled trial promotion patient response myocardial infarction teaching intervention offered nurses 2002 2004 enrollment,C0282443|C0205540|C0557651|C0442711|C0018704|C0282443|C0972401|C0679823|C1272753|G0000000|G0000000|C0030705|C0011900|C0475224|C0018787|C0012634|C0034656|C2587213|C0008976|C0033414|C0030705|C0871261|C0027061|C0021308|C0039401|C0886296|C1444648|C0028661|G0000000|G0000000|C1516879
"Three hundred fty-eight breast cancer failures occurred on AC and 312 on A 3 C. Sites were known for 639 of the following: opposite breast primaries (15%), local/regional relapses (28%), and distant metastases (57%).",fty-eight breast cancer failures occurred ac 312 3 sites 639 opposite breast primaries 15% local/regional relapses 28% distant metastases 57%,C0205454|C0006141|C0006826|C0231174|C1709305|C0003354|C1442061|G0000000|C0205145|C1442061|C1521805|C0006141|C0205225|C0450371|C0205276|C0035020|C0450371|C0443203|C0027627|C0450371
"A total of 164 female breast cancer patients, previously treated with anthracyclines, received anthracycline-based chemotherapy either with (n = 85) or without (n = 79) dexrazoxane for a maximum of six cycles.",total 164 female breast cancer patients treated anthracyclines received anthracycline-based chemotherapy = 85 = 79 dexrazoxane maximum cycles,C0439175|C1442061|C0015780|C0006141|C0006826|C0030705|C1522326|C0003234|C1514756|C0003234|C0013216|G0000000|C0450371|G0000000|C0450371|C0086444|C0806909|C1511572
Patients with symptomatic persistent AF7 (7 or 7 days requiring electrical or pharmacological cardioversion) refractory to at least one class I or class III antiarrhythmic drug were recruited.,patients symptomatic persistent af7 7 7 days requiring electrical pharmacological cardioversion refractory class class iii antiarrhythmic drug recruited,C0030705|C0231220|C0205322|C1333634|G0000000|G0000000|C0439228|G0000000|C0013790|C0031330|C0013778|C0205269|C0456387|C0456387|C0439070|C0003195|C0013227|G0000000
"RESULTS The median patient age at the time of recruitment (i.e., diagnosis of progressive HRPCA) was 68.9 years (range, 58 79 years); there was no signicant age difference between the two treatment arms (Table 1).",median patient age time recruitment diagnosis progressive hrpca 689 range 58 79 signicant age difference treatment arms table 1,C0549183|C0030705|C0001779|C0040223|C2949735|C0011900|C0205329|G0000000|C1442061|C1514721|C0450371|C0450371|G0000000|C0001779|C1705241|C0039798|C0206655|C0039224|G0000000
"The majority of the mothers were white (90%), were married (80%), and had delivered by cesarean section (80%).",majority mothers white 90% married 80% delivered cesarean 80%,C0680220|C0026591|C0007457|C0450371|C0024841|C0450371|C1705822|C3841297|C0450371
"DESIGN AND SETTING The Tobacco, Exercise and Diet Messages (TEXT ME) trial was a parallel-group, single-blind, randomized clinical trial that recruited 710 patients (mean age, 58 [SD, 9.2] years; 82% men; 53% current smokers) with proven coronary heart disease (prior myocardial infarction or proven angiographically) between September 2011 and November 2013 from a large tertiary hospital in Sydney, Australia.",design setting tobacco exercise diet messages text trial parallel-group single-blind randomized clinical trial recruited 710 patients age 58 sd 92 82% 53% current smokers proven coronary heart disease prior myocardial infarction proven angiographically september 2011 november 2013 tertiary hospital sydney australia,C1707689|C0542559|C0040329|C0015259|C0012155|C0470166|C1527021|C0008976|C2348042|C0242570|C0034656|C0205210|C0008976|G0000000|C1442061|C0030705|C0001779|C0450371|C2699239|C0450371|C0450371|C0450371|C0521116|C0337664|C0456369|C0018787|C0018787|C0012634|C0332152|C0027061|C0021308|C0456369|G0000000|C3828193|G0000000|C3828767|G0000000|C0205372|C0019994|G0000000|C0004340
"Inclusion criteria were: age 18 years or older, undergoing rst PCI and had access to a telephone.",inclusion criteria age 18 undergoing rst pci access telephone,C0007637|C0243161|C0001779|C0450371|G0000000|C1425219|C4049621|C0444454|C0039457
"Heart failure is commonly associated with vascular disease and a high rate of athero-thrombotic events, but the risks and benets of antithrombotic therapy are unknown.",heart failure commonly vascular disease rate athero-thrombotic events risks benets antithrombotic therapy unknown,C0018787|C0231174|G0000000|C0005847|C0012634|C0871208|C0087086|C0441471|C0035647|G0000000|G0000000|C0039798|C0439673
"Methods Between July 2006 and January 2008, a total of 1,024 patients undergoing coronary catheterization were randomly assigned to the transradial or transfemoral approach.",methods july 2006 january 2008 total 1024 patients undergoing coronary catheterization randomly assigned transradial transfemoral approach,C0025663|C3829447|G0000000|C3829466|G0000000|C0439175|G0000000|C0030705|G0000000|C0018787|C0007430|G0000000|C1516050|G0000000|G0000000|C0449445
We evaluated 28 consecutive patients diagnosed with osteosarcoma without prior therapy from March 1999 to December 2002.,evaluated 28 consecutive patients diagnosed osteosarcoma prior therapy march 1999 december 2002,C0220825|C0450371|C1707491|C0030705|C0011900|C0029463|C0332152|C0039798|C3829202|G0000000|C3830550|G0000000
Exclusion criteria included: being clinically unable to answer questions or talk on the telephone (e.g.,exclusion criteria included clinically unable answer questions talk telephone,C0680251|C0243161|C0332257|G0000000|C1299582|C1706817|C1522634|C0037817|C0039457
Patients with unstable angina pectoris were ineligible to participate.,patients unstable angina pectoris ineligible participate,C0030705|C0443343|C0002962|G0000000|C1512714|G0000000
"Exclusion criteria included (a) suicide ideation according to psychiatric assessment or MINI [51,52] evaluation; (b) major psychiatric comorbidity such as schizophrenia, personality disorder, or dementia; (c) planned surgery; (d) not diagnosed with HF in the past 3 months; (e) renal insufficiency (serum creatinine N2.5 mg/dL); (f) uncontrolled hypertension; (g) acute bereavement or loss of significant other within the last month or currently involved in family crisis such as divorce; (h) any disorder interfering with independent ambulation; and (i) terminal illness such as cancer.",exclusion criteria included suicide ideation psychiatric assessment mini 5152 evaluation major psychiatric comorbidity schizophrenia personality disorder dementia planned surgery diagnosed hf 3 months renal insufficiency serum creatinine n25 mg/dl uncontrolled hypertension acute bereavement loss month involved family crisis divorce disorder interfering independent ambulation terminal illness cancer,C0680251|C0243161|C0332257|C0038661|C0392348|C0205487|C1261322|C0445542|G0000000|C0220825|C0205082|C0205487|C0009488|C0036341|C0003944|C0012634|C0011265|C1301732|C0038894|C0011900|C0018488|G0000000|C0439231|C0022646|C0231179|C0229671|C0010294|G0000000|C0439269|C0205318|C0020538|C0205178|C0005119|C1517945|C0332177|C1314939|C0015576|C0231224|C0012828|C0012634|C0521102|C0085862|C0080331|C0205088|C0221423|C0006826
"For this analysis, we included only patients who had at least one follow-up echocardiogram of left ventricular (LV) structure and function obtained before April 1, 1997.",analysis included patients follow-up echocardiogram left ventricular lv structure function april 1 1997,C0002778|C0332257|C0030705|C0589120|C0013516|C0205091|C0018827|C0023128|C0678594|C0031843|C3715024|G0000000|G0000000
"Neonates were included if they were  3742 weeks gestation, born by spontaneous vaginal delivery  or planned cesarean section, had five-minute Apgar scores of  at least 7, and weighed $2,500 g. Neonates were excluded  from the study if they had evidence of congenital abnormalities or medical complications, required oxygen administration or ventilatory support, or if their mothers were substance  abusers during this pregnancy.",neonates included 3742 weeks gestation born spontaneous vaginal delivery planned cesarean five-minute apgar scores 7 weighed 2500 neonates excluded study evidence congenital abnormalities medical complications required oxygen administration ventilatory support mothers substance abusers pregnancy,C0021289|C0332257|G0000000|C0439230|C0032961|C0005615|C0205359|C0042232|C0011209|C1301732|C3841297|C0205451|C0741195|C0449820|G0000000|G0000000|G0000000|C0021289|C1554077|C0557651|C3887511|C0009678|C0000768|C0199168|C0009566|C1514873|C0030054|C0001554|G0000000|C0183683|C0026591|C0439861|G0000000|C0032961
"The  inclusion  criteria  were  infants: (1)  singleton  with  gestational  age  less  than  37  weeks,  (2) cared  for  in  an  incubator,  (3)  anticipated  to  have  at  least four  routine  capillary  blood  draws  within  2  weeks  after birth,  and  (4)  not  scheduled  to  receive  paralytic,  analgesic, or  sedative  medications  48  h  prior  to  a  study  session.",inclusion criteria infants 1 singleton gestational age 37 weeks 2 cared incubator 3 anticipated routine capillary blood draws 2 weeks birth 4 scheduled receive paralytic analgesic sedative medications 48 prior study session,C0007637|C0243161|C0021270|G0000000|C0481462|C0439671|C0001779|C0450371|C0439230|G0000000|C1947933|C0021178|G0000000|C3840775|C0205547|C0006901|C0005767|C0013113|G0000000|C0439230|C0005615|G0000000|C0086960|C1514756|G0000000|C0002771|C0020592|C0013227|C0450371|C0332152|C0557651|C1883016
We aimed to determine the effect of supplementation with coenzyme Q10 on conventional therapy of children with cardiac failure due to idiopathic dilated cardiomyopathy.,aimed determine supplementation coenzyme q10 conventional therapy children cardiac failure idiopathic dilated cardiomyopathy,C1947946|G0000000|C0242297|C0009235|G0000000|C0439858|C0039798|C0008059|C0018787|C0231174|C0332240|C0700124|C0878544
They were  deemed  to  be  eligible  if  the  infarct  artery  had  been treated successfully and there was stenosis  of 50% or more in one or more coronary arteries  other  than  the  infarct  artery  and  the  stenosis  was deemed to be treatable by PCI.,deemed eligible infarct artery treated stenosis 50% coronary arteries infarct artery stenosis deemed treatable pci,G0000000|C1548635|C0021308|C0003842|C1522326|C0678234|C0450371|C0018787|C0003842|C0021308|C0003842|C0678234|G0000000|G0000000|C4049621
Eligible patients with chronic ischemic cardiomyopathy had a severely hypokinetic area on the baseline left ventricular angiogram (LVA) and had had a myocardial infarction at least 3 months previously.,eligible patients chronic ischemic cardiomyopathy severely hypokinetic baseline left ventricular angiogram lva myocardial infarction 3 months,C1548635|C0030705|C0205191|C0475224|C0878544|C0205082|C0086439|C0168634|C0205091|C0018827|C0002978|C0023128|C0027061|C0021308|G0000000|C0439231
Preterm  infants  (gestational  age  less  than  37  weeks)  (n  =  80)  were  recruited  and randomly  assigned  using  a  random  table  format  to  either  an  incubator  group  (n  =  40)  or Kangaroo  Mother  Care  group  (n  =  40).,preterm infants gestational age 37 weeks = 80 recruited randomly assigned random table format incubator = 40 kangaroo mother care = 40,C0151526|C0021270|C0439671|C0001779|C0450371|C0439230|G0000000|C0450371|G0000000|G0000000|C1516050|C0034656|C0039224|C1301627|C0021178|G0000000|C0450371|C0022494|C0026591|C1947933|G0000000|C0450371
DM2 patients with symptomatic paroxysmal or persistent AF for 6 months refractory to 1 class 13 antiarrhythmic drugs (AADs) were eligible for the study.,dm2 patients symptomatic paroxysmal persistent af 6 months refractory 1 class 13 antiarrhythmic drugs aads eligible study,G0000000|C0030705|C0231220|C0205311|C0205322|C0344434|G0000000|C0439231|C0205269|G0000000|C0456387|C0450371|C0003195|C0013227|G0000000|C1548635|C0557651
"Eligible patients who died, relapsed, or discontinued treatment before their last follow-up echocardiogram were also excluded.",eligible patients died relapsed discontinued treatment follow-up echocardiogram excluded,C1548635|C0030705|C0011065|C0205336|C1444662|C0039798|C0589120|C0013516|C1554077
"Exclusion criteria were evidence of reversible ischaemia, mitral valvular disease or hypertrophic cardiomyopathy, atrial fibrillation, LV thrombi on echocardiography, other severe life-threatening diseases that might limit survival and/or compliance with the 2-year study period, contraindication to ASA or W, uncontrolled hypertension (BP > 160/ 100 mm Hg) or pregnancy.",exclusion criteria evidence reversible ischaemia mitral valvular disease hypertrophic cardiomyopathy atrial fibrillation lv thrombi echocardiography severe life-threatening diseases limit survival and/or compliance 2-year study period contraindication asa uncontrolled hypertension bp 160/ 100 mm hg pregnancy,C0680251|C0243161|C3887511|C0205343|C0022116|C0746591|C0184252|C0012634|C0020564|C0878544|C0018792|C0232197|C0023128|C0087086|C0013516|C0205082|C1517874|C0012634|C0439801|C0038952|G0000000|C0009563|C0439234|C0557651|C0439531|C0522473|C0004057|C0205318|C0020538|C0037623|C1442061|C1442061|G0000000|C0025424|C0032961
The trial enrolled consecutive patients of any age  with acute STEMI and multivessel coronary disease detected at the time of emergency PCI.,trial enrolled consecutive patients age acute stemi multivessel coronary disease detected time emergency pci,C0008976|G0000000|C1707491|C0030705|C0001779|C0205178|C3538872|G0000000|C0018787|C0012634|C0442726|C0040223|C0013956|C4049621
"Previous studies showed that only 2030% of all eligible cardiac patients participate in such a programme. Work and social obligations as well as reluctance to take part in group sessions form important barriers to participate in CR, especially in younger patients. Therefore, there is a need for innovative rehabilitation methods aiming at an increase of CR uptake.",previous studies 2030% eligible cardiac patients participate programme social obligations reluctance sessions form barriers participate cr patients innovative rehabilitation methods aiming increase cr uptake,C0205156|C0947630|G0000000|C1548635|C0018787|C0030705|G0000000|C1709697|C0728831|G0000000|C2347948|C1883016|C0348078|C1706912|G0000000|C0201975|C0030705|C0683243|C0034991|C0025663|C1947946|C0442805|C0201975|C0243144
"For example, Campos6 allowed infants either to suck a pacifier or to be held and rocked after completion of blood collection via heel stick.",campos6 allowed infants suck pacifier held rocked completion blood collection heel stick,G0000000|C0683607|C0021270|C0233927|C0030172|C0675390|G0000000|C0205197|C0005767|C1516698|C0018870|C1706582
"Infants were 32 weeks gestation (60%) and a mean 6.00 days old (SD 2.00 days) on the rst day of study, had a mean birth weight of 1,577 g (SD 327.00 g), and a mean of 22.00 (SD 6.00) prior painful experiences.",infants 32 weeks gestation 60% 600 days sd 200 days rst day study birth weight 1577 sd 32700 2200 sd 600 prior painful experiences,C0021270|C0450371|C0439230|C0032961|C0450371|C1442061|C0439228|C2699239|C1442061|C0439228|C1425219|C0332173|C0557651|C0005615|C0005910|G0000000|C2699239|G0000000|G0000000|C2699239|C1442061|C0332152|C0030193|C0596545
"We enrolled 4128 patients who were at least 60 years of age and had New York Heart  Association class II, III, or IV heart failure and an ejection fraction of at least 45%  and randomly assigned them to receive 300 mg of irbesartan or placebo per day.",enrolled 4128 patients 60 age york heart association class ii iii iv heart failure ejection fraction 45% randomly assigned receive 300 irbesartan placebo day,G0000000|G0000000|C0030705|C0450371|C0001779|G0000000|C0018787|C0004083|C0456387|G0000000|C0439070|C0022326|C0018787|C0231174|C0302131|C1264633|C0450371|G0000000|C1516050|C1514756|C1442061|C0288171|C0032042|C0332173
Inclusion criteria were infants: 1) who were 28 0/7 to 32 6/7 weeks gestational age and less than 14 days old when recruited to partially control for previous pain experiences; 2) who were cared for in an incubator; 3) who were either NPO or on bolus feeds to control for feeding effects on HRV;58 and 4) whose mothers were >18 years old and English speaking.,inclusion criteria infants 1 28 0/7 32 6/7 weeks gestational age 14 days recruited partially control previous pain experiences 2 cared incubator 3 npo bolus feeds control feeding effects hrv58 4 mothers 18 english speaking,C0007637|C0243161|C0021270|G0000000|C0450371|G0000000|C0450371|G0000000|C0439230|C0439671|C0001779|C0450371|C0439228|G0000000|G0000000|C0243148|C0205156|C0030193|C0596545|G0000000|C1947933|C0021178|G0000000|C0029247|C1511237|C1510670|C0243148|C0204695|C1280500|G0000000|G0000000|C0026591|C0450371|C0376245|C0234856
"Sixty consecutive patients undergoing rst-time elective  AVR  were  randomly  assigned  to  1  of  2  groups,  using  the closed envelop method: 30 underwent AVR through  a  full  median  sternotomy  (group  1)  and  the  other  30  had a ministernotomy (group 2).",sixty consecutive patients undergoing rst-time elective avr randomly assigned 1 2 closed envelop method 30 underwent avr median sternotomy 1 30 ministernotomy 2,C3816724|C1707491|C0030705|G0000000|C1425219|C0206058|C0449217|G0000000|C1516050|G0000000|G0000000|C0587267|G0000000|C0025663|C0450371|G0000000|C0449217|C0549183|C0185792|G0000000|C0450371|G0000000|G0000000
Patients had to be younger than 18 years with chronic symptomatic heart failure due to systemic ventricular systolic dysfunction.,patients 18 chronic symptomatic heart failure systemic ventricular systolic dysfunction,C0030705|C0450371|C0205191|C0231220|C0018787|C0231174|C0205373|C0018827|C0039155|C0031847
"This consent was reconrmed in labour provided the women presented in labour with a singleton pregnancy, in a cephalic position, at term or post-term (>37 weeks gestation).",consent reconrmed labour provided women labour singleton pregnancy cephalic position term post-term 37 weeks gestation,C1511481|G0000000|C0022864|C1999230|C0043210|C0022864|C0481462|C0032961|C0205096|C0733755|C0233324|C1398117|C0450371|C0439230|C0032961
"Of the other 15 hospitalizations, 2 (8%) were the result of hip fracture, 2 (8%) were the result of ischemic stroke, 1 (4%) was the result of unstable angina, and 10 (40%) were the result of worsening heart failure.",15 hospitalizations 2 8% result hip fracture 2 8% result ischemic stroke 1 4% result unstable angina 10 40% result worsening heart failure,C0450371|C0019993|G0000000|G0000000|C1274040|C0019552|C0016658|G0000000|G0000000|C1274040|C0475224|C0038454|G0000000|G0000000|C1274040|C0443343|C0002962|C0450371|C0450371|C1274040|C0332271|C0018787|C0231174
Study Design: Preterm neonates (n 90) between 32 0/7 and 36 0/7 weeks gestational age participated in a single-blind randomized crossover design.,study design preterm neonates 90 32 0/7 36 0/7 weeks gestational age participated single-blind randomized crossover design,C0557651|C1707689|C0151526|C0021289|C0450371|C0450371|G0000000|C0450371|G0000000|C0439230|C0439671|C0001779|G0000000|C0242570|C0034656|C0010366|C1707689
"The mean age was 14 years (range, 4-21 years).",age 14 range 4-21,C0001779|C0450371|C1514721|C0450371
"Inclusion criteria were: 60 years of age or older; diagnosed cardiac condition (i.e., arrhythmia, angina, myocardial infarction, congestive heart failure or valvular disease, as the physicians' recommendations for managing these conditions generally include the common topics of medication use, physical activity, diet, stress reduction, and smoking cessation); treated by daily heart medication; seen by a physician within the past year; and living within one hour of the study site.",inclusion criteria 60 age diagnosed cardiac condition arrhythmia angina myocardial infarction congestive heart failure valvular disease physicians recommendations managing conditions common topics medication physical activity diet stress reduction smoking cessation treated daily heart medication physician living hour study site,C0007637|C0243161|C0450371|C0001779|C0011900|C0018787|C0012634|C0003811|C0002962|C0027061|C0021308|C0742742|C0018787|C0231174|C0184252|C0012634|C0031831|C0034866|C1273870|C0012634|C0205214|C1522168|C0013227|C0031809|C0205177|C0012155|C0038435|C0301630|C0037369|C1880019|C1522326|C0332173|C0018787|C0013227|C0031831|C0376558|C0439227|C0557651|C0205145
"In a prospective, randomized, double-blinded, placebo-controlled trial, we randomized 38 patients younger than 18 years with idiopathic dilated cardiomyopathy to receive either coenzyme Q10, chosen for 17 patients, or placebo, administered in the remaining 21.",prospective randomized double-blinded placebo-controlled trial randomized 38 patients 18 idiopathic dilated cardiomyopathy receive coenzyme q10 chosen 17 patients placebo administered remaining 21,C0023981|C0034656|C0205173|C1706408|C0008976|C0034656|C0450371|C0030705|C0450371|C0332240|C0700124|C0878544|C1514756|C0009235|G0000000|C1707391|C0450371|C0030705|C0032042|C1521801|C1527428|C0450371
"Patients with active cardiac disease, including angina pectoris or cardiac arrhythmia requiring medication, severe conduction abnormalities, clinically signicant valvular disease, cardiomegaly, ventricular hypertrophy, or poorly controlled hypertension, were ineligible.",patients active cardiac disease including angina pectoris cardiac arrhythmia requiring medication severe conduction abnormalities clinically signicant valvular disease cardiomegaly ventricular hypertrophy controlled hypertension ineligible,C0030705|C0205177|C0018787|C0012634|C0332257|C0002962|G0000000|C0018787|C0003811|G0000000|C0013227|C0205082|C0232217|C0000768|G0000000|G0000000|C0184252|C0012634|C0018800|C0018827|C0020564|C2587213|C0020538|C1512714
"This study was conducted at nine heart failure centers in the U.S. patients with symptomatic, New York Heart Association (NYHA) class II to III heart failure between the ages of 18 and 80 years of age and with left ventricular ejection fractions #45% were enrolled.",study conducted heart failure centers patients symptomatic york heart association nyha class ii iii heart failure ages 18 80 age left ventricular ejection fractions #45% enrolled,C0557651|C0004927|C0018787|C0231174|C0205099|C0030705|C0231220|G0000000|C0018787|C0004083|G0000000|C0456387|G0000000|C0439070|C0018787|C0231174|C0001779|C0450371|C0450371|C0001779|C0205091|C0018827|C0302131|C1264633|C0450371|G0000000
"Patients  aged  18  years  and  older  who  had  symptomatic heart failure (New York Heart Association Class IIIV) of at least 4 weeks duration, left-ventricular ejection fraction 40%  or  less,  and  intolerance  to  ACE  inhibitors  were eligible.",patients aged 18 symptomatic heart failure york heart association class iiiv 4 weeks duration left-ventricular ejection fraction 40% intolerance ace inhibitors eligible,C0030705|C0001779|C0450371|C0231220|C0018787|C0231174|G0000000|C0018787|C0004083|C0456387|G0000000|G0000000|C0439230|C0449238|C0225897|C0302131|C1264633|C0450371|C0231199|C1452534|C0243077|C1548635
"Male or female patients (18 years of age) with CHF were eligible for enrollment if they had received ACE inhibitor therapy for at least 4 weeks, were stable in New York Heart Association (NYHA) class II-IV heart failure and had a left ventricular ejection fraction (LVEF) 35%.",male female patients 18 age chf eligible enrollment received ace inhibitor therapy 4 weeks stable york heart association nyha class ii-iv heart failure left ventricular ejection fraction lvef 35%,C0086582|C0015780|C0030705|C0450371|C0001779|C0018802|C1548635|C1516879|C1514756|C1452534|C1999216|C0039798|G0000000|C0439230|C0205360|G0000000|C0018787|C0004083|G0000000|C0456387|C0022326|C0018787|C0231174|C0205091|C0018827|C0302131|C1264633|C0428772|C0450371
"Patients were ineligible if they were in cardiogenic shock, were unable to provide consent for  any other reason, had undergone previous coronary-artery bypass grafting (CABG), had a noninfarct-artery stenosis of 50% or more in the left  main stem or the ostia of both the left anterior  descending and circumflex arteries (because these  are indications for CABG), or if the only noninfarct stenosis was a chronic total occlusion (because it was felt that PCI in such circumstances  was contraindicated owing to a low success rate).",patients ineligible cardiogenic shock unable provide consent reason undergone previous coronary-artery bypass grafting cabg noninfarct-artery stenosis 50% left main stem ostia left anterior descending circumflex arteries indications cabg noninfarct stenosis chronic total occlusion pci circumstances contraindicated low success rate,C0030705|C1512714|C1749797|C0036974|C1299582|C1999230|C1511481|C0392360|G0000000|C0205156|C0205042|C0741847|C0332835|C0010055|C0003842|C0678234|C0450371|C0205091|C0205225|C0242767|C0444567|C0205091|C0205094|C0205386|C1880089|C0003842|C0392360|C0010055|G0000000|C0678234|C0205191|C0439175|C0011382|C4049621|G0000000|C1444657|C0205251|C0597535|C0871208
"Exclusion criteria were musculoskeletal, neuromuscular, visual, cognitive, or serious mental illness, or any serious or terminal illness not otherwise specied that would preclude CR eligibility on the basis of CR guidelines; physician deemed patient not suitable for CR at the time of intake of exercise stress test; patient planned to leave the area before the anticipated end of participation; patient discharged to a long-term care facility; and part icipation in another RCT with behavioral interventions.",exclusion criteria musculoskeletal neuromuscular visual cognitive mental illness terminal illness specied preclude cr eligibility basis cr guidelines physician deemed patient suitable cr time intake exercise stress test patient planned leave anticipated participation patient discharged long-term care facility icipation rct behavioral interventions,C0680251|C0243161|C0497254|C1979768|C0234621|C1516691|C0229992|C0221423|C0205088|C0221423|G0000000|G0000000|C0201975|C0013893|C1527178|C0201975|C0162791|C0031831|G0000000|C0030705|C3900053|C0201975|C0040223|C1512806|C0015259|C0038435|C0022885|C0030705|C1301732|G0000000|C3840775|C0679823|C0030705|C0030685|C0443252|C1947933|C1547538|G0000000|G0000000|C0004927|C0886296
Mothers  were  eligible  if  they  were  healthy  enough  to  provide SSC and had chosen to have their neonates receive  the  hepatitis  B  vaccine  injection  in  the  hospital  rather  than after discharge.,mothers eligible healthy provide ssc chosen neonates receive hepatitis vaccine injection hospital discharge,C0026591|C1548635|C3898900|C1999230|C3897657|C1707391|C0021289|C1514756|C0019158|C0042210|C0021485|C0019994|C0012621
"Furthermore, patients with prior cardiac surgery as well patients with history of previous ablation for AF were excluded.",patients prior cardiac surgery patients history previous ablation af excluded,C0030705|C0332152|C0018787|C0038894|C0030705|C0019664|C0205156|C0547070|C0344434|C1554077
Patients undergoing elective AK reconstruction and those patients undergoing BK bypass where saphenous vein was of poor quality or unavailable were considered with the inclusion criteria listed in our rst paper.13 Sixteen participating surgeons at 11 hospitals in northwest England submitted 352 patients for possible recruitment.,patients undergoing elective ak reconstruction patients undergoing bk bypass saphenous vein poor quality unavailable considered inclusion criteria listed rst paper13 sixteen participating surgeons 11 hospitals northwest england submitted 352 patients recruitment,C0030705|G0000000|C0206058|C0001905|C0020912|C0030705|G0000000|C0006036|C0741847|G0000000|C0042449|C0032854|C0332306|C0686905|C0750591|C0007637|C0243161|C0745732|C1425219|G0000000|C3715157|C0679823|C0582175|C0450371|C0019994|C1709274|C0014282|C1515023|C1442061|C0030705|C2949735
Birth weights ranged from 2.6 through 3.7 kg (mean birth weight: 3.3 kg).,birth weights ranged 26 37 birth weight 33,C0005615|C0043100|C1514721|C0450371|C0450371|C0005615|C0005910|C0450371
"Exclusion criteria were haemodynamic instability (ie, Killip state .2 or cardiogenic shock), the need for an intra-aortic balloon pump or temporary pacemaker, a history of a coronary artery bypass graft (CABG) or intolerance to abciximab.",exclusion criteria haemodynamic instability killip 2 cardiogenic shock intra-aortic balloon pump temporary pacemaker history coronary artery bypass graft cabg intolerance abciximab,C0680251|C0243161|C0019010|C1444783|G0000000|G0000000|C1749797|C0036974|C0347985|C0336867|C0182537|C0205374|C0030163|C0019664|C0018787|C0003842|C0741847|C0181074|C0010055|C0231199|C0288672
"Eligible  patients  were  aged  18  years  or  older,  had  New York  Heart  Association  functional  class  IIIV  of  at  least 4 weeks duration, had a history of hospital admission for a  cardiac  reason,  and  had  LVEF  higher  than  40%.",eligible patients aged 18 york heart association functional class iiiv 4 weeks duration history hospital admission cardiac reason lvef 40%,C1548635|C0030705|C0001779|C0450371|G0000000|C0018787|C0004083|C0205245|C0456387|G0000000|G0000000|C0439230|C0449238|C0019664|C0019994|C0184666|C0018787|C0392360|C0428772|C0450371
A prospective randomized cross-over study with 10 preterm infants 2-9 days old (30-32 weeks postmenstrual age) was conducted.,prospective randomized cross-over study 10 preterm infants 2-9 days 30-32 weeks postmenstrual age conducted,C0023981|C0034656|C0010366|C0557651|C0450371|C0151526|C0021270|G0000000|C0439228|C0450371|C0439230|G0000000|C0001779|C0004927
White patients of either sex (aged 18-75 years) with mildto-moderate symptomatic CHF (New York Heart Association class II or III) and impaired left ventricular function (ejection fraction 40%) who provided written informed consent were enrolled.,white patients sex aged 18-75 mildto-moderate symptomatic chf york heart association class ii iii impaired left ventricular function ejection fraction 40% provided written informed consent enrolled,C0007457|C0030705|C0009253|C0001779|C0450371|C0205081|C0231220|C0018802|G0000000|C0018787|C0004083|C0456387|G0000000|C0439070|C0221099|C0205091|C0018827|C0031843|C0302131|C1264633|C0450371|C1999230|C0043266|C1522154|C1511481|G0000000
Mean left ventricular ejection fraction was 0.57  0.12 in group I versus 0.56  0.13 in group II (p = 0.73).,left ventricular ejection fraction 057 012 versus 056 013 ii = 073,C0205091|C0018827|C0302131|C1264633|C1442061|C1442061|G0000000|C1442061|C1442061|G0000000|G0000000|C1442061
"Patients were eligible for the study if they had a diagnosis of ischemic heart disease, confirmed by their physician or hospital medical record, and if they lived independently (i.e., not in an institutional setting).",patients eligible study diagnosis ischemic heart disease confirmed physician hospital medical record lived independently institutional setting,C0030705|C1548635|C0557651|C0011900|C0475224|C0018787|C0012634|C0521093|C0031831|C0019994|C0199168|C0034869|C1548795|G0000000|C0018704|C0542559
"Women aged 18 years with primary, operable, and histologically conrmed node-positive or high-risk node-negative invasive breast cancer, with no evidence of metastases, were eligible.",women aged 18 primary operable histologically conrmed node-positive high-risk node-negative invasive breast cancer evidence metastases eligible,C0043210|C0001779|C0450371|C0205225|C0205188|C0205462|G0000000|C0746319|C0332167|C0678034|C0205281|C0006141|C0006826|C3887511|C0027627|C1548635
Doxorubicin induced cardiotoxicity in children: Reduced incidence of  cardiac  dysfunction  associated  with  continuous  infusion  schedules  .,doxorubicin induced cardiotoxicity children reduced incidence cardiac dysfunction continuous infusion schedules,C0013089|C0205263|C0876994|C0008059|C0392756|C0021149|C0018787|C0031847|C0549178|C0574032|C0086960
"Patients were eligible for inclusion in the study if they required an above-knee or below-knee femoropopliteal bypass with the proximal anastomosis at the level of the distal external iliac, common femoral, profunda femoral, or proximal supercial femoral artery.",patients eligible inclusion study required above-knee below-knee femoropopliteal bypass proximal anastomosis level distal external iliac common femoral profunda femoral proximal supercial femoral artery,C0030705|C1548635|C0007637|C0557651|C1514873|C1282910|C0542339|C0545765|C0741847|C0205107|C0332853|C0441889|C0205108|C0205101|C0020889|C0205214|C0015811|G0000000|C0015811|C0205107|G0000000|C0015811|C0003842
"The exclusion criteria were earlier chemotherapy (CT) or radiotherapy, presence of congestive heart failure symptoms or established dilated or restrictive CMP, coronary arterial disease history, presence of moderate or severe mitral or aortic valve disease in baseline echocardiograph, any contraindication to carvedilol, bundle branch block, thyroid function disorder, or another comorbid disease.",exclusion criteria earlier chemotherapy ct radiotherapy presence congestive heart failure symptoms established dilated restrictive cmp coronary arterial disease history presence moderate severe mitral aortic valve disease baseline echocardiograph contraindication carvedilol bundle branch block thyroid function disorder comorbid disease,C0680251|C0243161|C1279919|C0013216|C0007673|C0034619|C0150312|C0742742|C0018787|C0231174|C0683368|C0443211|C0700124|C0443288|G0000000|C0018787|C0003842|C0012634|C0019664|C0150312|C0205081|C0205082|C0746591|C0003483|C0184252|C0012634|C0168634|C0183129|C0522473|C0054836|G0000000|C1253959|C0028778|C0040132|C0031843|C0012634|C0009488|C0012634
"The primary cause of heart failure was hypertension in 64% of the patients and ischemic heart  disease in 25%, and hypertension was present in  88% overall.",primary heart failure hypertension 64% patients ischemic heart disease 25% hypertension 88%,C0205225|C0018787|C0231174|C0020538|C0450371|C0030705|C0475224|C0018787|C0012634|C0450371|C0020538|C0450371
"Between November 2009 and November 2010, 20 neonates  undergoing cardiovascular surgery with CPB who were in stable",november 2009 november 2010 20 neonates undergoing cardiovascular surgery cpb stable,C3828767|G0000000|C3828767|G0000000|C0450371|C0021289|G0000000|C0007226|C0038894|G0000000|C0205360
Infants had been fed in their usual manner between 30 minutes and 4 hours before the start of the study.,infants fed usual manner 30 minutes 4 hours start study,C0021270|C0342895|C3538928|G0000000|C0450371|C0439232|G0000000|C0439227|C0439659|C0557651
"Mothers and their preterm neonates were eligible for enrollment in the study if the infants met the following criteria: were born between 32 0/7 and 36 0/7 completed weeks gestational age determined by ultrasound at 16 weeks, had informed parental consent, had Apgar scores >6 at 5 min, were within 10 days of birth, were breathing unassisted, did not have any major congenital anomalies, had not suffered Grade III or IV intraventricular hemorrhage or subsequent periventricular leukomalacia, had not undergone surgery and were not receiving paralytic, analgesic or sedative medications within 48 h of the study time.",mothers preterm neonates eligible enrollment study infants met criteria born 32 0/7 36 0/7 completed weeks gestational age determined ultrasound 16 weeks informed parental consent apgar scores 6 5 min 10 days birth breathing unassisted major congenital anomalies suffered grade iii iv intraventricular hemorrhage subsequent periventricular leukomalacia undergone surgery receiving paralytic analgesic sedative medications 48 study time,C0026591|C0151526|C0021289|C1548635|C1516879|C0557651|C0021270|C0268621|C0243161|C0005615|C0450371|G0000000|C0450371|G0000000|C0205197|C0439230|C0439671|C0001779|G0000000|C0041618|C0450371|C0439230|C1522154|C0030551|C1511481|C0741195|C0449820|G0000000|G0000000|C0702093|C0450371|C0439228|C0005615|C0004048|G0000000|C0205082|C0009678|C0000769|C0683278|C0441800|C0439070|C0022326|C1517569|C0019080|C0332282|G0000000|G0000000|G0000000|C0038894|C1514756|G0000000|C0002771|C0020592|C0013227|C0450371|C0557651|C0040223
"This prospective, double-blind, randomized, placebo-controlled trial evaluated IVIG in patients with a first episode of rheumatic fever, stratifying patients by the presence and severity of carditis before randomization.",prospective double-blind randomized placebo-controlled trial evaluated ivig patients episode rheumatic fever stratifying patients presence severity carditis randomization,C0023981|C0013072|C0034656|C1706408|C0008976|C0220825|C0085297|C0030705|C0332189|G0000000|C0015967|C0205363|C0030705|C0150312|C0439793|C0869523|C0034656
"Patients had to be adult women with adequate hepatic,  renal, and bone marrow function, an Eastern Cooperative  Oncology  Group  performance  status  1  or  lower,  and  a  left  ventricular  ejection  fraction  of  55%  or  higher  measured  by  multiple  gated  acquisition  scan  or  echocardiography.",patients adult women adequate hepatic renal bone marrow function eastern cooperative oncology performance status 1 lower left ventricular ejection fraction 55% measured multiple gated acquisition scan echocardiography,C0030705|C0001675|C0043210|C0205410|C0205054|C0022646|C0262950|C0086590|C0031843|C1707877|C0679729|C0027651|C0597198|C0449438|G0000000|C0441994|C0205091|C0018827|C0302131|C1264633|C0450371|C0444706|C0439064|G0000000|C1706701|C0034606|C0013516
"Criteria for exclusion were distant metastases,  pregnancy, severe hypertension, and cardiac disease (including cardiac failure of any degree, arrhythmia requiring regular medication, and myocardial infarction within the previous 12 months).",criteria exclusion distant metastases pregnancy severe hypertension cardiac disease including cardiac failure degree arrhythmia requiring regular medication myocardial infarction previous 12 months,C0243161|C0680251|C0443203|C0027627|C0032961|C0205082|C0020538|C0018787|C0012634|C0332257|C0018787|C0231174|C0441889|C0003811|G0000000|C0205272|C0013227|C0027061|C0021308|C0205156|C0450371|C0439231
"Outcomes and Follow-up Period The primary end point was a composite that involved correction of at least 1 of the following 3 cardiovascular risk factors between baseline and month 12: (1) smoking cessation (complete cessation for smokers, with nonsmokers at baseline and month 12 considered successes and nonsmokers at study inclusionwhostartedsmoking[orrelapsed]duringthe12months considered failures); (2) overweight or obesity (4% reduction in waist circumference or 5% reduction in weight, with patients having a body mass index of less than 25 at baseline and at 12 months considered successes and patients who be-",outcomes follow-up period primary composite involved correction 1 3 cardiovascular risk factors baseline month 12 1 smoking cessation complete cessation smokers nonsmokers baseline month 12 considered successes nonsmokers study inclusionwhostartedsmokingorrelapsedduringthe12months considered failures 2 overweight obesity 4% reduction waist circumference 5% reduction weight patients body mass 25 baseline 12 months considered successes patients be-,C1274040|C0589120|C0439531|C0205225|C0205199|C1314939|C1705565|G0000000|G0000000|C0007226|C0035647|C1521761|C0168634|C0332177|C0450371|G0000000|C0037369|C1880019|C0205197|C1880019|C0337664|C0337672|C0168634|C0332177|C0450371|C0750591|C0597535|C0337672|C0557651|G0000000|C0750591|C0231174|G0000000|C0497406|C0028754|G0000000|C0301630|C0230097|C0332520|G0000000|C0301630|C0005910|C0030705|C0242821|C0577559|C0450371|C0168634|C0450371|C0439231|C0750591|C0597535|C0030705|G0000000
All patients admitted to the Royal Cornwall Hospital during December 2000September 2003 with acute myocardial infarction from the areas served by two primary care trusts were assessed for eligibility.,patients admitted royal cornwall hospital december 2000september 2003 acute myocardial infarction served primary care trusts assessed eligibility,C0030705|C0184666|G0000000|C0454846|C0019994|C3830550|G0000000|G0000000|C0205178|C0027061|C0021308|G0000000|C0205225|C1947933|C0237935|C1516048|C0013893
"In all groups, the principal causes of CHF were coronary heart disease and/or cardiomyopathy.",principal chf coronary heart disease and/or cardiomyopathy,C0205225|C0018802|C0018787|C0018787|C0012634|G0000000|C0878544
hronic  heart  failure  (CHF)  is  a  complex  clinical syndrome  linked  to  abnormal  cardiac  function.,hronic heart failure chf complex clinical syndrome linked abnormal cardiac function,G0000000|C0018787|C0231174|C0018802|C0439855|C0205210|C0039082|C1517892|C0205161|C0018787|C0031843
"Eligible  patients  were  aged  18  years  or  older,  had  leftventricular  ejection  fraction  40%  or  lower  measured within  the  past  6  months,  New  York  Heart  Association functional  class  IIIV  (if  class  II,  patients  had  to  have admission to hospital for a cardiac reason in the previous 6  months),  and  treatment  with  an  ACE  inhibitor  at  a constant dose for 30 days or longer.",eligible patients aged 18 leftventricular ejection fraction 40% lower measured 6 months york heart association functional class iiiv class ii patients admission hospital cardiac reason previous 6 months treatment ace inhibitor constant dose 30 days,C1548635|C0030705|C0001779|C0450371|G0000000|C0302131|C1264633|C0450371|C0441994|C0444706|G0000000|C0439231|G0000000|C0018787|C0004083|C0205245|C0456387|G0000000|C0456387|G0000000|C0030705|C0184666|C0019994|C0018787|C0392360|C0205156|G0000000|C0439231|C0039798|C1452534|C1999216|C1547014|C0178602|C0450371|C0439228
"Twenty untreated patients, 60 years of age with newly-diagnosed aggressive NHL, eligible for a treatment with epirubicin-based chemotherapy were selected for the study.",twenty untreated patients 60 age newly-diagnosed aggressive nhl eligible treatment epirubicin-based chemotherapy selected study,C0724000|C0332155|C0030705|C0450371|C0001779|C0750546|C0001807|C0024305|C1548635|C0039798|C0014582|C0013216|C1707391|C0557651
"The median age of all patients was 52 years (range 3076 years), and the majority of patients were Caucasian, non-smokers and had an ECOG PS of 01.",median age patients 52 range 3076 majority patients caucasian non-smokers ecog ps 01,C0549183|C0001779|C0030705|C0450371|C1514721|G0000000|C0680220|C0030705|C0007457|C0337672|C0430797|C0242397|C0450371
The subset of nine patients already receiving medication at study entry may represent a subset of patients who had more severe heart failure although Ross score was not signicantly higher (Table 2 ).,subset patients receiving medication study entry represent subset patients severe heart failure ross score signicantly table 2,C1515021|C0030705|C1514756|C0013227|C0557651|C1705654|C1882932|C1515021|C0030705|C0205082|C0018787|C0231174|C0331968|C0449820|G0000000|C0039224|G0000000
"patients with dyspnea, confusion or unable to hear); having sequelae affecting daily activities (e.g.",patients dyspnea confusion unable hear sequelae daily activities,C0030705|C0013404|C0009676|C1299582|C0018767|C0243088|C0332173|C0441655
A total of 18 infants provided completed data for Study 1 (80-min study); 10 subjects completed Study 2 (30-min study).,total 18 infants provided completed data study 1 80-min study 10 subjects completed study 2 30-min study,C0439175|C0450371|C0021270|C1999230|C0205197|C1511726|C0557651|G0000000|C0450371|C0557651|C0450371|C0681850|C0205197|C0557651|G0000000|C0450371|C0557651
"We included 28 patients, mean age was 11.6 years, ve had metastatic disease.",included 28 patients age 116 ve metastatic disease,C0332257|C0450371|C0030705|C0001779|C1442061|C0042469|C0036525|C0012634
"The mean age  was 72 years, and 60% of the patients were women.",age 72 60% patients women,C0001779|C0450371|C0450371|C0030705|C0043210
"Of the 80 eligible patients, 35 men and 7 women were assigned to the TP, and 31 men and 7 women were assigned to the MP.",80 eligible patients 35 7 women assigned tp 31 7 women assigned mp,C0450371|C1548635|C0030705|C0450371|G0000000|C0043210|C1516050|C0036183|C0450371|G0000000|C0043210|C1516050|C0024944
"Cardiac disease was defined as any condition directly involving the heart (e.g., arrhythmia, angina,  myocardial  infarction,  and  valvular  disease).",cardiac disease defined condition directly involving heart arrhythmia angina myocardial infarction valvular disease,C0018787|C0012634|C1704788|C0012634|C1947931|C1314939|C0018787|C0003811|C0002962|C0027061|C0021308|C0184252|C0012634
Patients aged 3079 who had suffered MI or angina with electrocardiographic signs of ischaemia in the 6 years prior to recruitment were eligible.,patients aged 3079 suffered mi angina electrocardiographic signs ischaemia 6 prior recruitment eligible,C0030705|C0001779|G0000000|C0683278|C3810814|C0002962|C0013798|C0220912|C0022116|G0000000|C0332152|C2949735|C1548635
"The LifeMasters Supported SelfCare dem  onstration  program  provides  disease  man agement (DM) services to Florida Medicare  beneficiaries  who  are  also  enrolled  in  Medicaid and have congestive heart failure  (CHF), diabetes, or coronary artery disease  (CAD).",lifemasters supported selfcare dem onstration program disease agement dm services florida medicare beneficiaries enrolled medicaid congestive heart failure chf diabetes coronary artery disease cad,G0000000|C1521721|C0036592|C1833296|G0000000|C1709697|C0012634|G0000000|C3250443|C0557854|C0016253|C0018717|C1550502|G0000000|C0025071|C0742742|C0018787|C0231174|C0018802|C0011847|C0018787|C0003842|C0012634|C3813548
"Criteria for exclusion were previous ipsilateral femoropopliteal procedures, contra-indication for the use of acetyl salicylic acid or anticoagulants, patients receiving chemoor radiotherapy, malignancy diagnosed or treated within 12 months, known allergy to iodine or contrast medium, and impaired renal function.",criteria exclusion previous ipsilateral femoropopliteal procedures contra-indication acetyl salicylic acid anticoagulants patients receiving chemoor radiotherapy malignancy diagnosed treated 12 months allergy iodine contrast medium impaired renal function,C0243161|C0680251|C0205156|C0441989|C0545765|C0025664|C0392360|G0000000|C0036079|C0001128|C0003280|C0030705|C1514756|G0000000|C0034619|C0006826|C0011900|C1522326|C0450371|C0439231|C0002111|C0021966|C0009924|C0009458|C0221099|C0022646|C0031843
"Patients: After written informed consent, 40 infants undergoing  corrective open-heart surgery were included.",patients written informed consent 40 infants undergoing corrective open-heart surgery included,C0030705|C0043266|C1522154|C1511481|C0450371|C0021270|G0000000|C0719519|C0175566|C0038894|C0332257
"Patients with stenotic valvular disease, restrictive or hypertrophic cardiomyopathy or uncontrolled atrial brillation (mean heart rate .",patients stenotic valvular disease restrictive hypertrophic cardiomyopathy uncontrolled atrial brillation heart rate,C0030705|C0333181|C0184252|C0012634|C0443288|C0020564|C0878544|C0205318|C0018792|G0000000|C0018787|C0871208
"All patients who required an AK femoro-popliteal bypass for disabling claudication, rest pain or tissue loss, and in the absence of suitable venous conduit, were eligible for this trial.",patients required ak femoro-popliteal bypass disabling claudication rest pain tissue loss absence suitable venous conduit eligible trial,C0030705|C1514873|C0001905|C0545765|C0741847|G0000000|C0311395|C0035253|C0030193|C0040300|C1517945|C0332197|C3900053|C0042449|C0441247|C1548635|C0008976
"Also excluded were patients with serum creatinine >2.5 mg/dL, recent (<6 weeks) myocardial infarction or stroke, coagulation or bleeding disorders, and those receiving warfarin therapy where oral anticoagulation could not be withheld.",excluded patients serum creatinine 25 mg/dl <6 weeks myocardial infarction stroke coagulation bleeding disorders receiving warfarin therapy oral anticoagulation withheld,C1554077|C0030705|C0229671|C0010294|C0450371|C0439269|G0000000|C0439230|C0027061|C0021308|C0038454|C0005778|C0019080|C0012634|C1514756|C0043031|C0039798|C0442027|C0003281|G0000000
The selection of patients was based on the presence of disabling claudication or critical ischaemia.,selection patients based presence disabling claudication critical ischaemia,C0036576|C0030705|C1527178|C0150312|G0000000|C0311395|C1511545|C0022116
"Patients between the ages of 20 and 85 years were eligible for enrollment into the study if they (1) had clinically stable,  New  York  Heart  Association  (NYHA)  functional class  IIm  in  the  subcategory  of  NYHA  II,  which  means moderate  limitation  of  physical  activity,  or  NYHA  functional  class  III  chronic  heart  failure,  (2)  had  remained symptomatic  despite  conventional  therapy  with  digitalis, diuretics, angiotensin-converting enzyme (ACE) inhibitors, nitrates, Ca-blockers,(cid:1036)-blockers or antiarrhythmic etc for",patients ages 20 85 eligible enrollment study 1 clinically stable york heart association nyha functional class iim subcategory nyha ii moderate limitation physical activity nyha functional class iii chronic heart failure 2 remained symptomatic conventional therapy digitalis diuretics angiotensin-converting enzyme ace inhibitors nitrates ca-blockerscid1036-blockers antiarrhythmic,C0030705|C0001779|C0450371|C0450371|C1548635|C1516879|C0557651|G0000000|G0000000|C0205360|G0000000|C0018787|C0004083|G0000000|C0205245|C0456387|C0751356|C1515010|G0000000|G0000000|C0205081|C0449295|C0031809|C0205177|G0000000|C0205245|C0456387|C0439070|C0205191|C0018787|C0231174|G0000000|G0000000|C0231220|C0439858|C0039798|C0012252|C0012798|C0003018|C0014442|C1452534|C0243077|C0028125|C3887642|C0003195
"Exclusion criteria were infants with known congenital anomalies, periventricular/intraventricular hemorrhage (Grade III), history of surgery, having received sedation, vasopressor, or analgesics, exposure to drug abuse during pregnancy, multiples at birth, and showing signs of severe tissue breakdown of either heel as measured by the Neonatal Skin Condition Score [51].",exclusion criteria infants congenital anomalies periventricular/intraventricular hemorrhage grade iii history surgery received sedation vasopressor analgesics exposure drug abuse pregnancy multiples birth signs severe tissue breakdown heel measured neonatal skin condition score 51,C0680251|C0243161|C0021270|C0009678|C0000769|C1517569|C0019080|C0441800|C0439070|C0019664|C0038894|C1514756|C0235195|C0042397|C0002771|C0274281|C0013227|C0013146|C0032961|C0439064|C0005615|C0220912|C0205082|C0040300|C0443161|C0018870|C0444706|C1552240|C0444099|C0012634|C0449820|C0450371
"The main clinical exclusion criteria were the presence of significant lesions in vein grafts or arterial conduits or in segments previously treated with angioplasty or stent implantation, recent thrombolysis (less than 1 week), cardiogenic shock, defined as hypotension with systolic blood pressure <90 mmHg and tachycardia >100 beats/min, not due to hypovolemia or requiring inotropic support or balloon counterpulsation.",main clinical exclusion criteria presence lesions vein grafts arterial conduits segments treated angioplasty stent implantation thrombolysis 1 week cardiogenic shock defined hypotension systolic blood pressure <90 mmhg tachycardia 100 beats/min hypovolemia requiring inotropic support balloon counterpulsation,C0205225|C0205210|C0680251|C0243161|C0150312|C0221198|C0042449|C0332835|C0003842|C0441247|C0441635|C1522326|C0162577|C0038257|C0021107|C0520997|G0000000|C0332174|C1749797|C0036974|C1704788|C0020649|C0039155|C0005767|C0033095|C0450371|C0439475|C0039231|C1442061|C0439385|C0546884|G0000000|G0000000|C0183683|C0336867|C0010216
"Patients 18 years of age were eligible if they had symptomatic heart failure (New York Heart Association class II to IV) for 3 months before entry, had a left ventricular ejection fraction 35% measured within 3 months by any standard technique, were in sinus rhythm, and were treated with a diuretic and an ACE inhibitor for at least 60 days (unless not tolerated).",patients 18 age eligible symptomatic heart failure york heart association class ii iv 3 months entry left ventricular ejection fraction 35% measured 3 months standard technique sinus rhythm treated diuretic ace inhibitor 60 days tolerated,C0030705|C0450371|C0001779|C1548635|C0231220|C0018787|C0231174|G0000000|C0018787|C0004083|C0456387|G0000000|C0022326|G0000000|C0439231|C1705654|C0205091|C0018827|C0302131|C1264633|C0450371|C0444706|G0000000|C0439231|C1442989|C0449851|C0016169|C0871269|C1522326|C0012798|C1452534|C1999216|C0450371|C0439228|G0000000
"Ninety-ve preterm neonates of both genders with a postmenstrual age of 2836 weeks were studied and blood samples required for exams were obtained by heel lancing, which was chosen as the painful stimulus in the present study.",ninety-ve preterm neonates genders postmenstrual age 2836 weeks studied blood samples required exams heel lancing chosen painful stimulus study,C3816959|C0151526|C0021289|C0079399|G0000000|C0001779|G0000000|C0439230|C0557651|C0005767|C0370003|C1514873|C0582103|C0018870|C0522666|C1707391|C0030193|C0234402|C0557651
"The 61 infants remaining  in  the  study  were  a  mean  age  of  30.5  weeks  (SD  7 days),  at  birth  weighed  1421  gm  (SD  490  gm),  had  5minute Apgar scores of 8.2 (SD 1.3), and SNAP-PE-II score of 10.08 (SD 10.9).",61 infants remaining study age 305 weeks sd 7 days birth weighed 1421 gm sd 490 gm 5minute apgar scores 82 sd 13 snap-pe-ii score 1008 sd 109,C0450371|C0021270|C1527428|C0557651|C0001779|C1442061|C0439230|C2699239|G0000000|C0439228|C0005615|G0000000|G0000000|C0017480|C2699239|C1442061|C0017480|G0000000|C0741195|C0449820|C0450371|C2699239|C0450371|C0070939|C0449820|G0000000|C2699239|C1442061
"Participants: Of the 2042 eligible antenatal women, 1971 women in active term labour, following uncomplicated pregnancies, were randomised to either the standard of care or not.",participants 2042 eligible antenatal women 1971 women active term labour uncomplicated pregnancies randomised standard care,C0679646|G0000000|C1548635|C2828394|C0043210|G0000000|C0043210|C0205177|C0233324|C0022864|C0443334|C0032961|G0000000|C1442989|C1947933
"For enrolled patients, baseline evaluations preceding the rst intravenous infusion of pegylated liposomal doxorubicin included acquisition of a medical history and data on treatment of prostate carcinoma, physical examination, complete blood counts, liver function tests (for bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase [aP] levels), and PSA measurement.",enrolled patients baseline evaluations preceding rst intravenous infusion pegylated liposomal doxorubicin included acquisition medical history data treatment prostate carcinoma physical examination complete blood counts liver function tests bilirubin aspartate aminotransferase alanine aminotransferase alkaline phosphatase ap levels psa measurement,G0000000|C0030705|C0168634|C0220825|C0332152|C1425219|C0348016|C0574032|G0000000|C0023828|C0013089|C0332257|C1706701|C0199168|C0019664|C1511726|C0039798|C0033572|C0007097|C0031809|G0000000|C0205197|C0005767|C0439157|C0023884|C0031843|C0022885|C0005437|C0085845|C0002594|C0001898|C0002594|C1979842|C0031678|C3887950|C0441889|C3810537|C0242485
"All infants had been delivered at or beyond 37 completed weeks of gestation and were between 33 and 55 hours old at the time of testing, which generally began between 7 and 8 am.",infants delivered 37 completed weeks gestation 33 55 hours time testing 7 8,C0021270|C1705822|C0450371|C0205197|C0439230|C0032961|C0450371|C0450371|C0439227|C0040223|C0039593|G0000000|G0000000
"Briey, the HERA trial is  intergroup  open-label  phase  III  an  involving  women  with  centrally  randomised  conrmed  HER2-positive  (immunohistochemistry  score  3  or  uorescence  in-situ  hybridisation  positive)  early  stage  invasive  breast  cancer  who  had  completed  local regional therapy and a minimum of four courses of  predened  standard  adjuvant  or  neoadjuvant  chemotherapy.",briey hera trial intergroup open-label phase iii involving women centrally randomised conrmed her2-positive immunohistochemistry score 3 uorescence in-situ hybridisation positive stage invasive breast cancer completed local regional therapy minimum courses predened standard adjuvant neoadjuvant chemotherapy,G0000000|G0000000|C0008976|G0000000|C1709323|C0205390|C0439070|C1314939|C0043210|G0000000|G0000000|G0000000|C0439178|C0021044|C0449820|G0000000|G0000000|C0444498|C0020202|C0439178|C0205390|C0205281|C0006141|C0006826|C0205197|C0205276|C0205147|C0039798|C1524031|C0750729|G0000000|C1442989|C0001551|C0600558|C0013216
"Exclusion criteria were  emergency operations, depressed left ventricular function  (< 25%), a heavily calcied ascending aorta, redo valve  surgery,  and AVR  associated  with  other  valve  lesions.",exclusion criteria emergency operations depressed left ventricular function < 25% heavily calcied ascending aorta redo valve surgery avr valve lesions,C0680251|C0243161|C0013956|C0038895|C0344315|C0205091|C0018827|C0031843|G0000000|C0450371|G0000000|G0000000|C0205385|C0003483|C0439617|C0184252|C0038894|C0449217|C0184252|C0221198
"The study involved 1493 patients (980 intervention and 513 control), 62 pharmacists and 164 GPs.",study involved 1493 patients 980 intervention 513 control 62 pharmacists 164 gps,C0557651|C1314939|G0000000|C0030705|C1442061|C0886296|C1442061|C0243148|C0450371|C0031323|C1442061|C0272302
"In patients with acute coronary syndromes (ACS;  ST-segment elevation myocardial infarction [STEMI]  and non-ST-segment elevation ACS [NSTE-ACS]), major  bleeding  is as common as recurrent myocardial  infarction and occurs in about 5% of patients, depending  on the denition used.",patients acute coronary syndromes acs st-segment elevation myocardial infarction stemi non-st-segment elevation acs nste-acs major bleeding common recurrent myocardial infarction occurs 5% patients depending denition,C0030705|C0205178|C0018787|C0039082|G0000000|C0429029|C0439775|C0027061|C0021308|C3538872|C1518422|C0439775|G0000000|G0000000|C0205082|C0019080|C0205214|C2945760|C0027061|C0021308|C1709305|G0000000|C0030705|C0725813|G0000000
"The inclusion criteria for participation were any patient over 18 years old, strictly less than or equal to American Society of Anesthesiologists (ASA) 3 (severe systemic but not incapacitating disease), providing informed signed consent,",inclusion criteria participation patient 18 strictly equal american society anesthesiologists asa 3 severe systemic incapacitating disease providing informed signed consent,C0007637|C0243161|C0679823|C0030705|C0450371|G0000000|C0205163|C0596070|C0037455|C0334910|C0004057|G0000000|C0205082|C0205373|G0000000|C0012634|C1999230|C1522154|C1519316|C1511481
"Trastuzumab was initiated if patients had received at least four cycles of chemotherapy, LVEF was above 55% (or between 50% and 55% if cardiologist approved trastuzumab administration), and if there was no evidence of metastatic disease.",trastuzumab initiated patients received cycles chemotherapy lvef 55% 50% 55% cardiologist approved trastuzumab administration evidence metastatic disease,C0728747|C1548602|C0030705|C1514756|C1511572|C0013216|C0428772|C0450371|C0450371|C0450371|C0175906|C0205540|C0728747|C0001554|C3887511|C0036525|C0012634
"Patients: Sixty-two preterm neonates at 28 to 36 weeks gestational age who were expected to stay in the neonatal intensive care unit for at least 2 blood sampling procedures, without major congenital anomalies, grade III or IV intraventricular hemorrhage, or periventricular leukomalacia; without surgical interventions; not receiving parenteral analgesics or sedatives within 72 hours; and with parental consent.",patients sixty-two preterm neonates 28 36 weeks gestational age expected stay neonatal intensive care unit 2 blood sampling procedures major congenital anomalies grade iii iv intraventricular hemorrhage periventricular leukomalacia surgical interventions receiving parenteral analgesics sedatives 72 hours parental consent,C0030705|C3816724|C0151526|C0021289|C0450371|C0450371|C0439230|C0439671|C0001779|C1517001|G0000000|C1552240|C0162425|C1947933|C0439148|G0000000|C0005767|C0441621|C0025664|C0205082|C0009678|C0000769|C0441800|C0439070|C0022326|C1517569|C0019080|G0000000|G0000000|C0543467|C0886296|C1514756|C0030547|C0002771|C0036557|C0450371|C0439227|C0030551|C1511481
"At baseline 1,613 women who met the study criteria were available for recruitment.",baseline 1613 women met study criteria recruitment,C0168634|G0000000|C0043210|C0268621|C0557651|C0243161|C2949735
Patients younger than 30 or older than 90 years of age or patients with an ABI higher than 0.8 at rest were excluded.,patients 30 90 age patients abi 08 rest excluded,C0030705|C0450371|C0450371|C0001779|C0030705|C1328319|C0450371|C0035253|C1554077
"Only patients with a low to moderate risk of future cardiac events according to the Dutch CR guidelines were included. Finally, patients were required to have Internet access and a computer at home.",patients low moderate risk future cardiac events dutch cr guidelines included finally patients required internet access computer,C0030705|C0205251|C0205081|C0035647|C0016884|C0018787|C0441471|C0013331|C0201975|C0162791|C0332257|G0000000|C0030705|C1514873|C0282111|C0444454|C0009622
"Males and females, 18 years of age, with stable heart failure, New York Heart Association class II-III, left ventricular ejection fraction 0.45, on an angiotensin-converting enzyme inhibitor for heart failure since at least 3 months and able to perform a 6-min-walk test, were eligible.",males females 18 age stable heart failure york heart association class ii-iii left ventricular ejection fraction 045 angiotensin-converting enzyme inhibitor heart failure 3 months perform 6-min-walk test eligible,C0086582|C0015780|C0450371|C0001779|C0205360|C0018787|C0231174|G0000000|C0018787|C0004083|C0456387|C0439070|C0205091|C0018827|C0302131|C1264633|C1442061|C0003018|C0014442|C1999216|C0018787|C0231174|G0000000|C0439231|C0884358|C0702093|C0022885|C1548635
The infants mothers spoke English.,infants mothers spoke english,C0021270|C0026591|G0000000|C0376245
"Patients and methods: From October 2000 until June 2005, 1121 node-positive patients were randomized to sequential dose-dense epirubicin 110 mg/m2 and paclitaxel (Taxol, Bristol Myers-Squibb, Princeton, New Jersey, USA) 250 mg/m2 (group A), or concurrent epirubicin 83 mg/m2 and paclitaxel 187 mg/m2 (group B), both followed by three cycles of intensied combination chemotherapy with cyclophosphamide, methotrexate and uorouracil (CMF).",patients methods october 2000 june 2005 1121 node-positive patients randomized sequential dose-dense epirubicin 110 mg/m2 paclitaxel taxol bristol myers-squibb princeton jersey usa 250 mg/m2 concurrent epirubicin 83 mg/m2 paclitaxel 187 mg/m2 cycles intensied combination chemotherapy cyclophosphamide methotrexate uorouracil cmf,C0030705|C0025663|C3828732|G0000000|C3829443|G0000000|G0000000|C0746319|C0030705|C0034656|C1548958|C0178602|C0014582|C1442061|C0026410|C0144576|C0678133|G0000000|C0331904|C0331889|C0454673|C0041703|C1442061|C0026410|C0205420|C0014582|C0450371|C0026410|C0144576|C1442061|C0026410|C1511572|G0000000|C0205195|C0013216|C0010583|C0025677|G0000000|C0950521
"Women eligible for the study were less than 66  years of age, had a World Health Organization performance status of 0 or 1, and had undergone breast surgery with axillary-node dissection or sentinel-node biopsy for invasive breast carcinoma.",women eligible study 66 age health organization performance status 0 1 undergone breast surgery axillary-node dissection sentinel-node biopsy invasive breast carcinoma,C0043210|C1548635|C0557651|C0450371|C0001779|C0018684|C0029237|C0597198|C0449438|G0000000|G0000000|G0000000|C0006141|C0038894|C0729594|C0012737|C0677944|C0005558|C0205281|C0006141|C0007097
"Univariate analysis showed six variables to be associated with impaired rates of limb salvage: infragenicular anastomosis (p=0.0001), distal gangrene (p=0.0001), critical limb ischaemia (p=0.0004), duration of primary operation exceeding 3 h (p=0.003), poor run-off index (p=0.007), and operation in centre A (p=0.04).",univariate analysis variables impaired rates limb salvage infragenicular anastomosis p=00001 distal gangrene p=00001 critical limb ischaemia p=00004 duration primary operation exceeding 3 p=0003 poor run-off p=0007 operation centre p=004,G0000000|C0002778|C0439828|C0221099|C0871208|C0015385|C0085405|G0000000|C0332853|C0369773|C0205108|C0017086|C0369773|C1511545|C0015385|C0022116|C0369773|C0449238|C0205225|C0543467|G0000000|G0000000|C0369773|C0032854|C0035953|C0369773|C0543467|C0205099|C0369773
Patients were recruited within 2 weeks of entering cardiac rehabilitation and included men and women between 35 and 75 years of age who were classied as low to moderate risk7 and lived #30 miles from the facility.,patients recruited 2 weeks entering cardiac rehabilitation included women 35 75 age classied low moderate risk7 lived #30 miles facility,C0030705|G0000000|G0000000|C0439230|C1522196|C0018787|C0034991|C0332257|C0043210|C0450371|C0450371|C0001779|G0000000|C0205251|C0205081|G0000000|C1548795|C0450371|C0331865|C1547538
"Women were excluded if they were already in second stage of labour on admission or presented with a condition that, according to the doctor on duty, contraindicated labouring (eg, antepartum haemorrhage); if there was a diagnosis of intrauterine fetal death on admission; or if the woman was admitted for an elective caesarean delivery.",women excluded stage labour admission condition doctor duty contraindicated labouring antepartum haemorrhage diagnosis intrauterine fetal death admission woman admitted elective caesarean delivery,C0043210|C1554077|C0205390|C0022864|C0184666|C0012634|C0031831|G0000000|C1444657|C0022864|C0456336|C0019080|C0011900|C0694756|C0015965|C0011065|C0184666|C0043210|C0184666|C0206058|C3841297|C0011209
"Patients with prior myocardial infarction, CHF, or other cardiomyopathy were also excluded.",patients prior myocardial infarction chf cardiomyopathy excluded,C0030705|C0332152|C0027061|C0021308|C0018802|C0878544|C1554077
Patients still receiving doxorubicin therapy or whose doxorubicin dose was reduced for cardiac reasons during the treatment course and before the last follow-up echocardiogram were excluded.,patients receiving doxorubicin therapy doxorubicin dose reduced cardiac reasons treatment follow-up echocardiogram excluded,C0030705|C1514756|C0013089|C0039798|C0013089|C0178602|C0392756|C0018787|C0392360|C0039798|C0589120|C0013516|C1554077
903 patients with established coronary heart disease registered with one of 48 practices.,903 patients established coronary heart disease registered 48 practices,C1442061|C0030705|C0443211|C0018787|C0018787|C0012634|C1514821|C0450371|C0237607
"Our patients were representative of patients included in the major heart failure trials as regards baseline characteristics and medications used, although h-blockers were underused, in accordance with prescribing practice at the time the study was initiated.",patients representative patients included major heart failure trials baseline characteristics medications h-blockers underused prescribing practice time study initiated,C0030705|C1882932|C0030705|C0332257|C0205082|C0018787|C0231174|C0008976|C0168634|C1521970|C0013227|C0033727|G0000000|C0278329|C0237607|C0040223|C0557651|C1548602
"Eligible patients were 18 years of age or older and  had normal sinus rhythm, no contraindication to  warfarin therapy, and an LVEF of 35% or less as  assessed by quantitative echocardiography (or a  wall-motion index of 1.2) or as assessed by radionuclide or contrast ventriculography within  3 months before randomization.",eligible patients 18 age normal sinus rhythm contraindication warfarin therapy lvef 35% assessed quantitative echocardiography wall-motion 12 assessed radionuclide contrast ventriculography 3 months randomization,C1548635|C0030705|C0450371|C0001779|C0205307|C0016169|C0871269|C0522473|C0043031|C0039798|C0428772|C0450371|C1516048|C0392762|C0013516|C1980023|C0450371|C1516048|C0034595|C0009924|C0007800|G0000000|C0439231|C0034656
"Several exclusion criteria applied:  bilateral  breast  cancer;  metastases  (other  than  in  ipsilateral supraclavicular nodes); previous treatment for  invasive  malignant  disease;  previous  or  concurrent  malignant disease other than basal-cell carcinoma of the  skin  or  in-situ  cervical  cancer;  pregnancy  or  lactation;  use of other investigational drugs within the past 30 days;  and other serious illness or medical disorders including  cardiac  failure,  New  York  Heart  Association  (NYHA)  class II or higher.",exclusion criteria applied bilateral breast cancer metastases ipsilateral supraclavicular nodes previous treatment invasive malignant disease previous concurrent malignant disease basal-cell carcinoma skin in-situ cervical cancer pregnancy lactation investigational drugs 30 days illness medical disorders including cardiac failure york heart association nyha class ii,C0680251|C0243161|C4048755|C0238767|C0006141|C0006826|C0027627|C0441989|C0589496|C0746922|C0205156|C0039798|C0205281|C0205282|C0012634|C0205156|C0205420|C0205282|C0012634|C0596155|C0007097|C0444099|C0444498|C0027530|C0006826|C0032961|C0006147|C1517586|C0013227|C0450371|C0439228|C0221423|C0199168|C0012634|C0332257|C0018787|C0231174|G0000000|C0018787|C0004083|G0000000|C0456387|G0000000
Patients were excluded if they did not have an active mobile phone or sufficient English language proficiency to read text messages.,patients excluded active mobile phone sufficient english language proficiency read text messages,C0030705|C1554077|C0205177|C0231435|C1515258|C0205410|C0376245|C0023008|G0000000|C0034754|C1527021|C0470166
"Criteria for exclusion included distant metastases, severe hypertension, and cardiac disease (cardiac failure of any degree, arrhythmia requiring regular medication, and myocardial infarction within the previous 12 months).",criteria exclusion included distant metastases severe hypertension cardiac disease cardiac failure degree arrhythmia requiring regular medication myocardial infarction previous 12 months,C0243161|C0680251|C0332257|C0443203|C0027627|C0205082|C0020538|C0018787|C0012634|C0018787|C0231174|C0441889|C0003811|G0000000|C0205272|C0013227|C0027061|C0021308|C0205156|C0450371|C0439231
"Potential  participants  were  identified  through  physician practices affiliated with six medical centers in Southeastern Michigan  and  met  the  following  study  criteria:  aged  60 years or older, diagnosed with cardiac disease treated daily by at least one medication, and seen by a physician approximately every 6 months.",potential participants identified physician practices affiliated medical centers southeastern michigan met study criteria aged 60 diagnosed cardiac disease treated daily medication physician 6 months,C3245505|C0679646|C0205396|C0031831|C0237607|C1510825|C0199168|C0205099|C1711190|C0025939|C0268621|C0557651|C0243161|C0001779|C0450371|C0011900|C0018787|C0012634|C1522326|C0332173|C0013227|C0031831|G0000000|C0439231
Patients and Methods High-risk node-negative or low-risk node-positive breast cancer patients received AC given: (arm I) concurrently (AC) doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 intravenously (IV) every 3 weeks for six cycles; or (arm II) in sequence (A 3 C) doxorubicin 40.5 mg/m2 IV days 1 and 2 every 3 weeks for four cyles followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles.,patients methods high-risk node-negative low-risk node-positive breast cancer patients received ac arm concurrently ac doxorubicin 54 mg/m2 cyclophosphamide 12 g/m2 intravenously iv 3 weeks cycles arm ii sequence 3 doxorubicin 405 mg/m2 iv days 1 2 3 weeks cyles cyclophosphamide 24 gm/m2 iv 2 weeks cycles,C0030705|C0025663|C0332167|C0678034|C3272281|C0746319|C0006141|C0006826|C0030705|C1514756|C0003354|C0446516|G0000000|C0003354|C0013089|C0450371|C0026410|C0010583|C0450371|C0439267|G0000000|C0022326|G0000000|C0439230|C1511572|C0446516|G0000000|C0004793|G0000000|C0013089|C1442061|C0026410|C0022326|C0439228|G0000000|G0000000|G0000000|C0439230|G0000000|C0010583|C0450371|C0017480|C0022326|G0000000|C0439230|C1511572
"The FARMI (Five French Arterial access with Reopro in Myocardial Infarction) prospective and randomised trial was therefore designed to compare the radial and femoral approaches to PCI using abciximab and 5 French guidingcatheters, in AMI.",farmi french arterial access reopro myocardial infarction prospective randomised trial designed compare radial femoral approaches pci abciximab 5 french guidingcatheters ami,G0000000|C0376246|C0003842|C0444454|C0592046|C0027061|C0021308|C0023981|G0000000|C0008976|C1707689|C1707455|C0442038|C0015811|C0449445|C4049621|C0288672|G0000000|C0376246|G0000000|G0000000
"Each patient underwent detailed preoperative evaluation by the trial coordinator, including full medical history, examination of affected limb with palpation of pulses, and recording of ankle-brachial pressure",patient underwent detailed preoperative evaluation trial coordinator including medical history examination limb palpation pulses recording ankle-brachial pressure,C0030705|G0000000|C1522508|C0445204|C0220825|C0008976|C1711307|C0332257|C0199168|C0019664|G0000000|C0015385|C0030247|C0034107|G0000000|C0003086|C0033095
"All patients underwent symptom-limited graded exercise testing assessed via a modied Bruce protocol. Blood pressure, heart rate, and 12-lead electrocardiogram data were measured continuously throughout the test.",patients underwent symptom-limited graded exercise testing assessed modied bruce protocol blood pressure heart rate 12-lead electrocardiogram data measured continuously test,C0030705|G0000000|C1457887|C0441800|C0015259|C0039593|C1516048|C0342276|C1332417|C0442711|C0005767|C0033095|C0018787|C0871208|C0450371|C0013798|C1511726|C0444706|G0000000|C0022885
Inclusion criteria Indication for articial graft of at least 20 cm length with proximal anastomosis at the femoral artery.,inclusion criteria indication articial graft 20 cm length proximal anastomosis femoral artery,C0007637|C0243161|C0392360|G0000000|C0181074|C0450371|G0000000|C1444754|C0205107|C0332853|C0015811|C0003842
"Exclusion criteria were previous ipsilateral femoro-popliteal procedures, contraindication to long-term anticoagulant therapy, life expectancy less than 1 year and current treatment with chemotherapy or radiotherapy.",exclusion criteria previous ipsilateral femoro-popliteal procedures contraindication long-term anticoagulant therapy life expectancy 1 current treatment chemotherapy radiotherapy,C0680251|C0243161|C0205156|C0441989|C0545765|C0025664|C0522473|C0443252|C0003280|C0039798|C0376558|C0679138|G0000000|C0521116|C0039798|C0013216|C0034619
"To be eligible, patients had to have histologically proven  locally  advanced  breast  cancer,  dened  as  T3N1  or  T4  (skin or nipple invasion, peaudorange, extension into  chest  wall  or  inammatory  carcinoma),  or  any  T  plus  N2  or  N3,  or  any  T  plus  involvement  of  ipsilateral  supraclavicular nodes.",eligible patients histologically proven locally advanced breast cancer dened t3n1 t4 skin nipple invasion peaudorange extension chest wall inammatory carcinoma n2 n3 involvement ipsilateral supraclavicular nodes,C1548635|C0030705|C0205462|C0456369|C1517927|C0205179|C0006141|C0006826|G0000000|G0000000|C0041403|C0444099|C0028109|C1269955|G0000000|C0231448|C0817096|C0677535|G0000000|C0007097|C0445085|C0445085|C1314939|C0441989|C0589496|C0746922
"Between December 2000 and September 2003, 815 consecutive patients admitted with acute myocardial infarction were assessed (Fig. 1); 279 had an uncomplicated acute myocardial infarction without significant comorbidity.",december 2000 september 2003 815 consecutive patients admitted acute myocardial infarction assessed fig 1 279 uncomplicated acute myocardial infarction comorbidity,C3830550|G0000000|C3828193|G0000000|C1442061|C1707491|C0030705|C0184666|C0205178|C0027061|C0021308|C1516048|C0349966|G0000000|C1442061|C0443334|C0205178|C0027061|C0021308|C0009488
"Exclusion criteria were infants: 1) with known congenital anomalies; 2) with severe periventricular/intraventricular hemorrhage ($Grade III); 3) who had undergone minor or major surgery; 4) who were receiving sedation or vasopressors or analgesics to control for the effect of sedative medication on pain responses; 5) whose mothers had positive drug abuse history during pregnancy to control for the effects on pain responses; and 6) with any signs of tissue breakdown or inammation/necrosis of either heel, because tissue damage increases pain responsiveness.52 Tissue breakdown was measured by the Neonatal Skin Condition Score.38 Infants with a score of 5 or above were excluded from the study.",exclusion criteria infants 1 congenital anomalies 2 severe periventricular/intraventricular hemorrhage grade iii 3 undergone minor major surgery 4 receiving sedation vasopressors analgesics control sedative medication pain responses 5 mothers positive drug abuse history pregnancy control effects pain responses 6 signs tissue breakdown inammation/necrosis heel tissue damage increases pain responsiveness52 tissue breakdown measured neonatal skin condition score38 infants score 5 excluded study,C0680251|C0243161|C0021270|G0000000|C0009678|C0000769|G0000000|C0205082|C1517569|C0019080|C0441800|C0439070|G0000000|G0000000|C0026193|C0205082|C0038894|G0000000|C1514756|C0235195|C0042397|C0002771|C0243148|C0020592|C0013227|C0030193|C0871261|G0000000|C0026591|C0439178|C0013227|C0013146|C0019664|C0032961|C0243148|C1280500|C0030193|C0871261|G0000000|C0220912|C0040300|C0443161|C0027540|C0018870|C0040300|C0010957|C0205217|C0030193|G0000000|C0040300|C0443161|C0444706|C1552240|C0444099|C0012634|G0000000|C0021270|C0449820|G0000000|C1554077|C0557651
The main clinical inclusion criteria were the presence of ischemic chest pain started less than 12 hours before hospital admission and/or ST-segment elevation of at least 1 mm in two or more contiguous electrocardiographic leads (peripheral leads) or 2 mm in the pre-,main clinical inclusion criteria presence ischemic chest pain started 12 hours hospital admission and/or st-segment elevation 1 mm contiguous electrocardiographic leads peripheral leads 2 mm pre-,C0205225|C0205210|C0007637|C0243161|C0150312|C0475224|C0817096|C0030193|C1272689|C0450371|C0439227|C0019994|C0184666|G0000000|C0429029|C0439775|G0000000|G0000000|C0205283|C0013798|C0023175|C0205100|C0023175|G0000000|G0000000|C0332152
"Overall, 84.3% of patients were male, and the mean (SD) age was 56.9 (10.9) years.",843% patients male sd age 569 109,C1442061|C0030705|C0086582|C2699239|C0001779|C1442061|C1442061
Preterm  infants  were  recruited  from  a  level  III  NICU  at  a large  teaching  hospital  in  northeast  China  from  May 2012  to  October  2013.,preterm infants recruited level iii nicu teaching hospital northeast china 2012 october 2013,C0151526|C0021270|G0000000|C0441889|C0439070|C0021709|C0039401|C0019994|C1709272|C0008115|G0000000|C3828732|G0000000
Infants were evenly distributed between genders.,infants distributed genders,C0021270|C1704711|C0079399
Patients were recruited from those presenting with STEMI at 7 U.K. interventional centers.,patients recruited stemi 7 uk interventional centers,C0030705|G0000000|C3538872|G0000000|C0041700|C1948041|C0205099
987 consecutive patients admitted to the coronary angiography laboratory at our institution for coronary angiography with the suspicion of coronary artery disease (CAD) were screened and 873 eligible patients were randomized either to TRA or to TFA.,987 consecutive patients admitted coronary angiography laboratory institution coronary angiography suspicion coronary artery disease cad screened 873 eligible patients randomized tra tfa,C1442061|C1707491|C0030705|C0184666|C0018787|C0002978|C0022877|C0018704|C0018787|C0002978|C0242114|C0018787|C0003842|C0012634|C3813548|C0220908|C1442061|C1548635|C0030705|C0034656|C0040845|C0040982
Participants Individuals presenting with chest pain of less than 12 h  duration and ST-segment elevation greater than 01 mV in at least two contiguous leads were initially randomised to  primary PCI done with a deferred strategy of stent implantation or mechanical postconditioning versus conventional treatment consisting of conventional primary PCI (appendix p 4).,participants individuals chest pain 12 duration st-segment elevation 01 mv contiguous leads initially randomised primary pci deferred strategy stent implantation mechanical postconditioning versus conventional treatment consisting conventional primary pci appendix 4,C0679646|C0027361|C0817096|C0030193|C0450371|C0449238|C0429029|C0439775|C0450371|C0428679|C0205283|C0023175|C0205265|G0000000|C0205225|C4049621|C0205421|C0679199|C0038257|C0021107|C0443254|G0000000|G0000000|C0439858|C0039798|C0332529|C0439858|C0205225|C4049621|C0003617|G0000000
"In the United Kingdom an estimated 260,000 people have an acute myocardial infarction every year.",united kingdom estimated 260000 people acute myocardial infarction,C0166872|C1708611|C0750572|G0000000|C0027361|C0205178|C0027061|C0021308
Four hundred consecutive patients 75 years with known or suspected coronary artery disease were included in the study.,consecutive patients 75 suspected coronary artery disease included study,C1707491|C0030705|C0450371|C0332147|C0018787|C0003842|C0012634|C0332257|C0557651
"Briey,  children  with newly diagnosed ALL from nine centres in the USA,  Canada, and Puerto Rico were enrolled between January,  1996, and September, 2000.",briey children newly diagnosed centres usa canada puerto rico enrolled january 1996 september 2000,G0000000|C0008059|C0750546|C0011900|C0205099|C0041703|C0006823|G0000000|G0000000|G0000000|C3829466|G0000000|C3828193|G0000000
"Women eligible for the study presented an axillary nodepositive, nonmetastatic unilateral breast adenocarcinoma.",women eligible study axillary nodepositive nonmetastatic unilateral breast adenocarcinoma,C0043210|C1548635|C0557651|C0004454|G0000000|C1518409|C0205092|C0006141|C0001418
"Patients were excluded if they had any of the following: complicating serious co-morbidity such as a psychiatric illness or untreated malignancy, neurological disorder with impaired cognition, or inability to read or understand English.",patients excluded complicating co-morbidity psychiatric illness untreated malignancy neurological disorder impaired cognition inability read understand english,C0030705|C1554077|C0231242|C0009488|C0205487|C0221423|C0332155|C0006826|C0205494|C0012634|C0221099|C0009240|G0000000|C0034754|C0162340|C0376245
Men and women 18 years old or older with a history and clinical findings of heart failure for at least three months before screening were eligible.,women 18 history clinical findings heart failure months screening eligible,C0043210|C0450371|C0019664|C0205210|C2607943|C0018787|C0231174|C0439231|C0220908|C1548635
"Other exclusion criteria were: emergency surgery for trauma, acute thrombosis or embolism of the popliteal artery, the diagnosis or treatment for malignancy within 12 months, hospital in-patient treatment for cardiac failure in the previous six months, the absence of the possibility for adequate follow-up or for anticoagulant drug therapy.",exclusion criteria emergency surgery trauma acute thrombosis embolism popliteal artery diagnosis treatment malignancy 12 months hospital in-patient treatment cardiac failure previous months absence possibility adequate follow-up anticoagulant drug therapy,C0680251|C0243161|C0013956|C0038894|C0043251|C0205178|C0040053|C0013922|C0442037|C0003842|C0011900|C0039798|C0006826|C0450371|C0439231|C0019994|C0150312|C0039798|C0018787|C0231174|C0205156|C0439231|C0332197|C0332149|C0205410|C0589120|C0003280|C0013227|C0039798
"Women with a left ventricular ejection fraction  (LVEF) of less than 55% after completion of chemotherapy  and  radiotherapy,  congestive  cardiac  failure,  or  other  major cardiac problems8 were excluded.",women left ventricular ejection fraction lvef 55% completion chemotherapy radiotherapy congestive cardiac failure major cardiac problems8 excluded,C0043210|C0205091|C0018827|C0302131|C1264633|C0428772|C0450371|C0205197|C0013216|C0034619|C0742742|C0018787|C0231174|C0205082|C0018787|G0000000|C1554077
"Methods: Using a randomized crossover design, preterm neonates (n = 18) between 28 and 37 weeks gestational age within 10 days of life from two university-afliated level III NICUs undergoing routine heel lance were assigned to receive KC 30 min before and during the procedure from either their mother (MKC) or an unrelated woman.",methods randomized crossover design preterm neonates = 18 28 37 weeks gestational age 10 days life university-afliated level iii nicus undergoing routine heel lance assigned receive kc 30 min procedure mother mkc unrelated woman,C0025663|C0034656|C0010366|C1707689|C0151526|C0021289|G0000000|C0450371|C0450371|C0450371|C0439230|C0439671|C0001779|C0450371|C0439228|C0376558|C0041740|C0441889|C0439070|C0021709|G0000000|C0205547|C0018870|C0522666|C1516050|C1514756|C0022575|C0450371|C0702093|C0184661|C0026591|G0000000|C0445356|C0043210
This study sought to compare radial and femoral approaches in patients presenting with ST-segment elevation myocardial infarction (STEMI) and undergoing primary percutaneous coronary intervention (PCI) by high-volume operators experienced in both access sites.,study sought compare radial femoral approaches patients st-segment elevation myocardial infarction stemi undergoing primary percutaneous coronary intervention pci high-volume operators experienced access sites,C0557651|G0000000|C1707455|C0442038|C0015811|C0449445|C0030705|C0429029|C0439775|C0027061|C0021308|C3538872|G0000000|C0205225|C0522523|C0018787|C0886296|C4049621|C0205250|C1705273|C0237607|C0444454|C0205145
"We  enrolled  patients,  from  June,  1997,  to  May,  1998,  aged 60 years  or  older  (we  required  that  85%  be  aged  >65  years) with  NYHA  class  IIIV  heart  failure  and  left-ventricular ejection fraction of 40% or less, measured by echocardiography or  radionuclear  ventriculography.",enrolled patients june 1997 1998 aged 60 required 85% aged 65 nyha class iiiv heart failure left-ventricular ejection fraction 40% measured echocardiography radionuclear ventriculography,G0000000|C0030705|C3829443|G0000000|G0000000|C0001779|C0450371|C1514873|C0450371|C0001779|C0450371|G0000000|C0456387|G0000000|C0018787|C0231174|C0225897|C0302131|C1264633|C0450371|C0444706|C0013516|G0000000|C0007800
"Patients were ineligible for  RIVAL if they presented with cardiogenic shock, severe  peripheral vascular disease precluding a  femoral  approach, or previous coronary bypass surgery with use of more than one internal mammary artery.",patients ineligible rival cardiogenic shock severe peripheral vascular disease precluding femoral approach previous coronary bypass surgery internal mammary artery,C0030705|C1512714|G0000000|C1749797|C0036974|C0205082|C0205100|C0005847|C0012634|G0000000|C0015811|C0449445|C0205156|C0018787|C0741847|C0038894|C0205102|C0006141|C0003842
"All patients received heparin intra-operatively, and, in 224 limbs, the anastomoses of the bypass grafts were performed with prolene.",patients received heparin intra-operatively 224 limbs anastomoses bypass grafts performed prolene,C0030705|C1514756|C0019134|C0347985|C1442061|C0015385|C0332853|C0741847|C0332835|C0884358|C0917843
Patients diagnosed with malignancy and planned ANT therapy (adriamycin or epirubicin) in the oncology department of the Erciyes University Medical School between September 2003 and October 2004 were enrolled.,patients diagnosed malignancy planned ant therapy adriamycin epirubicin oncology department erciyes university medical school september 2003 october 2004 enrolled,C0030705|C0011900|C0006826|C1301732|C0003455|C0039798|C0085752|C0014582|C0027651|C1704729|G0000000|C0041740|C0199168|C0036375|C3828193|G0000000|C3828732|G0000000|G0000000
"Recently, we reported about the favorable preliminary results of b-blocker treatment in six infants with severe congestive heart failure due to left-to-right shunts [11].",reported favorable preliminary b-blocker treatment infants severe congestive heart failure left-to-right shunts 11,C0684224|C3640814|C0439611|G0000000|C0039798|C0021270|C0205082|C0742742|C0018787|C0231174|C0439757|C0232180|C0450371
Preterm neonates (n = 61) between 28 0/7 and 31 6/7 weeks gestational age in three Level III NICU's in Canada comprised the sample.,preterm neonates = 61 28 0/7 31 6/7 weeks gestational age level iii nicus canada comprised sample,C0151526|C0021289|G0000000|C0450371|C0450371|G0000000|C0450371|G0000000|C0439230|C0439671|C0001779|C0441889|C0439070|C0021709|C0006823|C2700400|C0370003
"Included were all patients with disabling claudication, rest pain, or tissue-loss who underwent arterial reconstruction.",included patients disabling claudication rest pain tissue-loss underwent arterial reconstruction,C0332257|C0030705|G0000000|C0311395|C0035253|C0030193|C0040300|G0000000|C0003842|C0020912
"Patients were included if they had ACS with or without ST segment elevation, an invasive approach was planned, the interventional cardiologist was willing to proceed with either radial or femoral access (and had expertise for both, including at least 50 radial procedures for coronary angiography or intervention within the previous year), and dual circulation of the hand was intact as assessed by an Allen's test.",patients included acs st segment elevation invasive approach planned interventional cardiologist proceed radial femoral access expertise including 50 radial procedures coronary angiography intervention previous dual circulation hand intact assessed allens test,C0030705|C0332257|G0000000|C0036056|C0441635|C0439775|C0205281|C0449445|C1301732|C1948041|C0175906|G0000000|C0442038|C0015811|C0444454|C0870520|C0332257|C0450371|C0442038|C0025664|C0018787|C0002978|C0886296|C0205156|C1554184|C0005775|C0018563|C0205266|C1516048|G0000000|C0022885
"Thus, 70 patients (group A) and 56 patients (group B) entered the study.",70 patients 56 patients entered study,C0450371|C0030705|C0450371|C0030705|C1521975|C0557651
"Patients 75 years old, diabetics (fasting blood glucose 125 mg/dl), patients with postcoronary artery bypass graft, known malignant disease, serious kidney or liver dysfunction (creatimine 1.5 mg/dl, alanine aminotransferase and aspartate aminotransferase 2 times normal value), or women of child-bearing age not using a reliable form of contra-ception were excluded.",patients 75 diabetics fasting blood glucose 125 mg/dl patients postcoronary artery bypass graft malignant disease kidney liver dysfunction creatimine 1 5 mg/dl alanine aminotransferase aspartate aminotransferase 2 times normal women child-bearing age reliable form contra-ception excluded,C0030705|C0450371|C0241863|C0015663|C0005767|C0017725|C1442061|C0439269|C0030705|G0000000|C0003842|C0741847|C0181074|C0205282|C0012634|C0022646|C0023884|C0031847|G0000000|G0000000|G0000000|C0439269|C0001898|C0002594|C0085845|C0002594|G0000000|C0040223|C0205307|C0043210|C0008059|C0001779|C3858758|C0348078|G0000000|C1554077
"Fifty-five patients (44%) had an acute infarction, 37 (67%) of those also had undergone angioplasty, and the remaining 71 patients (56%) were enrolled after angioplasty only.",fifty-five patients 44% acute infarction 37 67% undergone angioplasty remaining 71 patients 56% enrolled angioplasty,C3816723|C0030705|C0450371|C0205178|C0021308|C0450371|C0450371|G0000000|C0162577|C1527428|C0450371|C0030705|C0450371|G0000000|C0162577
Objective To compare the efcacy of oral with vaginal misoprostol for induction of labour at term.,objective compare efcacy oral vaginal misoprostol induction labour term,C0018017|C1707455|G0000000|C0442027|C0042232|C0085174|C0205263|C0022864|C0233324
A total of 160 women completed the study.,total 160 women completed study,C0439175|C1442061|C0043210|C0205197|C0557651
"Exclusion criteria included previous uterine scar, oligohydramnios (amniotic uid index ,2.5 th centile) 19 , intrauterine growth restriction (estimated fetal weight ,10 th centile) 20 , prelabour rupture of membranes, multifetal pregnancy, and cervix favourable for amniotomy.",exclusion criteria included previous uterine scar oligohydramnios amniotic uid 2 5 centile 19 intrauterine growth restriction estimated fetal weight 10 centile 20 prelabour rupture membranes multifetal pregnancy cervix favourable amniotomy,C0680251|C0243161|C0332257|C0205156|C0042149|C0241158|C0079924|C0002630|C2349022|G0000000|G0000000|G0000000|C0450371|C0694756|C0018270|C0443288|C0750572|C0015965|C0005910|C0450371|G0000000|C0450371|G0000000|C1881712|C0025255|G0000000|C0032961|C0007874|C3640814|G0000000
"In total, 103 patients were recruited, 51 in the misoprostol group and 52 in the placebo group.",total 103 patients recruited 51 misoprostol 52 placebo,C0439175|C1442061|C0030705|G0000000|C0450371|C0085174|C0450371|C0032042
The aim of this study was to examine the efficacy of oral misoprostol as an oxytocic agent in women with PROM and to monitor the incidence of adverse maternal and fetal effects in the treatment arm of the study.,aim study examine efficacy oral misoprostol oxytocic agent women prom monitor incidence adverse maternal fetal effects treatment arm study,C1947946|C0557651|G0000000|C1280519|C0442027|C0085174|C0030094|C0450442|C0043210|C0015944|C0030695|C0021149|G0000000|C2347083|C0015965|C1280500|C0039798|C0446516|C0557651
Only patients who had weak-to-moderate staining of the entire tumor-cell membrane for HER2 (referred to as a score of 2+) or more than moderate staining (referred to as a score of 3+) in more than 10 percent of tumor cells on immunohistochemical analysis were eligible for the study.,patients weak-to-moderate staining entire tumor-cell membrane her2 referred score 2+ moderate staining referred score 3+ 10 percent tumor cells immunohistochemical analysis eligible study,C0030705|C1762617|C0487602|C0439751|C0431085|C0025255|G0000000|C0205543|C0449820|G0000000|C0205081|C0487602|C0205543|C0449820|G0000000|C0450371|C0439165|C0027651|C0007634|C1441616|C0002778|C1548635|C0557651
We randomly assigned 234 patients to receive standard chemotherapy alone and 235 patients to receive standard chemotherapy plus trastuzumab.,randomly assigned 234 patients receive standard chemotherapy 235 patients receive standard chemotherapy trastuzumab,G0000000|C1516050|C1442061|C0030705|C1514756|C1442989|C0013216|C1442061|C0030705|C1514756|C1442989|C0013216|C0728747
Patients were also excluded if they were pregnant or had received any type of investigational agent within 30 days before the study began.,patients excluded pregnant received type investigational agent 30 days study,C0030705|C1554077|C0549206|C1514756|C0332307|C1517586|C0450442|C0450371|C0439228|C0557651
Women with progressive metastatic breast cancer that overexpressed HER2 who had not previously received chemotherapy for metastatic disease were eligible for the study.,women progressive metastatic breast cancer overexpressed her2 received chemotherapy metastatic disease eligible study,C0043210|C0205329|C0036525|C0006141|C0006826|C1514559|G0000000|C1514756|C0013216|C0036525|C0012634|C1548635|C0557651
"Patients were excluded if they had bilateral breast cancer, untreated brain metastases, osteoblastic bone metastases, pleural effusion or ascites as the only evidence of disease, a second type of primary cancer, or a Karnofsky score of less than 60.",patients excluded bilateral breast cancer untreated brain metastases osteoblastic bone metastases pleural effusion ascites evidence disease type primary cancer karnofsky score 60,C0030705|C1554077|C0238767|C0006141|C0006826|C0332155|C0006104|C0027627|G0000000|C0262950|C0027627|C0032225|C0013687|C0003962|C3887511|C0012634|C0332307|C0205225|C0006826|C0206065|C0449820|C0450371
Eligible patients were adults aged 18 years or older with chest pain or discomfort of at least 15 minutes' duration that occurred at rest or with minimal exertion within the 24-hour period preceding hospitalization and represented a change from their usual anginal pattern.,eligible patients adults aged 18 chest pain discomfort 15 minutes duration occurred rest minimal exertion 24-hour period preceding hospitalization represented change usual anginal pattern,C1548635|C0030705|C0001675|C0001779|C0450371|C0817096|C0030193|C0231218|C0450371|C0439232|C0449238|C1709305|C0035253|C0547040|C0015264|C0450371|C0439531|C0332152|C0019993|C1882932|C0392747|C3538928|C0002962|C0449774
Patients A total of 3086 adults aged 18 years or older with unstable angina or non-Q-wave acute myocardial infarction.,patients total 3086 adults aged 18 unstable angina non-q-wave acute myocardial infarction,C0030705|C0439175|G0000000|C0001675|C0001779|C0450371|C0443343|C0002962|C1518422|C0205178|C0027061|C0021308
A normal fetal heart tracing and a cervical Bishops score of less than 8 were also criteria for inclusion.,normal fetal heart tracing cervical bishops score 8 criteria inclusion,C0205307|C0015965|C0018787|G0000000|C0027530|C0649610|C0449820|G0000000|C0243161|C0007637
"Two hundred and forty-ve women were recruited for the trial, marginally over the intended sample size.",forty-ve women recruited trial marginally intended sample size,C3816449|C0043210|G0000000|C0008976|G0000000|C1283828|C0370003|C0456389
Objective To compare the efcacy of equivalent doses of orally administered with vaginally administered misoprostol in induction of labour at term.,objective compare efcacy equivalent doses orally administered vaginally administered misoprostol induction labour term,C0018017|C1707455|G0000000|C0205163|C0178602|C0442027|C1521801|G0000000|C1521801|C0085174|C0205263|C0022864|C0233324
"Participants Two hundred and forty-ve pregnant women at term, with medical or obstetric indications for labour induction and unfavourable cervices.",participants forty-ve pregnant women term medical obstetric indications labour induction unfavourable cervices,C0679646|C3816449|C0549206|C0043210|C0233324|C0199168|C0205484|C0392360|C0022864|C0205263|C3640815|C0007874
"Women with previous uterine surgery including a previous caesarean section, with signicant fetal or medical concerns or known contraindications to the use of prostaglandins were excluded.",women previous uterine surgery including previous caesarean signicant fetal medical concerns contraindications prostaglandins excluded,C0043210|C0205156|C0042149|C0038894|C0332257|C0205156|C3841297|G0000000|C0015965|C0199168|C2699424|C0079164|C0033554|C1554077
"They had not received any therapy, including phototherapy, at least 2 months before the study.",received therapy including phototherapy 2 months study,C1514756|C0039798|C0332257|C0031765|G0000000|C0439231|C0557651
"We aimed to assess endothelin-1 (ET-1), a potent melanocyte mitogen, in plasma of PUVA-treated paients with vitiligo.",aimed assess endothelin-1 et-1 potent melanocyte mitogen plasma puva-treated paients vitiligo,C1947946|C1516048|C0079284|G0000000|C3245505|C0025201|C0018284|C0032105|C0853073|G0000000|C0042900
METHODS We studied 118 consecutive patients with coronary artery disease (mean age 57  10 years) who underwent PTCA or CS on one (69%) or two (31%) native epicardial coronary arteries.,methods studied 118 consecutive patients coronary artery disease age 57 10 underwent ptca cs 69% 31% native epicardial coronary arteries,C0025663|C0557651|C1442061|C1707491|C0030705|C0018787|C0003842|C0012634|C0001779|C0450371|C0450371|G0000000|C2936173|C0010182|C0450371|C0450371|C0302891|C0442016|C0018787|C0003842
"Primary angioplasty, defined as angioplasty without thrombolytic therapy, was performed 148  63 min after the onset of an acute myocardial infarction (AMI) in 23 patients (11 in group T, 12 in group C).",primary angioplasty defined angioplasty thrombolytic therapy performed 148 63 min onset acute myocardial infarction ami 23 patients 11 12,C0205225|C0162577|C1704788|C0162577|C0016018|C0039798|C0884358|C1442061|C0450371|C0702093|C0206132|C0205178|C0027061|C0021308|G0000000|C0450371|C0030705|C0450371|C0450371
"OBJECTIVES The goal of this study was to determine the effects of exercise training (ET) on functional capacity and quality of life (QOL) in patients who received percutaneous transluminal coronary angioplasty (PTCA) or coronary stenting (CS), the effects on the restenosis rate and the outcome.",objectives goal study determine effects exercise training functional capacity quality life qol patients received percutaneous transluminal coronary angioplasty ptca coronary stenting cs effects restenosis rate outcome,C0018017|C0018017|C0557651|G0000000|C1280500|C0015259|C0040607|C0205245|C1516240|C0332306|C0376558|C0518214|C0030705|C1514756|C0522523|C0522520|C0018787|C0162577|C2936173|C0018787|C0038257|C0010182|C1280500|C0333186|C0871208|C1274040
"Approval was obtained from the Orlando Regional Investigational Review Committee; candidates had a singleton live gestation, Bishop score 2 under 7, estimated fetal weight under 4500 g, and gestational age exceeding 24 weeks.",approval orlando regional investigational review committee candidates singleton live gestation bishop score 2 7 estimated fetal weight 4500 gestational age exceeding 24 weeks,C0205540|G0000000|C0205147|C1517586|C0282443|C2699414|G0000000|C0481462|C1548795|C0032961|C1551458|C0449820|G0000000|G0000000|C0750572|C0015965|C0005910|G0000000|C0439671|C0001779|G0000000|C0450371|C0439230
"However, after a review of the overall rates of events among the first 3000 patients, the steering committee recommended that we enroll only patients who had either electrocardiographic changes or an elevation in the serum level of cardiac enzymes or markers at entry.",review rates events 3000 patients steering committee recommended enroll patients electrocardiographic elevation serum level cardiac enzymes markers entry,C0282443|C0871208|C0441471|G0000000|C0030705|C0553654|C2699414|C0034866|G0000000|C0030705|C0013798|C0439775|C0229671|C0441889|C0018787|C0014442|C0005516|C1705654
We did a multicentre randomised controlled trial to test the hypothesis that intrapartum monitoring with cardiotocography combined with automatic ST-waveform analysis results in an improved perinatal outcome compared with cardiotocography alone.,multicentre randomised controlled trial test hypothesis intrapartum monitoring cardiotocography combined automatic st-waveform analysis improved perinatal outcome compared cardiotocography,C0439743|G0000000|C2587213|C0008976|C0022885|C1512571|C0456337|C0150369|C0007208|C0205195|C0205554|C0036056|C0002778|C0184511|C0178795|C1274040|C1707455|C0007208
"Since the introduction of intrapartum electronic fetal monitoring, intrapartum death has become a rare event, 1 Methods At three Swedish labour wards, 4966 women with term fetuses in the cephalic presentation entered the trial during labour after a clinical decision had been made to apply a fetal scalp electrode for internal cardiotocography.",introduction intrapartum electronic fetal monitoring intrapartum death rare event 1 methods swedish labour wards 4966 women term fetuses cephalic presentation entered trial labour clinical decision apply fetal scalp electrode internal cardiotocography,C1293116|C0456337|C0013850|C0015965|C0150369|C0456337|C0011065|C0521114|C0441471|G0000000|C0025663|C1710263|C0022864|C1305702|G0000000|C0043210|C0233324|C0015965|C0205096|C0449450|C1521975|C0008976|C0022864|C0205210|C0679006|C1632850|C0015965|C0036270|C0013812|C0205102|C0007208
"Eligible participants were women in active labour at more than 36 completed gestational weeks, with singleton fetuses in the cephalic presentation, and about whom a clinical decision had been made to apply a fetal scalp electrode for continuous internal cardiotocography.",eligible participants women active labour 36 completed gestational weeks singleton fetuses cephalic presentation clinical decision apply fetal scalp electrode continuous internal cardiotocography,C1548635|C0679646|C0043210|C0205177|C0022864|C0450371|C0205197|C0439671|C0439230|C0481462|C0015965|C0205096|C0449450|C0205210|C0679006|C1632850|C0015965|C0036270|C0013812|C0549178|C0205102|C0007208
A total of 303 hypertensive patients with echocardiographic LV hypertrophy enrolled in PRESERVE in 28 centers in 10 countries (see Appendix).,total 303 hypertensive patients echocardiographic lv hypertrophy enrolled preserve 28 centers 10 countries appendix,C0439175|C1442061|C0857121|C0030705|C0013516|C0023128|C0020564|G0000000|G0000000|C0450371|C0205099|C0450371|C0454664|C0003617
"Patients with LV ejection fraction 40%, severe valvular disease, or coexisting cardiomyopathy on screening echocardiogram were excluded.",patients lv ejection fraction 40% severe valvular disease coexisting cardiomyopathy screening echocardiogram excluded,C0030705|C0023128|C0302131|C1264633|C0450371|C0205082|C0184252|C0012634|G0000000|C0878544|C0220908|C0013516|C1554077
"Objectives To determine the effects of titrated oral misoprostol solution, compared with vaginal dinoprostone.",objectives determine effects titrated oral misoprostol solution compared vaginal dinoprostone,C0018017|G0000000|C1280500|C1883350|C0442027|C0085174|C0037633|C1707455|C0042232|C0012472
The number of women randomised was 695.,women randomised 695,C0043210|G0000000|C1442061
"The exclusion criteria were: gestation less than 34 weeks, signicant antepartum haemorrhage, previous caesarean section, uncontrolled diabetes mellitus, severe pre-eclampsia or eclampsia and fetal distress.",exclusion criteria gestation 34 weeks signicant antepartum haemorrhage previous caesarean uncontrolled diabetes mellitus severe pre-eclampsia eclampsia fetal distress,C0680251|C0243161|C0032961|C0450371|C0439230|G0000000|C0456336|C0019080|C0205156|C3841297|C0205318|C0011847|G0000000|C0205082|C0032914|C0013537|C0015965|C0231303
Post-term inductions were considered when gestational age was 41 weeks (41 0 weeks).,post-term inductions considered gestational age 41 weeks 41 0 weeks,C1398117|C0857127|C0750591|C0439671|C0001779|C0450371|C0439230|C0450371|G0000000|C0439230
OBJECTIVE: To determine the efficacy of oral misoprostol (50 g) administered every 3 hours compared to vaginal misoprostol (50 g) administered every 6 hours for induction of labor.,objective determine efficacy oral misoprostol 50 administered 3 hours compared vaginal misoprostol 50 administered 6 hours induction labor,C0018017|G0000000|C1280519|C0442027|C0085174|C0450371|C1521801|G0000000|C0439227|C1707455|C0042232|C0085174|C0450371|C1521801|G0000000|C0439227|C0205263|C0022864
"There were 126 patients enrolled in this study, 62 in the oral group and 64 in the vaginal group.",126 patients enrolled study 62 oral 64 vaginal,C1442061|C0030705|G0000000|C0557651|C0450371|C0442027|C0450371|C0042232
"Specific exclusion criteria included oligohydramnios (amniotic fluid index, <2.5th percentile for gestational age), 14 intrauterine growth restriction (estimated fetal weight, <10th percentile for gestational age), abruptio placenta, premature rupture of the membranes, previous uterine scar, prior PG use for cervical ripening/labor induction, and any contraindication to vaginal delivery (eg, active genital herpes).",specific exclusion criteria included oligohydramnios amniotic fluid <2 5th percentile gestational age 14 intrauterine growth restriction estimated fetal weight <10th percentile gestational age abruptio placenta premature rupture membranes previous uterine scar prior pg cervical ripening/labor induction contraindication vaginal delivery active genital herpes,C0205369|C0680251|C0243161|C0332257|C0079924|C0002630|C0005889|G0000000|G0000000|C1264641|C0439671|C0001779|C0450371|C0694756|C0018270|C0443288|C0750572|C0015965|C0005910|G0000000|C1264641|C0439671|C0001779|G0000000|C0032043|C0151526|C1881712|C0025255|C0205156|C0042149|C0241158|C0332152|C1266240|C0027530|C1160534|C0205263|C0522473|C0042232|C0011209|C0205177|C0559522|C0019340
"This was a descriptive observational study using retrospective record review of all pregnant women in the second trimester (14-28 weeks) of pregnancy who failed to abort by misoprostol administration over a period of 12 years, between 1998 and 2010.",descriptive observational study retrospective record review pregnant women trimester 14-28 weeks pregnancy failed abort misoprostol administration period 12 1998 2010,C0678257|C1518527|C0557651|C0035363|C0034869|C0282443|C0549206|C0043210|C0032982|C0450371|C0439230|C0032961|C0231175|C1611646|C0085174|C0001554|C0439531|C0450371|G0000000|G0000000
"All women were admitted in the labor room of the Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.",women admitted labor department obstetrics gynecology faculty medicine chiang mai university chiang mai thailand,C0043210|C0184666|C0022864|C1704729|C0028773|C0018417|C0015535|C0013227|G0000000|C0026914|C0041740|G0000000|C0026914|C0039725
The present study included all women who failed to abort after 48 h of initiation of misoprostol.,study included women failed abort 48 initiation misoprostol,C0557651|C0332257|C0043210|C0231175|C1611646|C0450371|C0589507|C0085174
A total of 680 women underwent termination of pregnancy over the study period of 12 years from 1998 to 2010; 68 (10%) women failed to abort within 48 h of initiation of misoprostol.,total 680 women underwent termination pregnancy study period 12 1998 2010 68 10% women failed abort 48 initiation misoprostol,C0439175|C1442061|C0043210|G0000000|C1549081|C0032961|C0557651|C0439531|C0450371|G0000000|G0000000|C0450371|C0450371|C0043210|C0231175|C1611646|C0450371|C0589507|C0085174
"Misoprostol, a prostaglandin E1 analog, is highly effective for pregnancy termination of early pregnancy and for induction of labor in late pregnancy.",misoprostol prostaglandin e1 analog highly effective pregnancy termination pregnancy induction labor late pregnancy,C0085174|C0033554|C1704625|C0243071|C0205250|C1280519|C0032961|C1549081|C0032961|C0205263|C0022864|C0205087|C0032961
"Misoprostol, a prostaglandin E1 analogue, is an inexpensive and potentially useful drug to women requiring induction of labor.",misoprostol prostaglandin e1 analogue inexpensive drug women requiring induction labor,C0085174|C0033554|C1704625|C0243071|G0000000|C0013227|C0043210|G0000000|C0205263|C0022864
"These included: the presence of thick meconium-stained amniotic fluid, low 5-minute Apgar score (less than 7), admission to the neonatal intensive care unit, or the diagnosis of hypoxic ischemic encephalopathy by the pediatrician.",included presence thick meconium-stained amniotic fluid low 5-minute apgar score 7 admission neonatal intensive care unit diagnosis hypoxic ischemic encephalopathy pediatrician,C0332257|C0150312|C1280412|C1112318|C0002630|C0005889|C0205251|C0439232|C0741195|C0449820|G0000000|C0184666|C1552240|C0162425|C1947933|C0439148|C0011900|C0242184|C0475224|C0006111|C0237433
"However, the lack of any serious adverse events was noteworthy because this study was carried out among a group of women with high-risk pregnancies.",lack adverse events noteworthy study carried women high-risk pregnancies,C0332268|G0000000|C0441471|G0000000|C0557651|C0206243|C0043210|C0332167|C0032961
"From April 1999 to November 2000, all women with obstetric or medical indications for induction of labor were recruited to the trial.",april 1999 november 2000 women obstetric medical indications induction labor recruited trial,C3715024|G0000000|C3828767|G0000000|C0043210|C0205484|C0199168|C0392360|C0205263|C0022864|G0000000|C0008976
OBJECTIVE: To evaluate the efficacy of oral and vaginal misoprostol compared with the standard regimen using dinoprostone for induction of labor.,objective evaluate efficacy oral vaginal misoprostol compared standard regimen dinoprostone induction labor,C0018017|C0220825|C1280519|C0442027|C0042232|C0085174|C1707455|C1442989|C0040808|C0012472|C0205263|C0022864
A total of 573 women were recruited to the study.,total 573 women recruited study,C0439175|C1442061|C0043210|G0000000|C0557651
"Patients who had a Bishop score greater than 7, where amniotomy was possible without the prior use of prostaglandins, were also excluded.",patients bishop score 7 amniotomy prior prostaglandins excluded,C0030705|C1551458|C0449820|G0000000|G0000000|C0332152|C0033554|C1554077
"We excluded patients with secondary hypertension; myocardial infarction or stroke within the previous 6 months; angina pectoris requiring treatment with -blockers or calcium-antagonists; heart failure or left ventricular ejection fraction of 40% or less; or a disorder that, in the treating physician's opinion, required treatment with losartan or another angiotensin-II type 1-receptor antagonist, atenolol or another -blocker, hydrochlorothiazide, or angiotensin-converting-enzyme inhibitors.",excluded patients secondary hypertension myocardial infarction stroke previous 6 months angina pectoris requiring treatment -blockers calcium-antagonists heart failure left ventricular ejection fraction 40% disorder treating physicians opinion required treatment losartan angiotensin-ii type 1-receptor antagonist atenolol -blocker hydrochlorothiazide angiotensin-converting-enzyme inhibitors,C1554077|C0030705|C0027627|C0020538|C0027061|C0021308|C0038454|C0205156|G0000000|C0439231|C0002962|G0000000|G0000000|C0039798|G0000000|C0006684|C0018787|C0231174|C0205091|C0018827|C0302131|C1264633|C0450371|C0012634|C1522326|C0031831|C0871010|C1514873|C0039798|C0126174|C0003009|C0332307|C1421546|C0231491|C0004147|G0000000|C0020261|C0022709|C0243077
"We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death.",aimed establish selective blocking angiotensin ii improves lvh reducing blood pressure reduces cardiovascular morbidity death,C1947946|C0443211|C0036576|C0233660|C0003018|G0000000|C0184511|C0149721|C0392756|C0005767|C0033095|G0000000|C0007226|C0026538|C0011065
"The mean induction to vaginal delivery interval in the oral 50 mgs group in our earlier study (6) was 28 h with a standard deviation of 16 h. Taking a shortening of 7 h in this interval for the 100 mgs group as clinically significant, we calculated that 105 patients would be required to give the study a power of 80% (a  0.02, b  0.20; Instat Version 3.01, GraphPad Software Inc, San Diego CA, USA).",induction vaginal delivery interval oral 50 mgs earlier study 6 28 standard deviation 16 shortening 7 interval 100 mgs clinically calculated 105 patients required study power 80% 0 02 0 20 instat version 3 01 graphpad software san diego usa,C0205263|C0042232|C0011209|C1272706|C0442027|C0450371|C0024467|C1279919|C0557651|G0000000|C0450371|C1442989|C0012727|C0450371|C0441636|G0000000|C1272706|C1442061|C0024467|G0000000|C0444686|C1442061|C0030705|C1514873|C0557651|C0032863|C0450371|G0000000|C0450371|G0000000|C0450371|G0000000|C0333052|G0000000|C0450371|G0000000|C0037585|C1826357|G0000000|C0041703
METHODS: A total of 107 women with clinical indication for induction were randomly assigned to receive oral or vaginal misoprostol.,methods total 107 women clinical indication induction randomly assigned receive oral vaginal misoprostol,C0025663|C0439175|C1442061|C0043210|C0205210|C0392360|C0205263|G0000000|C1516050|C1514756|C0442027|C0042232|C0085174
"Patients with previous uterine surgery, known prostaglandin hypersensitiv- ity, three or more contractions per 10 minutes, nonreassuring fetal heart tracings, and those with vaginal birth contraindications were excluded from participation.",patients previous uterine surgery prostaglandin hypersensitiv- ity contractions 10 minutes nonreassuring fetal heart tracings vaginal birth contraindications excluded participation,C0030705|C0205156|C0042149|C0038894|C0033554|G0000000|G0000000|C1140999|C0450371|C0439232|G0000000|C0015965|C0018787|G0000000|C0042232|C0005615|C0079164|C1554077|C0679823
Patients were eligible for inclusion if they presented with indications for induction and a single live fetus older than 37 weeks' gestation in cephalic presentation and no contraindication to vaginal delivery.,patients eligible inclusion indications induction single live fetus 37 weeks gestation cephalic presentation contraindication vaginal delivery,C0030705|C1548635|C0007637|C0392360|C0205263|C0037179|C1548795|C0015965|C0450371|C0439230|C0032961|C0205096|C0449450|C0522473|C0042232|C0011209
OBJECTIVE: To compare the safety and effectiveness of vag-inal with oral misoprostol for induction of labor.,objective compare safety effectiveness vag-inal oral misoprostol induction labor,C0018017|C1707455|C0036043|C1280519|C0042232|C0442027|C0085174|C0205263|C0022864
"Patients were eligible for enrollment in the study if they had a total cholesterol level between 135 and 270 mg/dL (3.5-7.0 mmol/L), with fasting triglyceride levels of less than 400 mg/dL (4.5 mmol/L) before the index procedure.",patients eligible enrollment study total cholesterol level 135 270 mg/dl 3 5-7 0 mmol/l fasting triglyceride levels 400 mg/dl 4 5 mmol/l procedure,C0030705|C1548635|C1516879|C0557651|C0439175|C0008377|C0441889|C1442061|C1442061|C0439269|G0000000|G0000000|G0000000|C1532563|C0015663|C0041004|C0441889|C1442061|C0439269|G0000000|G0000000|C1532563|C0184661
"Patients A total of 1677 patients (aged 18-80 years) recruited between April 1996 and October 1998 with stable or unstable angina or silent ischemia following successful completion of their first PCI who had baseline total cholesterol levels between 135 and 270 mg/dL (3.5-7.0 mmol/L), with fasting triglyceride levels of less than 400 mg/dL (4.5 mmol/L).",patients total 1677 patients aged 18-80 recruited april 1996 october 1998 stable unstable angina silent ischemia successful completion pci baseline total cholesterol levels 135 270 mg/dl 3 5-7 0 mmol/l fasting triglyceride levels 400 mg/dl 4 5 mmol/l,C0030705|C0439175|G0000000|C0030705|C0001779|C0450371|G0000000|C3715024|G0000000|C3828732|G0000000|C0205360|C0443343|C0002962|C0443304|C0022116|C0597535|C0205197|C4049621|C0168634|C0439175|C0008377|C0441889|C1442061|C1442061|C0439269|G0000000|G0000000|G0000000|C1532563|C0015663|C0041004|C0441889|C1442061|C0439269|G0000000|G0000000|C1532563
"Men and women aged 18 to 80 years were recruited from 57 interventional centers in 10 countries (Belgium, France, Germany, Italy, United Kingdom, the Netherlands, Spain, Switzerland, Canada, and Brazil).",women aged 18 80 recruited 57 interventional centers 10 countries belgium france germany italy united kingdom netherlands spain switzerland canada brazil,C0043210|C0001779|C0450371|C0450371|G0000000|C0450371|C1948041|C0205099|C0450371|C0454664|C0004950|C0016674|C0017480|C0022277|C0166872|C1708611|C0027778|C0037747|C0039021|C0006823|C0006137
Patients Hypertensive patients with an echocardiographically documented left ventricular mass index (LVMI) > 120 g/m 2 (men) or > 105 g/m 2 (women).,patients hypertensive patients echocardiographically documented left ventricular mass lvmi 120 g/m 2 105 g/m 2 women,C0030705|C0857121|C0030705|G0000000|C1301725|C0205091|C0018827|C0577559|G0000000|C1442061|C0456715|G0000000|C1442061|C0456715|G0000000|C0043210
"Objective To compare the effects of the angiotensin II antagonist, losartan, with those of atenolol on left ventricular hypertrophy (LVH), blood pressure and neurohormone concentrations in hypertensive patients with LVH.",objective compare effects angiotensin ii antagonist losartan atenolol left ventricular hypertrophy lvh blood pressure neurohormone concentrations hypertensive patients lvh,C0018017|C1707455|C1280500|C0003018|G0000000|C0231491|C0126174|C0004147|C0205091|C0018827|C0020564|C0149721|C0005767|C0033095|C0597049|C0086045|C0857121|C0030705|C0149721
"The study included men and women, aged 21-80 years, with mild-to-moderate essential hypertension and echocardiographically documented LVH assessed up to 30 days before enrolment.",study included women aged 21-80 mild-to-moderate essential hypertension echocardiographically documented lvh assessed 30 days enrolment,C0557651|C0332257|C0043210|C0001779|C0450371|C1299392|C0205224|C0020538|G0000000|C1301725|C0149721|C1516048|C0450371|C0439228|C1516879
"Exclusion criteria included diastolic BP of less than 95 mm Hg, known history of diabetes mellitus (fasting glucose, 140 mg/dL or random glucose, 200 mg/ dL), urinary protein to creatinine ratio of more than 2.5, accelerated or malignant hypertension within 6 months, secondary hypertension, evidence of non-BP-related causes of chronic kidney disease, serious systemic disease, clinical congestive heart failure, or specific indication for or contraindication to a study drug or study procedure.",exclusion criteria included diastolic bp 95 mm hg history diabetes mellitus fasting glucose 140 mg/dl random glucose 200 mg/ dl urinary protein creatinine ratio 2 5 accelerated malignant hypertension 6 months secondary hypertension evidence non-bp-related chronic kidney disease systemic disease clinical congestive heart failure specific indication contraindication study drug study procedure,C0680251|C0243161|C0332257|C0012000|C0037623|C0450371|G0000000|C0025424|C0019664|C0011847|G0000000|C0015663|C0017725|C1442061|C0439269|C0034656|C0017725|C1442061|C0026410|C3642216|C0042027|C0033684|C0010294|C0456603|G0000000|G0000000|C0521110|C0205282|C0020538|G0000000|C0439231|C0027627|C0020538|C3887511|C1518422|C0205191|C0022646|C0012634|C0205373|C0012634|C0205210|C0742742|C0018787|C0231174|C0205369|C0392360|C0522473|C0557651|C0013227|C0557651|C0184661
"Patients were included into the study from July 1997 until May 1999, and were followed until mid 2000.",patients included study july 1997 1999 mid 2000,C0030705|C0332257|C0557651|C3829447|G0000000|G0000000|C0444598|G0000000
A total of 540 patients with an AMI were included in this study.,total 540 patients ami included study,C0439175|C1442061|C0030705|G0000000|C0332257|C0557651
"Results Five hundred and forty patients were included (83% male, age 6111 years); 43% had an anterior AMI and 50% were treated with fibrinolytics in the acute phase.",forty patients included 83% male age 6111 43% anterior ami 50% treated fibrinolytics acute phase,C3816449|C0030705|C0332257|C0450371|C0086582|C0001779|G0000000|C0450371|C0205094|G0000000|C0450371|C1522326|C0040044|C0205178|C0205390
Individuals with a history of hospitalized or treated symptomatic heart failure (HF) and/or known left ventricular ejection fraction of less than 35% were excluded.,individuals history hospitalized treated symptomatic heart failure hf and/or left ventricular ejection fraction 35% excluded,C0027361|C0019664|C0701159|C1522326|C0231220|C0018787|C0231174|C0018488|G0000000|C0205091|C0018827|C0302131|C1264633|C0450371|C1554077
"There has been considerable uncertainty regarding effects of some classes of antihypertensive drugs on risk of Main Outcome Measures The primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intent-to-treat.",considerable uncertainty effects classes antihypertensive drugs risk main outcome measures primary outcome combined fatal chd nonfatal myocardial infarction analyzed intent-to-treat,G0000000|C0087130|C1280500|C0456387|C0003364|C0013227|C0035647|C0205225|C1274040|C0079809|C0205225|C1274040|C0205195|C1302234|C0280604|G0000000|C0027061|C0021308|C0936012|C0162425
"Combined CVD indicates CHD death, nonfatal MI, stroke, coronary revascularization procedures, hospitalized or treated angina, treated or hospitalized heart failure, and peripheral arterial disease (hospitalized or outpatient revascularization).",combined cvd chd death nonfatal mi stroke coronary revascularization procedures hospitalized treated angina treated hospitalized heart failure peripheral arterial disease hospitalized outpatient revascularization,C0205195|C0007222|C0280604|C0011065|G0000000|C3810814|C0038454|C0018787|C0581603|C0025664|C0701159|C1522326|C0002962|C1522326|C0701159|C0018787|C0231174|C0205100|C0003842|C0012634|C0701159|C0029921|C0581603
"Among participants with unknown vital status, the distributions of most baseline factors were similar among the 3 treatment groups, but participants assigned to lisinopril were less likely to be black and more likely to be women, have untreated hypertension, evidence of CHD or atherosclerotic CVD, and a lower mean serum glucose.",participants unknown vital status distributions baseline factors 3 treatment participants assigned lisinopril black women untreated hypertension evidence chd atherosclerotic cvd lower serum glucose,C0679646|C0439673|C0442732|C0449438|C0037775|C0168634|C1521761|G0000000|C0039798|C0679646|C1516050|C0065374|C0005680|C0043210|C0332155|C0020538|C3887511|C0280604|C0333482|C0007222|C0441994|C0229671|C0017725
"Our aim in this randomised controlled trial was to see if active management with oral misoprostol resulted in significantly more women going into labour within 24 hours of the prelabour rupture of membranes, and to assess patient preferences for management.",aim randomised controlled trial active management oral misoprostol women labour 24 hours prelabour rupture membranes assess patient preferences management,C1947946|G0000000|C2587213|C0008976|C0205177|C0001554|C0442027|C0085174|C0043210|C0022864|C0450371|C0439227|G0000000|C1881712|C0025255|C1516048|C0030705|C0558295|C0001554
Objective To compare the active management of term prelabour rupture of membranes with oral misoprostol with conservative management for 24 hours followed by induction with oxytocin or prostaglandin E 2 (PGE 2) gel.,objective compare active management term prelabour rupture membranes oral misoprostol conservative management 24 hours induction oxytocin prostaglandin 2 pge 2 gel,C0018017|C1707455|C0205177|C0001554|C0233324|G0000000|C1881712|C0025255|C0442027|C0085174|G0000000|C0001554|C0450371|C0439227|C0205263|C0030095|C0033554|G0000000|C0033559|G0000000|C0017243
Population Sixty-one women with confirmed prelabour rupture of the membranes at !,population sixty-one women confirmed prelabour rupture membranes,C0032659|C3816724|C0043210|C0521093|G0000000|C1881712|C0025255
Methods: Singleton pregnancies indicated for induction of labor between 34 and 42 weeks of gestation in the condition of unfavorable cervix (Bishop score  4) and no contraindication for prostaglandins therapy were recruited into the study.,methods singleton pregnancies induction labor 34 42 weeks gestation condition unfavorable cervix bishop score 4 contraindication prostaglandins therapy recruited study,C0025663|C0481462|C0032961|C0205263|C0022864|C0450371|C0450371|C0439230|C0032961|C0012634|C3640815|C0007874|C1551458|C0449820|G0000000|C0522473|C0033554|C0039798|G0000000|C0557651
Objective: To compare the efficacy and safety of 100 m g oral misoprostol for induction of labor between the regimen of 3 hour and 6 hour interval administration.,objective compare efficacy safety 100 oral misoprostol induction labor regimen 3 hour 6 hour interval administration,C0018017|C1707455|C1280519|C0036043|C1442061|C0442027|C0085174|C0205263|C0022864|C0040808|G0000000|C0439227|G0000000|C0439227|C1272706|C0001554
"All patients were referred at least 6 months after a major coronary event, including acute myocardial infarction, coronary artery bypass grafting or percutaneous balloon angioplasty for acute coronary syndrome.",patients referred 6 months major coronary event including acute myocardial infarction coronary artery bypass grafting percutaneous balloon angioplasty acute coronary syndrome,C0030705|C0205543|G0000000|C0439231|C0205082|C0018787|C0441471|C0332257|C0205178|C0027061|C0021308|C0018787|C0003842|C0741847|C0332835|C0522523|C0336867|C0162577|C0205178|C0018787|C0039082
"Thirty-eight elderly males (mean age, 70 years) with CAD were stratified as the intervention group (n=20) and the control group (n=18).",thirty-eight elderly males age 70 cad stratified intervention n=20 control n=18,C3816446|C0001792|C0086582|C0001779|C0450371|C3813548|C0205363|C0886296|C0369718|C0243148|C0369718
The purpose of this prospective randomized controlled trial was to assess the impact of phase III comprehensive cardiac rehabilitation (CR) on health-related quality of life (HRQOL) in elderly patients with coronary artery disease (CAD).,purpose prospective randomized controlled trial assess impact phase iii comprehensive cardiac rehabilitation cr health-related quality life hrqol elderly patients coronary artery disease cad,C1285529|C0023981|C0034656|C2587213|C0008976|C1516048|C1825598|C0205390|C0439070|C1880156|C0018787|C0034991|C0201975|C0018684|C0332306|C0376558|G0000000|C0001792|C0030705|C0018787|C0003842|C0012634|C3813548
"Women admitted for induction of labor at more than 37 weeks of gestation, with a live single fetus in vertex presentation, were eligible for the study if the Bishop score was 6 or less.",women admitted induction labor 37 weeks gestation live single fetus vertex presentation eligible study bishop score 6,C0043210|C0184666|C0205263|C0022864|C0450371|C0439230|C0032961|C1548795|C0037179|C0015965|C0230003|C0449450|C1548635|C0557651|C1551458|C0449820|G0000000
A total of 202 women were randomized.,total 202 women randomized,C0439175|C1442061|C0043210|C0034656
"Exclusion criteria were the presence of uterine scar, suspected fetal distress (nonreassuring FHR, oligohydramnios, or intrauterine growth retardation), malformation, vaginal bleeding, or contraindication for prostaglandin administration.",exclusion criteria presence uterine scar suspected fetal distress nonreassuring fhr oligohydramnios intrauterine growth retardation malformation vaginal bleeding contraindication prostaglandin administration,C0680251|C0243161|C0150312|C0042149|C0241158|C0332147|C0015965|C0231303|G0000000|G0000000|C0079924|C0694756|C0018270|C0521111|C0000768|C0042232|C0019080|C0522473|C0033554|C0001554
"OBJECTIVE: The objective of the study was to compare the effectiveness, safety, and side effects of low-dose oral misoprostol with vaginal dinoprostone for cervical ripening and labor induction.",objective objective study compare effectiveness safety effects low-dose oral misoprostol vaginal dinoprostone cervical ripening labor induction,C0018017|C0018017|C0557651|C1707455|C1280519|C0036043|C1280500|C0445550|C0442027|C0085174|C0042232|C0012472|C0027530|C1160534|C0022864|C0205263
"The IDNT was designed to compare the effect of therapy with the angiotensin-1 antagonist irbesartan, the calcium-channel blocker amlodipine, or placebo for similar decrement in blood pressure on the occurrence of various cardiovascular events.",idnt designed compare therapy angiotensin-1 antagonist irbesartan calcium-channel blocker amlodipine placebo decrement blood pressure occurrence cardiovascular events,G0000000|C1707689|C1707455|C0039798|C0003018|C0231491|C0288171|C0006685|G0000000|C0051696|C0032042|G0000000|C0005767|C0033095|C0243132|C0007226|C0441471
"Entry criteria required that patients be between 30 and 70 years of age and have type 2 diabetes mellitus and overt nephropathy, as evidenced by current treatment for hypertension or by a protein excretion rate of 900 mg/d or greater, serum creatinine level of 89 mol/L (1.0 mg/ dL) to 266 mol/L (3.0 mg/dL) in women or of 106 mol/L (1.2 mg/dL) to 266 mol/L (3.0 mg/dL) in men, and baseline seated blood pressure greater than 135/85 mm Hg.",entry criteria required patients 30 70 age type 2 diabetes mellitus overt nephropathy evidenced current treatment hypertension protein excretion rate 900 mg/d serum creatinine level 89 mol/l 1 0 mg/ dl 266 mol/l 3 0 mg/dl women 106 mol/l 1 2 mg/dl 266 mol/l 3 0 mg/dl baseline seated blood pressure 135/85 mm hg,C1705654|C0243161|C1514873|C0030705|C0450371|C0450371|C0001779|C0332307|G0000000|C0011847|G0000000|G0000000|C0022658|C3887511|C0521116|C0039798|C0020538|C0033684|C0221102|C0871208|C1442061|C0439422|C0229671|C0010294|C0441889|C0450371|C0347982|G0000000|G0000000|C0026410|C3642216|C1442061|C0347982|G0000000|G0000000|C0439269|C0043210|C1442061|C0347982|G0000000|G0000000|C0439269|C1442061|C0347982|G0000000|G0000000|C0439269|C0168634|C0277814|C0005767|C0033095|C1442061|G0000000|C0025424
Cardiovascular Events in Type 2 Diabetic Nephropathy pared with placebo in patients with type 2 diabetic nephropathy.,cardiovascular events type 2 diabetic nephropathy pared placebo patients type 2 diabetic nephropathy,C0007226|C0441471|C0332307|G0000000|C0241863|C0022658|G0000000|C0032042|C0030705|C0332307|G0000000|C0241863|C0022658
OBJECTIVE: To determine if oral misoprostol can replace oxytocin for labor stimulation in women with ruptured membranes at term and without evidence of labor.,objective determine oral misoprostol replace oxytocin labor stimulation women ruptured membranes term evidence labor,C0018017|G0000000|C0442027|C0085174|C0559956|C0030095|C0022864|C1292856|C0043210|C0443294|C0025255|C0233324|C3887511|C0022864
"Using these inclusion criteria, the sample size was calculated to be 102 randomized women to demonstrate a reduction in the requirement for oxytocin infusion from 35% to 10%.",inclusion criteria sample size calculated 102 randomized women demonstrate reduction requirement oxytocin infusion 35% 10%,C0007637|C0243161|C0370003|C0456389|C0444686|C1442061|C0034656|C0043210|G0000000|C0301630|C1514873|C0030095|C0574032|C0450371|C0450371
The trial was originally limited to women with ruptured membranes-admission intervals of less than 3 hours.,trial originally limited women ruptured membranes-admission intervals 3 hours,C0008976|G0000000|C0439801|C0043210|C0443294|C0025255|C1272706|G0000000|C0439227
"During the 12-month study period, a total of 102 women were enrolled.",12-month study period total 102 women enrolled,C0450371|C0557651|C0439531|C0439175|C1442061|C0043210|G0000000
"Of 773 screened for eligibility, 270 patients (67.8% males; age range, 46 to 86 years) were enrolled, and 503 (65.1%) were excluded (Figure 1) for cardiological reasons (36.2%), comorbidities that contraindicated vigorous physical exercise (15.0%), disability or cognitive impairment (3.9%), and refusal or logistic reasons (10.0%).",773 screened eligibility 270 patients 67 8% males age range 46 86 enrolled 503 65 1% excluded figure 1 cardiological reasons 36 2% comorbidities contraindicated vigorous physical exercise 15 0% disability cognitive impairment 3 9% refusal logistic reasons 10 0%,C1442061|C0220908|C0013893|C1442061|C0030705|C0450371|G0000000|C0086582|C0001779|C1514721|C0450371|C0450371|G0000000|C1442061|C0450371|G0000000|C1554077|G0000000|G0000000|C0007189|C0392360|C0450371|G0000000|C0009488|C1444657|G0000000|C0031809|C0015259|C0450371|G0000000|C0231170|C1516691|C0221099|G0000000|G0000000|G0000000|C0242415|C0392360|C0450371|G0000000
"An age-and gender-stratified factorial design was used, with 3 age groups predefined as middle-aged (45 to 65 years), old (66 to 75 years), and very old (75 years).",age-and gender-stratified factorial design 3 age predefined middle-aged 45 65 66 75 75,C0001779|C0079399|C2826344|C1707689|G0000000|C0001779|G0000000|C0205847|C0450371|C0450371|C0450371|C0450371|C0450371
"Comparing the 4 h time interval between doses in intravaginal and oral misoprostol, this study established that the effectiveness was comparable with respect to the rate of failed induction.",comparing 4 time interval doses intravaginal oral misoprostol study established effectiveness comparable respect rate failed induction,C1707455|G0000000|C0040223|C1272706|C0178602|C0442122|C0442027|C0085174|C0557651|C0443211|C1280519|G0000000|C0679133|C0871208|C0231175|C0205263
"Women with previous uterine surgery including a previous cesarean section, with significant fetal or medical concern or known contraindications to the use of prostaglandins were excluded.",women previous uterine surgery including previous cesarean fetal medical concern contraindications prostaglandins excluded,C0043210|C0205156|C0042149|C0038894|C0332257|C0205156|C3841297|C0015965|C0199168|C2699424|C0079164|C0033554|C1554077
"One hundred and six women were recruited to the trial for elective induction, 53 received misoprostol orally and 53 vaginally.",women recruited trial elective induction 53 received misoprostol orally 53 vaginally,C0043210|G0000000|C0008976|C0206058|C0205263|C0450371|C1514756|C0085174|C0442027|C0450371|G0000000
"All women requiring elective induction of labor at or beyond term (37-42 completed weeks of gestation with ultrasound confirmed date), which coordinated with the study were assessed for entry into the study.",women requiring elective induction labor term 37-42 completed weeks gestation ultrasound confirmed coordinated study assessed entry study,C0043210|G0000000|C0206058|C0205263|C0022864|C0233324|C0450371|C0205197|C0439230|C0032961|C0041618|C0521093|C0427184|C0557651|C1516048|C1705654|C0557651
"Women who had had a previous caesarean section (CS) or those with a malpresentation or who were parity~ 5, were excluded.",women previous caesarean cs malpresentation parity~ 5 excluded,C0043210|C0205156|C3841297|C0010182|C0233256|C0030563|G0000000|C1554077
Institutional ethical permission was obtained and 400 women with viable term or near-term pregnancies who fulfilled the criteria for induction of labour were enrolled.,institutional ethical permission 400 women viable term near-term pregnancies fulfilled criteria induction labour enrolled,C0018704|C0026531|C0521104|C1442061|C0043210|C0443348|C0233324|C0475806|C0032961|C1550543|C0243161|C0205263|C0022864|G0000000
Meconium staining was found in 16 women in the dinoprostone group (8.2%) and 22 in the misoprostol group (10.9%) (p = 0.33).,meconium staining 16 women dinoprostone 8 2% 22 misoprostol 10 9% = 0 33,C0025047|C0487602|C0450371|C0043210|C0012472|G0000000|G0000000|C0450371|C0085174|C0450371|G0000000|G0000000|G0000000|C0450371
"Furthermore, many women in our setting take traditional herbal medications during late pregnancy to facilitate labour.",women setting traditional herbal medications late pregnancy facilitate labour,C0043210|C0542559|C0443324|C3146288|C0013227|C0205087|C0032961|G0000000|C0022864
"Women with previous uterine surgery, a malpresentation, and 5 or more pregnancies were excluded.",women previous uterine surgery malpresentation 5 pregnancies excluded,C0043210|C0205156|C0042149|C0038894|C0233256|G0000000|C0032961|C1554077
Eligible women with clinical indications for labour induction at or after 34 weeks' gestation and intact membranes were recruited into the study at Coronation Women's and Children's Hospital and at Chris Hani Baragwanath Hospital in Johannesburg.,eligible women clinical indications labour induction 34 weeks gestation intact membranes recruited study coronation womens childrens hospital chris hani baragwanath hospital johannesburg,C1548635|C0043210|C0205210|C0392360|C0022864|C0205263|C0450371|C0439230|C0032961|C0205266|C0025255|G0000000|C0557651|G0000000|G0000000|G0000000|C0019994|G0000000|C1551922|G0000000|C0019994|G0000000
Adult high-risk coronary patients to undergo OPCAB.,adult high-risk coronary patients undergo opcab,C0001675|C0332167|C0018787|C0030705|G0000000|G0000000
This prospective and randomized study evaluates the efficacy and safety of pre-and periopera-tive IABC in high-risk OPCAB.,prospective randomized study evaluates efficacy safety pre-and periopera-tive iabc high-risk opcab,C0023981|C0034656|C0557651|C0220825|C1280519|C0036043|C0332152|G0000000|G0000000|C0332167|G0000000
"Definition of high risks: Any CAD patient presenting with a minimum of two of the following objective preoperative criteria and planned for OPCAB revascularization was enrolled in this study: Left ventricular dysfunction, left ventricular ejection fraction (LVEF) equal or less than 0.30, re-operative CABG (or previous cardiac operation), preoperative unstable angina despite optimal medical treatment (including nitroglycerin and heparin therapy), left coronary main stem stenosis greater than 70%, and recent myocardial infarction less than 10 days prior to surgery (Table 1).",definition risks cad patient minimum objective preoperative criteria planned opcab revascularization enrolled study left ventricular dysfunction left ventricular ejection fraction lvef equal 0 30 re-operative cabg previous cardiac operation preoperative unstable angina optimal medical treatment including nitroglycerin heparin therapy left coronary main stem stenosis 70% myocardial infarction 10 days prior surgery table 1,C1550452|C0035647|C3813548|C0030705|C1524031|C0018017|C0445204|C0243161|C1301732|G0000000|C0581603|G0000000|C0557651|C0205091|C0018827|C0031847|C0205091|C0018827|C0302131|C1264633|C0428772|C0205163|G0000000|C0450371|C0556581|C0010055|C0205156|C0018787|C0543467|C0445204|C0443343|C0002962|C2698651|C0199168|C0039798|C0332257|C0017887|C0019134|C0039798|C0205091|C0018787|C0205225|C0242767|C0678234|C0450371|C0027061|C0021308|C0450371|C0439228|C0332152|C0038894|C0039224|G0000000
"One hundred five women were enrolled, 52 in the misoprostol group and 53 in the oxytocin group.",women enrolled 52 misoprostol 53 oxytocin,C0043210|G0000000|C0450371|C0085174|C0450371|C0030095
"Inclusion criteria were women with live singleton gestations in the cephalic presentation at 37 or more completed weeks with reassuring fetal heart rate tracings and presenting with PROM diagnosed by at least two of the following: (1) a speculum examination with aseptic technique revealing pooling of amniotic fluid in the vagina, (2) a nitrazine test of vaginal fluid positive with a pH >6.5, or (3) a fern pattern present (arborization of vaginal fluid) by microscopic examination.",inclusion criteria women live singleton gestations cephalic presentation 37 completed weeks reassuring fetal heart rate tracings prom diagnosed 1 speculum examination aseptic technique revealing pooling amniotic fluid vagina 2 nitrazine test vaginal fluid positive ph 6 5 3 fern pattern arborization vaginal fluid microscopic examination,C0007637|C0243161|C0043210|C1548795|C0481462|C0032961|C0205096|C0449450|C0450371|C0205197|C0439230|C0557055|C0015965|C0018787|C0871208|G0000000|C0015944|C0011900|G0000000|C0037816|G0000000|C0232920|C0449851|C0443289|C2349200|C0002630|C0005889|C0042232|G0000000|G0000000|C0022885|C0042232|C0005889|C0439178|C0450407|G0000000|G0000000|G0000000|C0331729|C0449774|G0000000|C0042232|C0005889|C0205288|G0000000
"Women were excluded if they were in active labor (three or more contractions in a 10-minute period), had any contraindication to vaginal delivery, previous uterine surgery, active maternal bleeding, chorioamnionitis, major fetal anomalies, contraindication to prostaglandin use, or were younger than 19 years.",women excluded active labor contractions 10-minute period contraindication vaginal delivery previous uterine surgery active maternal bleeding chorioamnionitis major fetal anomalies contraindication prostaglandin 19,C0043210|C1554077|C0205177|C0022864|C1140999|C0450371|C0439531|C0522473|C0042232|C0011209|C0205156|C0042149|C0038894|C0205177|C2347083|C0019080|C0008495|C0205082|C0015965|C0000769|C0522473|C0033554|C0450371
"OBJECTIVE: The study was undertaken to compare the efficacy, safety, and maternal satisfaction of oral misoprostol and intravenous oxytocin for labor induction in women with premature rupture of membranes at term.",objective study undertaken compare efficacy safety maternal satisfaction oral misoprostol intravenous oxytocin labor induction women premature rupture membranes term,C0018017|C0557651|G0000000|C1707455|C1280519|C0036043|C2347083|C0242428|C0442027|C0085174|C0348016|C0030095|C0022864|C0205263|C0043210|C0151526|C1881712|C0025255|C0233324
"We enrolled 306 women between April 1, 1999, and January 10, 2002.",enrolled 306 women april 1 1999 january 10 2002,G0000000|C1442061|C0043210|C3715024|G0000000|G0000000|C3829466|C0450371|G0000000
We present the results for the 305 enrolled women.,305 enrolled women,C1442061|G0000000|C0043210
"Ann Arbor, Royal Oak, and Grand Rapids, Mich, Dallas, Tex, Albuquerque, NM, Springfield, Mass, Baton Rouge, La, Madison, Wis, and New Britain, Conn OBJECTIVE: This study was undertaken to determine whether induction of labor with oral misoprostol will result in fewer cesarean deliveries than intravenous oxytocin in nulliparous women with premature rupture of membranes at term.",ann arbor royal oak grand rapids mich dallas tex albuquerque nm springfield mass baton rouge la madison wis britain conn objective study undertaken determine induction labor oral misoprostol result fewer cesarean deliveries intravenous oxytocin nulliparous women premature rupture membranes term,G0000000|G0000000|G0000000|C0330302|G0000000|C0456962|C0279189|G0000000|G0000000|G0000000|C0312860|G0000000|C0577559|G0000000|G0000000|C0023031|G0000000|G0000000|G0000000|G0000000|C0018017|C0557651|G0000000|G0000000|C0205263|C0022864|C0442027|C0085174|C1274040|C0205388|C3841297|C0011209|C0348016|C0030095|C0425979|C0043210|C0151526|C1881712|C0025255|C0233324
"Another 3 patients were excluded from further echocardiographic evaluation because of unsatisfactory registrations, and 2 patients with diabetes mellitus were excluded from analyses of insulin and glucose.",3 patients excluded echocardiographic evaluation unsatisfactory registrations 2 patients diabetes mellitus excluded analyses insulin glucose,G0000000|C0030705|C1554077|C0013516|C0220825|C0439856|C1514821|G0000000|C0030705|C0011847|G0000000|C1554077|C0002778|C0021641|C0017725
"We examined long-term influence of the angiotensin II Key Words: aldosterone, angiotensin II, insulin, left ventricular hy-pertrophy, norepinephrine, renin type 1-receptor blocker irbesartan and the beta 1-adrenergic receptor blocker atenolol on some neurohormonal systems implicated in the pathophysiology of cardiac hypertrophy.",examined long-term influence angiotensin ii key aldosterone angiotensin ii insulin left ventricular hy-pertrophy norepinephrine renin type 1-receptor blocker irbesartan beta 1-adrenergic receptor blocker atenolol neurohormonal systems implicated pathophysiology cardiac hypertrophy,C0332128|C0443252|C4054723|C0003018|G0000000|G0000000|C0002006|C0003018|G0000000|C0021641|C0205091|C0018827|C1539791|C0028351|C0035094|C0332307|C1421546|G0000000|C0288171|C0330390|C0599756|C0597357|G0000000|C0004147|G0000000|C0449913|G0000000|C0031847|C0018787|C0020564
A total of 115 hypertensive patients with LV hypertrophy verified by echocardiography were enrolled in the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).,total 115 hypertensive patients lv hypertrophy verified echocardiography enrolled swedish irbesartan left ventricular hypertrophy investigation versus atenolol silvhia,C0439175|C1442061|C0857121|C0030705|C0023128|C0020564|C1711411|C0013516|G0000000|C1710263|C0288171|C0205091|C0018827|C0020564|C0220825|G0000000|C0004147|G0000000
All women who required induction of labor because of an obstetric or medical indication were evaluated for study eligibility.,women required induction labor obstetric medical indication evaluated study eligibility,C0043210|C1514873|C0205263|C0022864|C0205484|C0199168|C0392360|C0220825|C0557651|C0013893
Objectives: To determine the efficacy of 200 mg single dose oral misoprostol as a cervical priming agent at term.,objectives determine efficacy 200 single dose oral misoprostol cervical priming agent term,C0018017|G0000000|C1280519|C1442061|C0037179|C0178602|C0442027|C0085174|C0027530|C0871133|C0450442|C0233324
Patients taking -blockers within 2 weeks of randomization or taking -blockers for an MI that occurred in the previous 12 months were excluded to avoid withdrawal phenomena in patients randomized to the CAS group.,patients -blockers 2 weeks randomization -blockers mi occurred previous 12 months excluded avoid withdrawal phenomena patients randomized cas,C0030705|G0000000|G0000000|C0439230|C0034656|G0000000|C3810814|C1709305|C0205156|C0450371|C0439231|C1554077|G0000000|C2349954|C1882365|C0030705|C0034656|G0000000
"We designed a randomized trial, the International Verapamil-Trandolapril Study (INVEST), to compare outcomes in older hypertensive patients with CAD treated with a calcium antagonist strategy (CAS; verapamil sustained release [SR]) or a non-calcium",designed randomized trial international verapamil-trandolapril study invest compare outcomes hypertensive patients cad treated calcium antagonist strategy cas verapamil sustained release sr non-calcium,C1707689|C0034656|C0008976|C1512888|C0718096|C0557651|G0000000|C1707455|C1274040|C0857121|C0030705|C3813548|C1522326|C0006675|C0231491|C0679199|G0000000|C0042523|C0443318|C0030685|C3813610|C1518422
Objective To compare mortality and morbidity outcomes in patients with hyper-tension and CAD treated with a calcium antagonist strategy (CAS) or a non-calcium antagonist strategy (NCAS).,objective compare mortality morbidity outcomes patients hyper-tension cad treated calcium antagonist strategy cas non-calcium antagonist strategy ncas,C0018017|C1707455|C0026565|C0026538|C1274040|C0030705|C0020538|C3813548|C1522326|C0006675|C0231491|C0679199|G0000000|C1518422|C0231491|C0679199|C1413309
"In total, 220 eligible patients were asked to participate and 10.5% refused to participate primarily because of the long distance from their home or to lack of time.",total 220 eligible patients participate 10 5% refused participate distance lack time,C0439175|C1442061|C1548635|C0030705|G0000000|C0450371|G0000000|C1548564|G0000000|C0012751|C0332268|C0040223
"The purpose of the present two-year follow-up study was to assess the long-term effect of lifestyle measures in CHD patient's randomised to a comprehensive interventional programme versus usual care on dietary intake of fat, fibre, cholesterol and sugar, level of physical exercise and smoking cessation.",purpose two-year follow-up study assess long-term lifestyle measures chd patients randomised comprehensive interventional programme versus usual care dietary intake fat fibre cholesterol sugar level physical exercise smoking cessation,C1285529|C0205448|C0589120|C0557651|C1516048|C0443252|C0023676|C0079809|C0280604|C0030705|G0000000|C1880156|C1948041|C1709697|G0000000|C3538928|C1947933|C0012155|C1512806|C0424612|C0012173|C0008377|C0007004|C0441889|C0031809|C0015259|C0037369|C1880019
"In total, 137 (70%) of these patients had suffered a previous AMI, 15 (7%) had diabetes mellitus and 103 (52%) had an available coronary angiogram verifying significant CHD as defined by at least one stenosis of < 50% of the luminal area.",total 137 70% patients suffered previous ami 15 7% diabetes mellitus 103 52% coronary angiogram verifying chd defined stenosis < 50% luminal,C0439175|C1442061|C0450371|C0030705|C0683278|C0205156|G0000000|C0450371|G0000000|C0011847|G0000000|C1442061|C0450371|C0018787|C0002978|C1553511|C0280604|C1704788|C0678234|G0000000|C0450371|C0524462
"The study population comprised 197 patients (162 males and 35 females), 167 of whom were 5-39 days (median 12 days) after one of the following events: an acute myocardial infarction (AMI, WHO criteria), n = 74; hospitalisation for unstable angina pectoris (UAP) and stabilised on medical treatment, n = 4; percutaneous coronary intervention (PCI), n = 39; or coronary artery bypass grafting (CABG), n = 50.",study population comprised 197 patients 162 males 35 females 167 5-39 days median 12 days events acute myocardial infarction ami criteria = 74 hospitalisation unstable angina pectoris uap stabilised medical treatment = 4 percutaneous coronary intervention pci = 39 coronary artery bypass grafting cabg = 50,C0557651|C0032659|C2700400|C1442061|C0030705|C1442061|C0086582|C0450371|C0015780|C1442061|C0450371|C0439228|C0549183|C0450371|C0439228|C0441471|C0205178|C0027061|C0021308|G0000000|C0243161|G0000000|C0450371|C0019993|C0443343|C0002962|G0000000|C4036465|G0000000|C0199168|C0039798|G0000000|G0000000|C0522523|C0018787|C0886296|C4049621|G0000000|C0450371|C0018787|C0003842|C0741847|C0332835|C0010055|G0000000|C0450371
Design A total of 197 patients with proven coronary heart disease were included and randomised to a lifestyle intervention programme or to usual care.,design total 197 patients proven coronary heart disease included randomised lifestyle intervention programme usual care,C1707689|C0439175|C1442061|C0030705|C0456369|C0018787|C0018787|C0012634|C0332257|G0000000|C0023676|C0886296|C1709697|C3538928|C1947933
"Inclusion criteria included a singleton pregnancy in cephalic presentation at a gestation of 37 weeks or more, with a medical or obstetric indication for induction, an unfavourable cervix (modified Bishop's score of less than 8) and intact membranes.",inclusion criteria included singleton pregnancy cephalic presentation gestation 37 weeks medical obstetric indication induction unfavourable cervix modified bishops score 8 intact membranes,C0007637|C0243161|C0332257|C0481462|C0032961|C0205096|C0449450|C0032961|C0450371|C0439230|C0199168|C0205484|C0392360|C0205263|C3640815|C0007874|C0392747|C0649610|C0449820|G0000000|C0205266|C0025255
Objective To compare the efficacy of 100 Ag of oral misoprostol with 3 mg prostaglandin E 2 vaginal tablets in term labour induction.,objective compare efficacy 100 ag oral misoprostol 3 prostaglandin 2 vaginal tablets term labour induction,C0018017|C1707455|C1280519|C1442061|C0002037|C0442027|C0085174|G0000000|C0033554|G0000000|C0042232|C0039225|C0233324|C0022864|C0205263
Population Two hundred women at term with indications for labour induction and modified Bishop's cervical score of less than 8.,population women term indications labour induction modified bishops cervical score 8,C0032659|C0043210|C0233324|C0392360|C0022864|C0205263|C0392747|C0649610|C0027530|C0449820|G0000000
"The aim of this multicenter trial, the CardioVascular Irbesartan Project (CVIP), was to compare the cardiac effects of antihypertensive therapy with irbesartan versus atenolol in subjects with essential hypertension.",aim multicenter trial cardiovascular irbesartan project cvip compare cardiac effects antihypertensive therapy irbesartan versus atenolol subjects essential hypertension,C1947946|C0439743|C0008976|C0007226|C0288171|C1709701|G0000000|C1707455|C0018787|C1280500|C0003364|C0039798|C0288171|G0000000|C0004147|C0681850|C0205224|C0020538
The aim of this trial was to compare the effects of irbesartan versus atenolol on LVH in subjects with essential hypertension.,aim trial compare effects irbesartan versus atenolol lvh subjects essential hypertension,C1947946|C0008976|C1707455|C1280500|C0288171|G0000000|C0004147|C0149721|C0681850|C0205224|C0020538
"Subjects were excluded for known or suspected secondary hypertension; coronary heart disease; cerebrovascular disease; peripheral vascular disease; renovascular disease; insulin-dependent diabetes mellitus; uncontrolled non-insulin-dependent diabetes mellitus; history of intolerance to atenolol, irbesartan, other angiotensin receptor blockers, hydrochlorothiazide, or amlodipine; and pretreatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker within the last 6 months.",subjects excluded suspected secondary hypertension coronary heart disease cerebrovascular disease peripheral vascular disease renovascular disease insulin-dependent diabetes mellitus uncontrolled non-insulin-dependent diabetes mellitus history intolerance atenolol irbesartan angiotensin receptor blockers hydrochlorothiazide amlodipine pretreatment angiotensin-converting enzyme inhibitor angiotensin receptor blocker 6 months,C0681850|C1554077|C0332147|C0027627|C0020538|C0018787|C0018787|C0012634|C1880018|C0012634|C0205100|C0005847|C0012634|C0268790|C0012634|C0021641|C0011847|G0000000|C0205318|C1518422|C0011847|G0000000|C0019664|C0231199|C0004147|C0288171|C0003018|C0597357|G0000000|C0020261|C0051696|C1550147|C0003018|C0014442|C1999216|C0003018|C0597357|G0000000|G0000000|C0439231
"In the randomized, double-blind, multicenter trial CardioVascular Irbesartan Project, 240 patients with essential hypertension were treated with irbesartan or atenolol for 18 months.",randomized double-blind multicenter trial cardiovascular irbesartan project 240 patients essential hypertension treated irbesartan atenolol 18 months,C0034656|C0013072|C0439743|C0008976|C0007226|C0288171|C1709701|C1442061|C0030705|C0205224|C0020538|C1522326|C0288171|C0004147|C0450371|C0439231
"Patients The study population comprised 166 newly diagnosed hypertensive individuals (aged 60-75 years) with diastolic blood pressure between 95 and 115 mmHg or systolic blood pressure between 160 and 220 mmHg, or both.",patients study population comprised 166 newly diagnosed hypertensive individuals aged 60-75 diastolic blood pressure 95 115 mmhg systolic blood pressure 160 220 mmhg,C0030705|C0557651|C0032659|C2700400|C1442061|C0750546|C0011900|C0857121|C0027361|C0001779|C0450371|C0012000|C0005767|C0033095|C0450371|C1442061|C0439475|C0039155|C0005767|C0033095|C1442061|C1442061|C0439475
Patients with hypertension and aged between 60 and 75 years were selected for the study and advised to restrict their salt intake (low-salt diet).,patients hypertension aged 60 75 selected study advised restrict salt intake low-salt diet,C0030705|C0020538|C0001779|C0450371|C0450371|C1707391|C0557651|G0000000|C0443288|C0036140|C1512806|C0205251|C0012155
"Population and treatment VALUE included patients 50 years or older, with treated or untreated hypertension at baseline and predefined combinations of cardiovascular risk factors and cardiovascular disease.",population treatment included patients 50 treated untreated hypertension baseline predefined combinations cardiovascular risk factors cardiovascular disease,C0032659|C0039798|C0332257|C0030705|C0450371|C1522326|C0332155|C0020538|C0168634|G0000000|C0453882|C0007226|C0035647|C1521761|C0007226|C0012634
"Valsartanbased regimen 18 The qualifying risk factors were male sex, age older than 50 years, verified diabetes mellitus, current smoking, high total cholesterol, left ventricular hypertrophy by electrocardiogram, proteinuria on dipstick and raised serum creatinine between 150 and 265 mol/L (if >265 mol/L patients were judged to have severe renal failure and were excluded).",valsartanbased regimen 18 qualifying risk factors male sex age 50 verified diabetes mellitus current smoking total cholesterol left ventricular hypertrophy electrocardiogram proteinuria dipstick raised serum creatinine 150 265 mol/l 265 mol/l patients judged severe renal failure excluded,G0000000|C0040808|C0450371|C1514624|C0035647|C1521761|C0086582|C0009253|C0001779|C0450371|C1711411|C0011847|G0000000|C0521116|C0037369|C0439175|C0008377|C0205091|C0018827|C0020564|C0013798|C0033687|C0441090|C0442818|C0229671|C0010294|C1442061|C1442061|C0347982|C1442061|C0347982|C0030705|C0221191|C0205082|C0022646|C0231174|C1554077
"Additional inclusion criteria were: men or women of any racial background, 50 years of age and older, and presence of cardiovascular risk factors or disease according to an algorithm based on age and sex.",additional inclusion criteria women racial background 50 age presence cardiovascular risk factors disease algorithm based age sex,C1524062|C0007637|C0243161|C0043210|C0034510|C1706907|C0450371|C0001779|C0150312|C0007226|C0035647|C1521761|C0012634|C0002045|C1527178|C0001779|C0009253
"Inclusion criteria for BMSC implantation included age 70 years old, no cardiac shock or cardiac block, stable hemodynamics, and no severe co-morbidities.",inclusion criteria bmsc implantation included age 70 cardiac shock cardiac block stable hemodynamics severe co-morbidities,C0007637|C0243161|G0000000|C0021107|C0332257|C0001779|C0450371|C0018787|C0036974|C0018787|C0028778|C0205360|C0019010|C0205082|C0009488
Seventy-eight patients with acute myocardial infarction according to World Health Organization criteria and within 12 hours of the onset of continuous chest pain were enrolled into the present study and underwent emergency angiography or angioplasty from November 2002 to May 2003.,seventy-eight patients acute myocardial infarction health organization criteria 12 hours onset continuous chest pain enrolled study underwent emergency angiography angioplasty november 2002 2003,C3816957|C0030705|C0205178|C0027061|C0021308|C0018684|C0029237|C0243161|C0450371|C0439227|C0206132|C0549178|C0817096|C0030193|G0000000|C0557651|G0000000|C0013956|C0002978|C0162577|C3828767|G0000000|G0000000
"The inclusion criteria were as follows: (1) singleton gestation, (2) Bishop score of 6 or more, (3) uterine contractions of 12 or less per hour, (4) cephalic presentation, and (5) reactive fetal heart rate (FHR) pattern.",inclusion criteria 1 singleton gestation 2 bishop score 6 3 uterine contractions 12 hour 4 cephalic presentation 5 reactive fetal heart rate fhr pattern,C0007637|C0243161|G0000000|C0481462|C0032961|G0000000|C1551458|C0449820|G0000000|G0000000|C0042149|C1140999|C0450371|C0439227|G0000000|C0205096|C0449450|G0000000|C0205332|C0015965|C0018787|C0871208|G0000000|C0449774
Study design: One hundred ninety-eight women with indications for labor induction and favorable cervical examinations were assigned randomly to receive oral misoprostol or oxytocin induction.,study design ninety-eight women indications labor induction favorable cervical examinations assigned randomly receive oral misoprostol oxytocin induction,C0557651|C1707689|C3816959|C0043210|C0392360|C0022864|C0205263|C3640814|C0027530|C0031809|C1516050|G0000000|C1514756|C0442027|C0085174|C0030095|C0205263
Objective: The purpose of this study was to compare orally administered misoprostol with intravenous oxytocin infusion for labor induction in women with favorable cervical examinations (de-fined as a Bishop score of 6 or more).,objective purpose study compare orally administered misoprostol intravenous oxytocin infusion labor induction women favorable cervical examinations de-fined bishop score 6,C0018017|C1285529|C0557651|C1707455|C0442027|C1521801|C0085174|C0348016|C0030095|C0574032|C0022864|C0205263|C0043210|C3640814|C0027530|C0031809|C0011198|C1551458|C0449820|G0000000
Efficacy of misoprostol was studied for induction of labor at term.,efficacy misoprostol studied induction labor term,C1280519|C0085174|C0557651|C0205263|C0022864|C0233324
This study consisted of 70 patients: 35 randomized to atorvastatin and 35 control subject.,study consisted 70 patients 35 randomized atorvastatin 35 control subject,C0557651|C0332529|C0450371|C0030705|C0450371|C0034656|C0286651|C0450371|C0243148|C0681850
Methods and Results-Seventy patients with ACS were enrolled.,methods results-seventy patients acs enrolled,C0025663|C1274040|C0030705|G0000000|G0000000
The mean patient age was 61.910.6 years; 60 patients (85.7%) were men; and 10 patients (14.3%) had prior coronary artery disease.,patient age 61 910 6 60 patients 85 7% 10 patients 14 3% prior coronary artery disease,C0030705|C0001779|C0450371|C1442061|G0000000|C0450371|C0030705|C0450371|G0000000|C0450371|C0030705|C0450371|G0000000|C0332152|C0018787|C0003842|C0012634
"The 2 groups had similar demographic characteristics, including use of -blockers, ACE inhibitors, and angiotensin type 1 antagonists (Table 1).",2 demographic characteristics including -blockers ace inhibitors angiotensin type 1 antagonists table 1,G0000000|C0011298|C1521970|C0332257|G0000000|C1452534|C0243077|C0003018|C0332307|G0000000|C0243076|C0039224|G0000000
"Because vasodilatory treatment may correct abnormal structure better than nonvasodilating treatment, we compared whether long-term angiotensin-converting enzyme (ACE) inhibition has a greater effect on coronary reserve and cardiovascular structure than -blockade in patients with essential hypertension.",vasodilatory treatment correct abnormal structure nonvasodilating treatment compared long-term angiotensin-converting enzyme ace inhibition coronary reserve cardiovascular structure -blockade patients essential hypertension,G0000000|C0039798|C2349182|C0205161|C0678594|G0000000|C0039798|C1707455|C0443252|C0003018|C0014442|C1452534|C0021467|C0018787|C2347957|C0007226|C0678594|C0332206|C0030705|C0205224|C0020538
Previously untreated patients were recruited from general practitioners and the outpatient clinic.,untreated patients recruited practitioners outpatient clinic,C0332155|C0030705|G0000000|C1709627|C0029921|C0002424
None of the patients had chest pain.,patients chest pain,C0030705|C0817096|C0030193
A total of 151 women completed the study.,total 151 women completed study,C0439175|C1442061|C0043210|C0205197|C0557651
Objective: To compare the efficacy of oral with vaginal misoprostol for induction of labor at term.,objective compare efficacy oral vaginal misoprostol induction labor term,C0018017|C1707455|C1280519|C0442027|C0042232|C0085174|C0205263|C0022864|C0233324
One in each group was excluded because they were found to have breech presentation when the membranes were ruptured.,excluded breech presentation membranes ruptured,C1554077|C3841404|C0449450|C0025255|C0443294
One hundred and fifty-one women eligible for the trial received the medication by the route they were assigned.,fifty-one women eligible trial received medication route assigned,C3816723|C0043210|C1548635|C0008976|C1514756|C0013227|C0013153|C1516050
"All women requiring induction of labor at or beyond term (37-42 weeks of gestation) with a single live cephalic presenting fetus, an unfavorable cervix (Bishop score 6) 8 and intact membranes were recruited for this study.",women requiring induction labor term 37-42 weeks gestation single live cephalic fetus unfavorable cervix bishop score 6 8 intact membranes recruited study,C0043210|G0000000|C0205263|C0022864|C0233324|C0450371|C0439230|C0032961|C0037179|C1548795|C0205096|C0015965|C3640815|C0007874|C1551458|C0449820|G0000000|G0000000|C0205266|C0025255|G0000000|C0557651
There were 1958 (44%) patients who underwent PCI to treat the index ACS event prior to enrollment.,1958 44% patients underwent pci treat acs event prior enrollment,G0000000|C0450371|C0030705|G0000000|C4049621|C0087111|G0000000|C0441471|C0332152|C1516879
Objective To compare early initiation of an intensive statin regimen with delayed initiation of a less intensive regimen in patients with ACS.,objective compare initiation intensive statin regimen delayed initiation intensive regimen patients acs,C0018017|C1707455|C0589507|C0162425|C0360714|C0040808|C0205421|C0589507|C0162425|C0040808|C0030705|G0000000
The medianfollow-upperiodwas721daysand 22 patients in each treatment group were lost to follow-up ( Figure 1).,medianfollow-upperiodwas721daysand 22 patients treatment lost follow-up figure 1,G0000000|C0450371|C0030705|C0039798|C0745777|C0589120|G0000000|G0000000
The following randomized study was designed to further assess the benefit of thrombolysis in combination with HBO on the remodeling process and left ventricular function preservation in patients with acute myocardial infarction.,randomized study designed assess benefit thrombolysis combination hbo remodeling process left ventricular function preservation patients acute myocardial infarction,C0034656|C0557651|C1707689|C1516048|C0814225|C0520997|C0205195|G0000000|G0000000|C1184743|C0205091|C0018827|C0031843|C0033085|C0030705|C0205178|C0027061|C0021308
"Thus, the final study population consisted of 74 patients (63 men, 11 women; mean age, 55  7 years).",final study population consisted 74 patients 63 11 women age 55 7,C0205088|C0557651|C0032659|C0332529|C0450371|C0030705|C0450371|C0450371|C0043210|C0001779|C0450371|G0000000
"The study population consisted of consecutive patients with first myocardial infarction who met the following criteria: (1) age 70 years, (2) chest pain lasting 30 to 360 minutes, (3) ST-segment elevation 2 mm in 2 contagious electrocardiographic leads, (4) transient creatine phosphokinase and/or MB isoenzyme increase, and (5) first echocardiogram performed within 24 hours of the onset of pain.",study population consisted consecutive patients myocardial infarction met criteria 1 age 70 2 chest pain lasting 30 360 minutes 3 st-segment elevation 2 mm 2 contagious electrocardiographic leads 4 transient creatine phosphokinase and/or mb isoenzyme increase 5 echocardiogram performed 24 hours onset pain,C0557651|C0032659|C0332529|C1707491|C0030705|C0027061|C0021308|C0268621|C0243161|G0000000|C0001779|C0450371|G0000000|C0817096|C0030193|C1517741|C0450371|C1442061|C0439232|G0000000|C0429029|C0439775|G0000000|G0000000|G0000000|C0598197|C0013798|C0023175|G0000000|C0040704|C0010286|C0031727|G0000000|C0024853|C0022173|C0442805|G0000000|C0013516|C0884358|C0450371|C0439227|C0206132|C0030193
All patients were assessed clinically at study entry for the presence or absence of heart failure on the basis of Killip criteria.,patients assessed clinically study entry presence absence heart failure basis killip criteria,C0030705|C1516048|G0000000|C0557651|C1705654|C0150312|C0332197|C0018787|C0231174|C1527178|G0000000|C0243161
"Patients were required to have been diagnosed with diabetes for >2 years and to have mild hypertension based on World Health Organization-International Society of Hypertension criteria (ie, diastolic blood pressure [DBP] 90-99 mm Hg on repeated measurements).",patients required diagnosed diabetes 2 mild hypertension based health organization-international society hypertension criteria diastolic blood pressure dbp 90-99 mm hg repeated measurements,C0030705|C1514873|C0011900|C0011847|G0000000|C2945599|C0020538|C1527178|C0018684|C0029237|C0037455|C0020538|C0243161|C0012000|C0005767|C0033095|C0536221|C0450371|G0000000|C0025424|C0205341|C0242485
"Patients with secondary hypertension, malignant hypertension, unstable angina, myocardial infarction within the preceding 6 months, abnormalities of liver or renal function, or contraindications to or current use of ARBs or ACE inhibitors were excluded from participation.",patients secondary hypertension malignant hypertension unstable angina myocardial infarction preceding 6 months abnormalities liver renal function contraindications current arbs ace inhibitors excluded participation,C0030705|C0027627|C0020538|C0205282|C0020538|C0443343|C0002962|C0027061|C0021308|C0332152|G0000000|C0439231|C0000768|C0023884|C0022646|C0031843|C0079164|C0521116|C3888198|C1452534|C0243077|C1554077|C0679823
"Objective: This study was conducted to evaluate blood pressure control, glucose homeostasis, and the plasma lipid profile in patients with type 2 diabetes mellitus and mild hypertension during 12 months of treatment with the ARB telmisartan or nifedipine gastrointestinal therapeutic system (GITS).",objective study conducted evaluate blood pressure control glucose homeostasis plasma lipid profile patients type 2 diabetes mellitus mild hypertension 12 months treatment arb telmisartan nifedipine gastrointestinal therapeutic system gits,C0018017|C0557651|C0004927|C0220825|C0005767|C0033095|C0243148|C0017725|C0019868|C0032105|C0023779|C1979963|C0030705|C0332307|G0000000|C0011847|G0000000|C2945599|C0020538|C0450371|C0439231|C0039798|C3888198|C0248719|C0028066|C0521362|C0087111|C0449913|C1418224
"Nonsmoking patients with type 2 diabetes, diagnosed according to American Diabetes Association criteria, 2. who had achieved adequate glycemic control (glycosylated hemoglobin [HbAlc] <7.0%) were eligible for inclusion in the study.",nonsmoking patients type 2 diabetes diagnosed american diabetes association criteria 2 achieved adequate glycemic control glycosylated hemoglobin hbalc <7 0% eligible inclusion study,G0000000|C0030705|C0332307|G0000000|C0011847|C0011900|C0596070|C0011847|C0004083|C0243161|G0000000|G0000000|C0205410|C0005802|C0243148|G0000000|C0019046|G0000000|G0000000|G0000000|C1548635|C0007637|C0557651
"Of the 269 Chinese patients recruited, 193 were recruited after recent AMI and 76 after elective PCI (fig 1).",269 chinese patients recruited 193 recruited ami 76 elective pci fig 1,C1442061|C0008120|C0030705|G0000000|C1442061|G0000000|G0000000|C0450371|C0206058|C4049621|C0349966|G0000000
"Participants: A total of 269 patients (76% men; mean age, 6411y) with recent acute myocardial infarction (AMI; n193) or after elective percutaneous coronary intervention (PCI; n76) were randomized in a ratio of 2 to 1.",participants total 269 patients 76% age 6411y acute myocardial infarction ami n193 elective percutaneous coronary intervention pci n76 randomized ratio 2 1,C0679646|C0439175|C1442061|C0030705|C0450371|C0001779|G0000000|C0205178|C0027061|C0021308|G0000000|G0000000|C0206058|C0522523|C0018787|C0886296|C4049621|G0000000|C0034656|C0456603|G0000000|G0000000
"The aims of this RCT were to investigated (1) whether an 8-week course of exercise training and education program improved long-term (2y) QOL, and (2) whether the CRPP was cost effective in the provision of better QOL in patients with recent AMI or after percutaneous coronary intervention (PCI).",aims rct investigated 1 8-week exercise training education program improved long-term 2y qol 2 crpp cost effective provision qol patients ami percutaneous coronary intervention pci,C1947946|G0000000|C1292732|G0000000|C0332174|C0015259|C0040607|C0013621|C1709697|C0184511|C0443252|C1710693|C0518214|G0000000|G0000000|C0010186|C1280519|C1549071|C0518214|C0030705|G0000000|C0522523|C0018787|C0886296|C4049621
"This study describes the effects on the secondary end points, urinary albumin excretion, endothelial function and inflammatory activity.",study describes effects secondary urinary albumin excretion endothelial function inflammatory activity,C0557651|G0000000|C1280500|C0027627|C0042027|C0001924|C0221102|C0014257|C0031843|C0333348|C0205177
"Inclusion criteria for the run-in period were type II diabetes mellitus for X6 months (WHO criteria 1985), age between 35 and 70 years, Caucasian ethnicity, and urinary albumin excretion o 100 mg/24 h. Individuals were excluded in case of pregnancy or planning pregnancy, a history of myocardial infarction, angina pectoris, coronary artery bypass surgery, angioplasty, stroke, congestive heart failure, malignancy or other serious illnesses, serum creatinine 4140 mmol/l, body mass index 435 kg/m 2 , alcohol and/or drug abuse, or participation in other clinical trials.",inclusion criteria run-in period type ii diabetes mellitus x6 months criteria 1985 age 35 70 caucasian ethnicity urinary albumin excretion 100 mg/24 individuals excluded pregnancy planning pregnancy history myocardial infarction angina pectoris coronary artery bypass surgery angioplasty stroke congestive heart failure malignancy illnesses serum creatinine 4140 mmol/l body mass 435 kg/m 2 alcohol and/or drug abuse participation clinical trials,C0007637|C0243161|C3274438|C0439531|C0332307|G0000000|C0011847|G0000000|C0450371|C0439231|C0243161|G0000000|C0001779|C0450371|C0450371|C0007457|C0015031|C0042027|C0001924|C0221102|C1442061|C0026410|C0027361|C1554077|C0032961|C0032074|C0032961|C0019664|C0027061|C0021308|C0002962|G0000000|C0018787|C0003842|C0741847|C0038894|C0162577|C0038454|C0742742|C0018787|C0231174|C0006826|C0221423|C0229671|C0010294|G0000000|C1532563|C0242821|C0577559|C1442061|C1532718|G0000000|C0001962|G0000000|C0013227|C0013146|C0679823|C0205210|C0008976
"We investigated the effects of aggressive antihyperten-sive therapy based on hydrochlorothiazide, candesartan or lisinopril on urinary albumin excretion, endothelial function and inflammatory activity in hypertensive type II diabetic individuals.",investigated effects aggressive antihyperten-sive therapy based hydrochlorothiazide candesartan lisinopril urinary albumin excretion endothelial function inflammatory activity hypertensive type ii diabetic individuals,C1292732|C1280500|C0001807|G0000000|C0039798|C1527178|C0020261|C0717550|C0065374|C0042027|C0001924|C0221102|C0014257|C0031843|C0333348|C0205177|C0857121|C0332307|G0000000|C0241863|C0027361
"The goal of the study was to investigate the effects of aggressive antihypertensive treatment based on hydrochlorothiazide, candesartan or lisinopril on left ventricular mass and arterial stiffness (as primary outcomes), and on other cardiovascular risk factors (as secondary outcomes).",goal study investigate effects aggressive antihypertensive treatment based hydrochlorothiazide candesartan lisinopril left ventricular mass arterial stiffness primary outcomes cardiovascular risk factors secondary outcomes,C0018017|C0557651|C1292732|C1280500|C0001807|C0003364|C0039798|C1527178|C0020261|C0717550|C0065374|C0205091|C0018827|C0577559|C0003842|C0427008|C0205225|C1274040|C0007226|C0035647|C1521761|C0027627|C1274040
"A total of 49 study subjects was enrolled in the study; 23 received misoprostol doses of 25 Ag, while 26 received 50 Ag doses.",total 49 study subjects enrolled study 23 received misoprostol doses 25 ag 26 received 50 ag doses,C0439175|C0450371|C0557651|C0681850|G0000000|C0557651|C0450371|C1514756|C0085174|C0178602|C0450371|C0002037|C0450371|C1514756|C0450371|C0002037|C0178602
"Women with a maternal or fetal indication for delivery were excluded, as were noncephalic presentations and patients with a history of previous cesarean delivery.",women maternal fetal indication delivery excluded noncephalic presentations patients history previous cesarean delivery,C0043210|C2347083|C0015965|C0392360|C0011209|C1554077|G0000000|C0449450|C0030705|C0019664|C0205156|C3841297|C0011209
Criteria for enrollment included (1) gestational age of at least 40 weeks (determined by the date of the last menstrual period [LMP] preceded by regular menstrual cycles and confirmatory ultrasound b20 weeks); (2) an unfavorable cervix (Bishop score b5) with the absence of active labor and no evidence of fetal heart rate (FHR) abnormalities; (3) singleton pregnancy (cephalic presentation) and no contraindication to vaginal delivery; (4) no contraindications to the use of prostaglandins.,criteria enrollment included 1 gestational age 40 weeks determined menstrual period lmp preceded regular menstrual cycles confirmatory ultrasound b20 weeks 2 unfavorable cervix bishop score b5 absence active labor evidence fetal heart rate fhr abnormalities 3 singleton pregnancy cephalic presentation contraindication vaginal delivery 4 contraindications prostaglandins,C0243161|C1516879|C0332257|G0000000|C0439671|C0001779|C0450371|C0439230|G0000000|C0025344|C0439531|C0425932|C0332152|C0205272|C0025344|C1511572|C0750484|C0041618|G0000000|C0439230|G0000000|C3640815|C0007874|C1551458|C0449820|C0005558|C0332197|C0205177|C0022864|C3887511|C0015965|C0018787|C0871208|G0000000|C0000768|G0000000|C0481462|C0032961|C0205096|C0449450|C0522473|C0042232|C0011209|G0000000|C0079164|C0033554
"KEYWORDS Objective: Within the obstetric community, several studies suggest that cervical ripening and labor induction after 40 weeks' gestation leads to improved maternal and neonatal outcomes.",keywords objective obstetric community studies cervical ripening labor induction 40 weeks gestation leads improved maternal neonatal outcomes,C1708608|C0018017|C0205484|C0009462|C0947630|C0027530|C1160534|C0022864|C0205263|C0450371|C0439230|C0032961|C0023175|C0184511|C2347083|C1552240|C1274040
KEYWORDS Objectives: To compare oral misoprostol with dinoprostone for induction of labor and their effects on the fetal heart rate patterns.,keywords objectives compare oral misoprostol dinoprostone induction labor effects fetal heart rate patterns,C1708608|C0018017|C1707455|C0442027|C0085174|C0012472|C0205263|C0022864|C1280500|C0015965|C0018787|C0871208|C0449774
A total of 200 women were randomized from 12 October 2001 to 21 November 2002.,total 200 women randomized 12 october 2001 21 november 2002,C0439175|C1442061|C0043210|C0034656|C0450371|C3828732|G0000000|C0450371|C3828767|G0000000
"Women were included if the gestational age was known to be at least 34 weeks, with a single fetus, and cephalic presentation and induction of labor was planned.",women included gestational age 34 weeks single fetus cephalic presentation induction labor planned,C0043210|C0332257|C0439671|C0001779|C0450371|C0439230|C0037179|C0015965|C0205096|C0449450|C0205263|C0022864|C1301732
Results: Data from 96 patients in the misoprostol group and 95 in the dinoprostone group were analyzed.,data 96 patients misoprostol 95 dinoprostone analyzed,C1511726|C0450371|C0030705|C0085174|C0450371|C0012472|C0936012
"Subjects with a glycosylated hemoglobin level of 11 percent or greater, nondiabetic renal disease, and a specific indication for or contraindication to ACE-inhibitor therapy or non-dihydropyridine calcium-channel blocker therapy were not included.",subjects glycosylated hemoglobin level 11 percent nondiabetic renal disease specific indication contraindication ace-inhibitor therapy non-dihydropyridine calcium-channel blocker therapy included,C0681850|G0000000|C0019046|C0441889|C0450371|C0439165|G0000000|C0022646|C0012634|C0205369|C0392360|C0522473|C0003015|C0039798|C1518422|C0006685|G0000000|C0039798|C0332257
Arterial hypertension was defined as an untreated systolic blood pressure of 130 mm Hg or more or a diastolic blood pressure of 85 mm Hg or more or as the need for antihypertensive therapy to attain a systolic or diastolic blood pressure under these levels.,arterial hypertension defined untreated systolic blood pressure 130 mm hg diastolic blood pressure 85 mm hg antihypertensive therapy attain systolic diastolic blood pressure levels,C0003842|C0020538|C1704788|C0332155|C0039155|C0005767|C0033095|C1442061|G0000000|C0025424|C0012000|C0005767|C0033095|C0450371|G0000000|C0025424|C0003364|C0039798|G0000000|C0039155|C0012000|C0005767|C0033095|C0441889
Objective: The purpose of this study was to compare the efficacy and safety of stepwise oral misoprostol vs vaginal misoprostol for cervical ripening before induction of labor.,objective purpose study compare efficacy safety stepwise oral misoprostol vaginal misoprostol cervical ripening induction labor,C0018017|C1285529|C0557651|C1707455|C1280519|C0036043|G0000000|C0442027|C0085174|C0042232|C0085174|C0027530|C1160534|C0205263|C0022864
"Of the 204 women included, 93 (45.6%) received oral misoprostol, and 111 (54.4%) received vaginal misoprostol.",204 women included 93 45 6% received oral misoprostol 111 54 4% received vaginal misoprostol,C1442061|C0043210|C0332257|C0450371|C0450371|G0000000|C1514756|C0442027|C0085174|C1442061|C0450371|G0000000|C1514756|C0042232|C0085174
We evaluated 96 hypertensive diabetic patients who were randomized to 12 months of double-blind treatment with doxazosin 4 mg/d or irbesartan 300 mg/d.,evaluated 96 hypertensive diabetic patients randomized 12 months double-blind treatment doxazosin 4 mg/d irbesartan 300 mg/d,C0220825|C0450371|C0857121|C0241863|C0030705|C0034656|C0450371|C0439231|C0013072|C0039798|C0114873|G0000000|C0439422|C0288171|C1442061|C0439422
"Patients with secondary hypertension, malignant hypertension, unstable angina, myocardial infarction within the preceding 6 months, and/or liver/renal function abnormalities were excluded from the study.",patients secondary hypertension malignant hypertension unstable angina myocardial infarction preceding 6 months and/or liver/renal function abnormalities excluded study,C0030705|C0027627|C0020538|C0205282|C0020538|C0443343|C0002962|C0027061|C0021308|C0332152|G0000000|C0439231|G0000000|C0023884|C0031843|C0000768|C1554077|C0557651
The objective of this trial was to compare the metabolic effects of long-term treatment with doxazosin to those of irbesartan in patients with type 2 diabetes and hypertension.,objective trial compare metabolic effects long-term treatment doxazosin irbesartan patients type 2 diabetes hypertension,C0018017|C0008976|C1707455|C0311400|C1280500|C0443252|C0039798|C0114873|C0288171|C0030705|C0332307|G0000000|C0011847|C0020538
"All patients were in good general health, were nonsmokers, were not taking hypocholesterolemic drugs, and did not have evidence of macroangiopathy [by electrocardiogram (ECG) and Doppler examination], nephropathy [by microalbuminuria, defined as albumin excretion rate (AER) ,30 mg/24 hours, performed on overnight urine collections], 17 or neuropathy (by vibration perception threshold).",patients health nonsmokers hypocholesterolemic drugs evidence macroangiopathy electrocardiogram ecg doppler examination nephropathy microalbuminuria defined albumin excretion rate aer 30 mg/24 hours performed overnight urine collections 17 neuropathy vibration perception threshold,C0030705|C0018684|C0337672|C0151718|C0013227|C3887511|C1096293|C0013798|C1623258|C0554756|G0000000|C0022658|C0730345|C1704788|C0001924|C0221102|C0871208|G0000000|C0450371|C0026410|C0439227|C0884358|C0439583|C0042036|C0600644|C0450371|C0442874|C0455941|C0030971|C0449864
"Patients who had significant cardiac insufficiency (New York Heart Association III or IV), myocardial infarction within the previous 6 months, unstable angina pectoris, uncontrolled arrhythmia, or advanced pulmonary disease or severe dyspnea at rest due to complications of advanced malignancy, or who required supplementary oxygen therapy, were also ineligible for the trial.",patients cardiac insufficiency york heart association iii iv myocardial infarction previous 6 months unstable angina pectoris uncontrolled arrhythmia advanced pulmonary disease severe dyspnea rest complications advanced malignancy required supplementary oxygen therapy ineligible trial,C0030705|C0018787|C0231179|G0000000|C0018787|C0004083|C0439070|C0022326|C0027061|C0021308|C0205156|G0000000|C0439231|C0443343|C0002962|G0000000|C0205318|C0003811|C0205179|C0024109|C0012634|C0205082|C0013404|C0035253|C0009566|C0205179|C0006826|C1514873|G0000000|C0030054|C0039798|C1512714|C0008976
"Eligible patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status of  2, life expectancy  12 weeks, and at least one bidimensionally measurable lesion (according to WHO criteria).",eligible patients eastern cooperative oncology ecog performance status 2 life expectancy 12 weeks bidimensionally measurable lesion criteria,C1548635|C0030705|C1707877|C0679729|C0027651|C0430797|C0597198|C0449438|G0000000|C0376558|C0679138|C0450371|C0439230|G0000000|C1513040|C0221198|C0243161
"Bone marrow, renal, and hepatic function had to meet the following criteria: hemoglobin  10 g/dL and no blood transfusion within the previous 2 weeks; neutrophil count  2.0  10 9 cells/L; platelet count  100  10 9 cells/L; no evidence of myelodysplastic syndrome or abnormal bone marrow reserve; creatinine  1.5  upper limit of normal (ULN) or creatinine clearance  60 mL/ min; total bilirubin less than 1  ULN; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)  2.5  ULN; and alkaline phosphatase  5  ULN (patients with AST and/or ALT  1.5  ULN concomitantly with alkaline phosphatase  2.5  ULN were ineligible for the study).",bone marrow renal hepatic function meet criteria hemoglobin 10 g/dl blood transfusion previous 2 weeks neutrophil count 2 0 10 9 cells/l platelet count 100 10 9 cells/l evidence myelodysplastic syndrome abnormal bone marrow reserve creatinine 1 5 upper limit normal uln creatinine clearance 60 ml/ min total bilirubin 1 uln aspartate aminotransferase ast and/or alanine aminotransferase alt 2 5 uln alkaline phosphatase 5 uln patients ast and/or alt 1 5 uln concomitantly alkaline phosphatase 2 5 uln ineligible study,C0262950|C0086590|C0022646|C0205054|C0031843|C1550543|C0243161|C0019046|C0450371|C0439267|C0005767|C0005841|C0205156|G0000000|C0439230|C0027950|C0750480|G0000000|G0000000|C0450371|G0000000|C0347983|C0005821|C0750480|C1442061|C0450371|G0000000|C0347983|C3887511|G0000000|C0039082|C0205161|C0262950|C0086590|C2347957|C0010294|G0000000|G0000000|C1282910|C0439801|C0205307|C1519815|C0010294|C0449297|C0450371|C0439526|C0702093|C0439175|C0005437|G0000000|C1519815|C0085845|C0002594|C3891303|G0000000|C0001898|C0002594|C1266129|G0000000|G0000000|C1519815|C1979842|C0031678|G0000000|C1519815|C0030705|C3891303|G0000000|C1266129|G0000000|G0000000|C1519815|G0000000|C1979842|C0031678|G0000000|G0000000|C1519815|C1512714|C0557651
Patients who had received prior chemotherapy for their metastatic disease or any prior taxanes or anti-HER therapy were excluded.,patients received prior chemotherapy metastatic disease prior taxanes anti-her therapy excluded,C0030705|C1514756|C0332152|C0013216|C0036525|C0012634|C0332152|C0796419|G0000000|C0039798|C1554077
All women who required induction of labor with a gestational age of at least 32 weeks were considered for admission to the trial.,women required induction labor gestational age 32 weeks considered admission trial,C0043210|C1514873|C0205263|C0022864|C0439671|C0001779|C0450371|C0439230|C0750591|C0184666|C0008976
A total of 99 subjects were included to the study.,total 99 subjects included study,C0439175|C0450371|C0681850|C0332257|C0557651
Patients with premature rupture of membranes (PROM) were also included to this trial.,patients premature rupture membranes prom included trial,C0030705|C0151526|C1881712|C0025255|C0015944|C0332257|C0008976
"Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril.",aim compare non-fatal myocardial infarction fatal chd combinations atenolol thiazide versus amlodipine perindopril,C1947946|C1707455|C1518422|C0027061|C0021308|C1302234|C0280604|C0453882|C0004147|C0541746|G0000000|C0051696|C0136123
"In addition, the study population had to have at least three of the following cardiovascular risk factors: left-ventricular hypertrophy (detected by electrocardiogram or echocardiogram); other specified abnormalities on electrocardiogram, type 2 diabetes; peripheral arterial disease; previous stroke or transient ischaemic attack; male sex; age 55 years or older; microalbuminuria or proteinuria; smoking; ratio of plasma total cholesterol to HDLcholesterol of six or higher; or family history of premature CHD.",addition study population cardiovascular risk factors left-ventricular hypertrophy detected electrocardiogram echocardiogram abnormalities electrocardiogram type 2 diabetes peripheral arterial disease previous stroke transient ischaemic attack male sex age 55 microalbuminuria proteinuria smoking ratio plasma total cholesterol hdlcholesterol family history premature chd,C0332287|C0557651|C0032659|C0007226|C0035647|C1521761|C0225897|C0020564|C0442726|C0013798|C0013516|C0000768|C0013798|C0332307|G0000000|C0011847|C0205100|C0003842|C0012634|C0205156|C0038454|C0040704|C0475224|C0277793|C0086582|C0009253|C0001779|C0450371|C0730345|C0033687|C0037369|C0456603|C0032105|C0439175|C0008377|G0000000|C0015576|C0019664|C0151526|C0280604
"Patients were eligible for inclusion if they were aged under 75 years, self-caring, adequately literate in the English Objective: To estimate the incremental effects on cost and quality of life of cardiac rehabilitation after an acute coronary syndrome.",patients eligible inclusion aged 75 self-caring adequately literate english objective estimate incremental effects cost quality life cardiac rehabilitation acute coronary syndrome,C0030705|C1548635|C0007637|C0001779|C0450371|C0036588|G0000000|C0023864|C0376245|C0018017|C0750572|C1705117|C1280500|C0010186|C0332306|C0376558|C0018787|C0034991|C0205178|C0018787|C0039082
"METHODS Participants Consecutive patients from two tertiary teaching hospitals of the Central Sydney Area Health Service, New South Wales, were recruited over a 2-year period after uncomplicated acute myocardial infarction (AMI) or recovery from unstable angina, and followed up for 12 months.",methods participants consecutive patients tertiary teaching hospitals central sydney health service south wales recruited 2-year period uncomplicated acute myocardial infarction ami recovery unstable angina 12 months,C0025663|C0679646|C1707491|C0030705|C0205372|C0039401|C0019994|C0205099|G0000000|C0018684|C0557854|C1710133|C0043015|G0000000|C0439234|C0439531|C0443334|C0205178|C0027061|C0021308|G0000000|C0237820|C0443343|C0002962|C0450371|C0439231
Participants: 113 patients aged 41-75 years who were self-caring and literate in English.,participants 113 patients aged 41-75 self-caring literate english,C0679646|C1442061|C0030705|C0001779|C0450371|C0036588|C0023864|C0376245
Our aim was to investigate the effect of autologous bone marrow-derived stem cell (BMSC) transfer in the infarct-related artery on LV function and structure.,aim investigate autologous bone marrow-derived stem cell bmsc transfer infarct-related artery lv function structure,C1947946|C1292732|C0439859|C0262950|C0086590|C0242767|C0007634|G0000000|C0040671|C0021308|C0003842|C0023128|C0031843|C0678594
"Microvascular obstruction, prevalent in more than half of patients, irrespective of cell transfer (n=19 controls, n=17 BMSC), precluded LV function recovery (mean ejection fraction at 4 months 47% [SD 9%] vs 46% [8] at baseline) and was associated with adverse remodelling (LVEDV 162 mL [33] at day 4 vs 175 mL [43] at follow-up, p=0014).",microvascular obstruction prevalent half patients irrespective cell transfer n=19 controls n=17 bmsc precluded lv function recovery ejection fraction 4 months 47% sd 9% 46% 8 baseline adverse remodelling lvedv 162 33 day 4 175 43 follow-up p=0014,C0443258|C0028778|C0033105|C2825407|C0030705|G0000000|C0007634|C0040671|C0369718|C0243148|C0369718|G0000000|G0000000|C0023128|C0031843|C0237820|C0302131|C1264633|G0000000|C0439231|C0450371|C2699239|G0000000|C0450371|G0000000|C0168634|G0000000|G0000000|G0000000|C1442061|C0450371|C0332173|G0000000|C1442061|C0450371|C0589120|C0369773
"To avoid dilution of any treatment effect, resulting from aborted infarctions, we excluded patients who presented within 2 h of symptom onset.",avoid dilution treatment aborted infarctions excluded patients 2 symptom onset,G0000000|C0079240|C0039798|C1550015|C0021308|C1554077|C0030705|G0000000|C1457887|C0206132
"We included patients, aged 18-75 years, with acute myocardial infarction with cumulative ST-segment elevation of 6 mm or more, successful epicardial reperfusion after percutaneous coronary intervention with stent replacement, and significant LV dysfunction (hypokinesia or akinesia, involving more than half of the anterior, septal, or inferior wall, using angiography, or involving three contiguous segments or more out of 17, using echocardiography).",included patients aged 18-75 acute myocardial infarction cumulative st-segment elevation 6 mm successful epicardial reperfusion percutaneous coronary intervention stent replacement lv dysfunction hypokinesia akinesia involving half anterior septal inferior wall angiography involving contiguous segments 17 echocardiography,C0332257|C0030705|C0001779|C0450371|C0205178|C0027061|C0021308|C1511559|C0429029|C0439775|G0000000|G0000000|C0597535|C0442016|C0035124|C0522523|C0018787|C0886296|C0038257|C0035139|C0023128|C0031847|C0086439|C0085623|C1314939|C2825407|C0205094|C0442004|C0542339|C0677535|C0002978|C1314939|C0205283|C0441635|C0450371|C0013516
Objective To compare oral misoprostol solution with vaginal prostaglandin gel (dinoprostone) for induction of labour at term to determine whether misoprostol is superior.,objective compare oral misoprostol solution vaginal prostaglandin gel dinoprostone induction labour term determine misoprostol superior,C0018017|C1707455|C0442027|C0085174|C0037633|C0042232|C0033554|C0017243|C0012472|C0205263|C0022864|C0233324|G0000000|C0085174|C1282910
"We excluded women with a ""favourable"" cervix (defined as a modified Bishop score of  7), any contraindication to vaginal birth, previous uterine surgery (including caesarean section), or ruptured membranes.",excluded women favourable cervix defined modified bishop score 7 contraindication vaginal birth previous uterine surgery including caesarean ruptured membranes,C1554077|C0043210|C3640814|C0007874|C1704788|C0392747|C1551458|C0449820|G0000000|C0522473|C0042232|C0005615|C0205156|C0042149|C0038894|C0332257|C3841297|C0443294|C0025255
"Results 741 women were randomised, 365 to the misoprostol group and 376 to the vaginal dinoprostone group.",741 women randomised 365 misoprostol 376 vaginal dinoprostone,C1442061|C0043210|G0000000|C1442061|C0085174|C1442061|C0042232|C0012472
"The trial was managed Patients were eligible to enroll in the trial if they were 45 years of age or older and had one of the following conditions: multiple atherothrombotic risk factors, documented coronary disease, documented cerebrovascular disease, or documented symptomatic peripheral arterial disease.",trial managed patients eligible enroll trial 45 age conditions multiple atherothrombotic risk factors documented coronary disease documented cerebrovascular disease documented symptomatic peripheral arterial disease,C0008976|C1273870|C0030705|C1548635|G0000000|C0008976|C0450371|C0001779|C0012634|C0439064|G0000000|C0035647|C1521761|C1301725|C0018787|C0012634|C1301725|C1880018|C0012634|C1301725|C0231220|C0205100|C0003842|C0012634
"Patients who were enrolled because they had documented cardiovascular disease were designated ""symptomatic,"" whereas those who were enrolled because they had multiple atherothrombotic risk factors without documented cardiovascular disease were designated ""asymp tomatic.""",patients enrolled documented cardiovascular disease designated symptomatic enrolled multiple atherothrombotic risk factors documented cardiovascular disease designated asymp tomatic,C0030705|G0000000|C1301725|C0007226|C0012634|C1524084|C0231220|G0000000|C0439064|G0000000|C0035647|C1521761|C1301725|C0007226|C0012634|C1524084|G0000000|G0000000
"The subgroups included symptomatic patients (defined as patients enrolled on the basis of established cardiovascular disease) as compared with asymptomatic patients (those enrolled on the basis of multiple atherothrombotic risk factors), as well as patients with and those without a history of diabetes, hypertension, hypercholesterolemia, peripheral arterial disease, prior cardiac or vascular surgery, prior myocardial infarction, prior stroke, prior transient ischemic attack, or prior use of other antiplatelet agents, angiotensin-converting-enzyme (ACE) inhibitors (overall and ramipril vs. other ACE inhibitors), statins (overall and atorvastatin, simvastatin, and pravastatin), beta-blockers, calcium antagonists, antidiabetic agents, angiotensin II-receptor blockers, cyclooxygenase-2 inhibitors, and anticoagulants.",subgroups included symptomatic patients defined patients enrolled basis established cardiovascular disease compared asymptomatic patients enrolled basis multiple atherothrombotic risk factors patients history diabetes hypertension hypercholesterolemia peripheral arterial disease prior cardiac vascular surgery prior myocardial infarction prior stroke prior transient ischemic attack prior antiplatelet agents angiotensin-converting-enzyme ace inhibitors ramipril ace inhibitors statins atorvastatin simvastatin pravastatin beta-blockers calcium antagonists antidiabetic agents angiotensin ii-receptor blockers cyclooxygenase-2 inhibitors anticoagulants,C1079230|C0332257|C0231220|C0030705|C1704788|C0030705|G0000000|C1527178|C0443211|C0007226|C0012634|C1707455|C0231221|C0030705|G0000000|C1527178|C0439064|G0000000|C0035647|C1521761|C0030705|C0019664|C0011847|C0020538|C0020443|C0205100|C0003842|C0012634|C0332152|C0018787|C0005847|C0038894|C0332152|C0027061|C0021308|C0332152|C0038454|C0332152|C0040704|C0475224|C0277793|C0332152|G0000000|C0450442|C0022709|C1452534|C0243077|C0072973|C1452534|C0243077|C0360714|C0286651|C0074554|C0085542|C0001645|C0006675|C0243076|C0935929|C0450442|C0003018|C0597357|G0000000|C0033551|C0243077|C0003280
"To meet the criterion for enrollment on the basis of multiple risk factors, patients were required to have two major or three minor or one major and two minor atherothrombotic risk factors.",meet criterion enrollment basis multiple risk factors patients required major minor major minor atherothrombotic risk factors,C1550543|C0243161|C1516879|C1527178|C0439064|C0035647|C1521761|C0030705|C1514873|C0205082|C0026193|C0205082|C0026193|G0000000|C0035647|C1521761
"The participants were consecutive women in active labour with term ( 36 + 0 gestational weeks) pregnancy, having a singleton fetus in a cephalic presentation and among whom amniotomy had been decided.",participants consecutive women active labour term 36 + 0 gestational weeks pregnancy singleton fetus cephalic presentation amniotomy decided,C0679646|C1707491|C0043210|C0205177|C0022864|C0233324|C0450371|G0000000|G0000000|C0439671|C0439230|C0032961|C0481462|C0015965|C0205096|C0449450|G0000000|G0000000
"Objective To examine whether intrapartum monitoring by means of automatic ST analysis (STAN) of fetal electrocardiography could reduce the rate of neonatal acidemia and the rate of operative intervention during labour, compared with monitoring by means of cardiotocography (CTG).",objective examine intrapartum monitoring automatic st analysis stan fetal electrocardiography reduce rate neonatal acidemia rate operative intervention labour compared monitoring cardiotocography ctg,C0018017|G0000000|C0456337|C0150369|C0205554|C0036056|C0002778|C2985331|C0015965|C0013798|G0000000|C0871208|C1552240|C0001122|C0871208|C1882154|C0886296|C0022864|C1707455|C0150369|C0007208|G0000000
Sample A total of 1483 women in active labour with singleton term fetus in cephalic presentation.,sample total 1483 women active labour singleton term fetus cephalic presentation,C0370003|C0439175|G0000000|C0043210|C0205177|C0022864|C0481462|C0233324|C0015965|C0205096|C0449450
Patients with left ventricular ejection fraction <40% were included only if they did not have inducible ventricular tachycardia at electrophysiologic studies.,patients left ventricular ejection fraction <40% included inducible ventricular tachycardia electrophysiologic studies,C0030705|C0205091|C0018827|C0302131|C1264633|C0450371|C0332257|C0205263|C0018827|C0039231|C0013865|C0947630
"If left ventricular ejection fraction was 40%, patients could have electrophysiologic studies; if there was no inducible ventricular tachycardia (cycle length 230 ms), they were eligible to be included in the trial.",left ventricular ejection fraction 40% patients electrophysiologic studies inducible ventricular tachycardia cycle length 230 ms eligible included trial,C0205091|C0018827|C0302131|C1264633|C0450371|C0030705|C0013865|C0947630|C0205263|C0018827|C0039231|C1511572|C1444754|C1442061|C0039676|C1548635|C0332257|C0008976
"During the trial period 1,249 patients who were 75 years of age were screened (Figure 1).",trial period 1 249 patients 75 age screened figure 1,C0008976|C0439531|G0000000|C1442061|C0030705|C0450371|C0001779|C0220908|G0000000|G0000000
"The sample size estimate of 1152 patients considered the assumptions: SiDBP differences of 3.5 mm Hg, standard deviation of the difference of 8 mm Hg, two-sided significance level of 0.050, power of 80%, and a 15% dropout rate.",sample size estimate 1152 patients considered assumptions sidbp differences 3 5 mm hg standard deviation difference 8 mm hg two-sided significance level 0 050 power 80% 15% dropout rate,C0370003|C0456389|C0750572|G0000000|C0030705|C0750591|G0000000|G0000000|C1705241|G0000000|G0000000|G0000000|C0025424|C1442989|C0012727|C1705241|G0000000|G0000000|C0025424|C0205448|C0237881|C0441889|G0000000|C1442061|C0032863|C0450371|C0450371|C0013135|C0871208
"Subgroup analyses of sitting BP based on age (65 years versus 65 years), ethnicity (African American versus non-African American), sex, and a diagnosis of diabetes failed to identify significant treatment by subgroup interactions; however the power of the test was low given the many subgroups, some with small sample sizes.",subgroup analyses sitting bp based age 65 versus 65 ethnicity african american versus non-african american sex diagnosis diabetes failed identify treatment subgroup interactions power test low subgroups sample sizes,C1079230|C0002778|C0277814|C0037623|C1527178|C0001779|C0450371|G0000000|C0450371|C0015031|C0027567|C0596070|G0000000|C1518422|C0596070|C0009253|C0011900|C0011847|C0231175|G0000000|C0039798|C1079230|C1704675|C0032863|C0022885|C0205251|C1079230|C0370003|C0456389
Investigators enrolled men and women ages 18 to 80 years with uncomplicated essential hypertension whose sitting diastolic BP (SiDBP) following a 4-or 5-week placebo run-in period was between 95 and 114 mm Hg.,investigators enrolled women ages 18 80 uncomplicated essential hypertension sitting diastolic bp sidbp 4-or 5-week placebo run-in period 95 114 mm hg,C0035173|G0000000|C0043210|C0001779|C0450371|C0450371|C0443334|C0205224|C0020538|C0277814|C0012000|C0037623|G0000000|G0000000|C0332174|C0032042|C3274438|C0439531|C0450371|C1442061|G0000000|C0025424
The study included African Americans (13%) and diabetic patients (11%).,study included african americans 13% diabetic patients 11%,C0557651|C0332257|C0027567|C0596070|C0450371|C0241863|C0030705|C0450371
A little more than half of the patients were men; 15% were 65 years of age (mean age 54 years) and most had a long history of hypertension (mean 9 years) ( Table 1).,half patients 15% 65 age age 54 history hypertension 9 table 1,C2825407|C0030705|C0450371|C0450371|C0001779|C0001779|C0450371|C0019664|C0020538|G0000000|C0039224|G0000000
"To examine the effect of statins in Japanese patients with AMI, a prospective, randomized, open-label trial was conducted in 486 patients with normal total cholesterol levels.",examine statins japanese patients ami prospective randomized open-label trial conducted 486 patients normal total cholesterol levels,G0000000|C0360714|C1556094|C0030705|G0000000|C0023981|C0034656|C1709323|C0008976|C0004927|C1442061|C0030705|C0205307|C0439175|C0008377|C0441889
"Main exclusion criteria included were 18 years of age, use of lipid-lowering agents within the previous 3 months, The American Journal of Cardiology (www.AJConline.org) known familial dyslipidemia, severe renal failure, known hepatic disease, signs and symptoms of severe heart failure (Killip's class III or IV), a scheduled PCI or coronary artery bypass grafting (CABG), previous PCI (within 6 months) or CABG (within 3 months), and the presence of malignant disease or allergy to statins.",main exclusion criteria included 18 age lipid-lowering agents previous 3 months american journal cardiology ajconline org familial dyslipidemia severe renal failure hepatic disease signs symptoms severe heart failure killips class iii iv scheduled pci coronary artery bypass grafting cabg previous pci 6 months cabg 3 months presence malignant disease allergy statins,C0205225|C0680251|C0243161|C0332257|C0450371|C0001779|C0023779|C0450442|C0205156|G0000000|C0439231|C0596070|C0162443|C0007189|G0000000|C1522486|C0015576|C0242339|C0205082|C0022646|C0231174|C0205054|C0012634|C0220912|C0683368|C0205082|C0018787|C0231174|G0000000|C0456387|C0439070|C0022326|C0086960|C4049621|C0018787|C0003842|C0741847|C0332835|C0010055|C0205156|C4049621|G0000000|C0439231|C0010055|G0000000|C0439231|C0150312|C0205282|C0012634|C0002111|C0360714
It was estimated that 230 patients were required in each group.,estimated 230 patients required,C0750572|C1442061|C0030705|C1514873
"Methods Study population: Between February 2002 and Septem-ber 2004, 486 eligible consecutive patients with AMI who were admitted to 54 medical centers in 28 prefectures of Japan (see Appendix) were enrolled.",methods study population february 2002 septem-ber 2004 486 eligible consecutive patients ami admitted 54 medical centers 28 prefectures japan appendix enrolled,C0025663|C0557651|C0032659|C3830166|G0000000|C1075351|G0000000|C1442061|C1548635|C1707491|C0030705|G0000000|C0184666|C0450371|C0199168|C0205099|C0450371|C1709636|C0022341|C0003617|G0000000
A randomized controlled study included 44 patients with acute myocardial infarction.,randomized controlled study included 44 patients acute myocardial infarction,C0034656|C2587213|C0557651|C0332257|C0450371|C0030705|C0205178|C0027061|C0021308
Here we studied the safety and efficiency of transplantation of bone marrow mononuclear cells (BMMC) in patients with acute myocardial infarc-tion (AMI) and evaluated the effect of BMMC trans-plantation on reparative regeneration in AMI.,studied safety efficiency transplantation bone marrow mononuclear cells bmmc patients acute myocardial infarc-tion ami evaluated bmmc trans-plantation reparative regeneration ami,C0557651|C0036043|C0013682|C0040732|C0262950|C0086590|C1513475|C0007634|G0000000|C0030705|C0205178|C0027061|G0000000|G0000000|C0220825|G0000000|C2826298|G0000000|C0034963|G0000000
Objective: To study whether emergent intracoronary autologous bone marrow cell transplantation (BMT) is applicable for the treatment of acute myocardial infarction (AMI).,objective study emergent intracoronary autologous bone marrow cell transplantation bmt applicable treatment acute myocardial infarction ami,C0018017|C0557651|C0750573|C0595454|C0439859|C0262950|C0086590|C0007634|C0040732|C0005961|C1272460|C0039798|C0205178|C0027061|C0021308|G0000000
Background and objective: We have compared the effects of gabapentin on arterial pressure and heart rate at induction of anaesthesia and tracheal intubation in a randomized double-blind study.,background objective compared effects gabapentin arterial pressure heart rate induction anaesthesia tracheal intubation randomized double-blind study,C1706907|C0018017|C1707455|C1280500|C0060926|C0003842|C0033095|C0018787|C0871208|C0205263|C0002903|C0040578|C0021925|C0034656|C0013072|C0557651
"Patients were excluded if they had received previous chemotherapy for metastatic disease, brain, or bone metastases as the only site of disease, a history of other cancers, except in situ cervix cancer radically resected and nonmelanoma skin cancer, prior history of cardiac disease or hypertension.",patients excluded received previous chemotherapy metastatic disease brain bone metastases site disease history cancers situ cervix cancer radically resected nonmelanoma skin cancer prior history cardiac disease hypertension,C0030705|C1554077|C1514756|C0205156|C0013216|C0036525|C0012634|C0006104|C0262950|C0027627|C0205145|C0012634|C0019664|C0006826|G0000000|C0007874|C0006826|G0000000|C0015252|G0000000|C0444099|C0006826|C0332152|C0019664|C0018787|C0012634|C0020538
Patients may have received anthracycline and/or taxane containing regimens as adjuvant chemotherapy and relapsed >12 months following the end of chemotherapy.,patients received anthracycline and/or taxane regimens adjuvant chemotherapy relapsed 12 months chemotherapy,C0030705|C1514756|C0003234|G0000000|C0215136|C2945654|C0001551|C0013216|C0205336|C0450371|C0439231|C0013216
Patients with peripheral neuropathy of grade 2 or pregnancy were also ineligible.,patients peripheral neuropathy grade 2 pregnancy ineligible,C0030705|C0205100|C0442874|C0441800|G0000000|C0032961|C1512714
Background: Induction of labour with misoprostol is often augmented with oxytocin with the possible consequence of uterine hypercontractility.,background induction labour misoprostol augmented oxytocin consequence uterine hypercontractility,C1706907|C0205263|C0022864|C0085174|C0205217|C0030095|C0686907|C0042149|G0000000
"Women with a uterine scar, parity  3, heart disease, antepartum haemorrhage and severe hypertension were excluded.",women uterine scar parity 3 heart disease antepartum haemorrhage severe hypertension excluded,C0043210|C0042149|C0241158|C0030563|G0000000|C0018787|C0012634|C0456336|C0019080|C0205082|C0020538|C1554077
The aim of this study was to evaluate labour induction in women with an unfavourable cervix with oral misoprostol routinely followed by oxytocin and to compare it with oral misoprostol ( oxytocin augmentation if needed).,aim study evaluate labour induction women unfavourable cervix oral misoprostol routinely oxytocin compare oral misoprostol oxytocin augmentation,C1947946|C0557651|C0220825|C0022864|C0205263|C0043210|C3640815|C0007874|C0442027|C0085174|G0000000|C0030095|C1707455|C0442027|C0085174|C0030095|C1293122
"During this period, 200 women who were admitted for labour induction and who fulfilled the study criteria (i.e.",period 200 women admitted labour induction fulfilled study criteria,C0439531|C1442061|C0043210|C0184666|C0022864|C0205263|C1550543|C0557651|C0243161
We investigated whether these treatments have different effects on cardiac and large-artery remodelling and evaluated the relation of arterial remodelling to hemodynamic changes in subjects with hypertension.,investigated treatments effects cardiac large-artery remodelling evaluated relation arterial remodelling hemodynamic subjects hypertension,C1292732|C0087111|C1280500|C0018787|C0226003|G0000000|C0220825|C0080103|C0003842|G0000000|C0019010|C0681850|C0020538
Background and Purpose-Angiotensin receptor blocker (ARB)-based treatment reduces cardiovascular events and stroke more than does -blocker-based treatment despite similar blood pressure (BP) reduction.,background purpose-angiotensin receptor blocker arb -based treatment reduces cardiovascular events stroke -blocker-based treatment blood pressure bp reduction,C1706907|C1285529|C0597357|G0000000|C3888198|C1527178|C0039798|G0000000|C0007226|C0441471|C0038454|C1527178|C0039798|C0005767|C0033095|C0037623|C0301630
One hundred Chinese women with confirmed PROM at 37 42 weeks of gestation were recruited.,chinese women confirmed prom 37 42 weeks gestation recruited,C0008120|C0043210|C0521093|C0015944|C0450371|C0450371|C0439230|C0032961|G0000000
"To compare the efficacy of two different dosages of oral misoprostol (50 and 100 mg) with control, in medical induction of labor for patients with prelabor rupture of membranes (PROM) at term.",compare efficacy dosages oral misoprostol 50 100 control medical induction labor patients prelabor rupture membranes prom term,C1707455|C1280519|C0178602|C0442027|C0085174|C0450371|C1442061|C0243148|C0199168|C0205263|C0022864|C0030705|G0000000|C1881712|C0025255|C0015944|C0233324
"Inclusion criteria were an age of 40 to 75 years, the presence of ST-elevation myocardial infarction of the anterior wall and treatment with PCI 2 to 12 hours after the onset of symptoms, successful PCI with stent implantation performed on the culprit lesion in the left anterior descending coronary artery proximal to the second diagonal branch, three or more hypokinetic leftventricle segments observed on echocardiography, and a creatine kinase MB level more than three times the upper reference value.",inclusion criteria age 40 75 presence st-elevation myocardial infarction anterior wall treatment pci 2 12 hours onset symptoms successful pci stent implantation performed culprit lesion left anterior descending coronary artery proximal diagonal branch hypokinetic leftventricle segments observed echocardiography creatine kinase mb level times upper reference,C0007637|C0243161|C0001779|C0450371|C0450371|C0150312|C0520886|C0027061|C0021308|C0205094|C0677535|C0039798|C4049621|G0000000|C0450371|C0439227|C0206132|C0683368|C0597535|C4049621|C0038257|C0021107|C0884358|G0000000|C0221198|C0205091|C0205094|C0205386|C0018787|C0003842|C0205107|C0443198|C1253959|C0086439|G0000000|C0441635|C1441672|C0013516|C0010286|C0031727|C0024853|C0441889|C0040223|C1282910|C1514811
"Among all patients, the mean age was 57.49.1 years, the median time from the onset of symptoms to PCI was 210 minutes (interquartile range, 180 to 330), and the median value for maximum creatine kinase MB was 369 g per liter (interquartile range, 220 to 444).",patients age 57 49 1 median time onset symptoms pci 210 minutes interquartile range 180 330 median maximum creatine kinase mb 369 liter interquartile range 220 444,C0030705|C0001779|C0450371|C0450371|G0000000|C0549183|C0040223|C0206132|C0683368|C4049621|C1442061|C0439232|G0000000|C1514721|C1442061|C1442061|C0549183|C0806909|C0010286|C0031727|C0024853|C1442061|C0475211|G0000000|C1514721|C1442061|C1442061
"Since the study was carried out in 20 cities of Russia in patients with IHD after hospital treatment because of IHD, this panel can be considered representative, and allows extrapolating results of the analysis on the whole given patient population.",study carried 20 cities russia patients ihd hospital treatment ihd panel considered representative extrapolating analysis patient population,C0557651|C0206243|C0450371|C0008848|C0035970|C0030705|C0151744|C0019994|C0039798|C0151744|C0441833|C0750591|C1882932|G0000000|C0002778|C0030705|C0032659
"This study was a part of Russian cooperative research ""Physical training at the post hospital stage of rehabilitation after acute coronary incidents"", the results of which were partially published earlier [13,14].",study russian cooperative physical training post hospital stage rehabilitation acute coronary incidents partially published earlier 13 14,C0557651|C0035967|C0679729|C0031809|C0040607|C0687676|C0019994|C0205390|C0034991|C0205178|C0018787|C1551358|G0000000|C0034037|C1279919|C0450371|C0450371
"The study population had a mean age of 53 years; about half were men; 26% were African American; 57% were overweight (BMI 30); and 72% were taking antihypertensive drugs before study entry (49% monotherapy, 24% two or more agents; 23% were taking a diuretic and 17% a -blocker).",study population age 53 half 26% african american 57% overweight bmi 30 72% antihypertensive drugs study entry 49% monotherapy 24% agents 23% diuretic 17% -blocker,C0557651|C0032659|C0001779|C0450371|C2825407|C0450371|C0027567|C0596070|C0450371|C0497406|G0000000|C0450371|C0450371|C0003364|C0013227|C0557651|C1705654|C0450371|G0000000|C0450371|C0450442|C0450371|C0012798|C0450371|G0000000
Study investigators representing 130 sites enrolled 2831 patients of whom 1571 were randomized.,study investigators representing 130 sites enrolled 2831 patients 1571 randomized,C0557651|C0035173|C1882932|C1442061|C0205145|G0000000|G0000000|C0030705|G0000000|C0034656
"Men and women 18 to 80 years of age with newly diagnosed or treated essential hypertension entered a singleblind, placebo run-in period, after which subjects with a sitting diastolic BP (SiDBP) 95 to 114 mm Hg and systolic BP (SiSBP) 180 mm Hg were eligible for randomization.",women 18 80 age newly diagnosed treated essential hypertension entered singleblind placebo run-in period subjects sitting diastolic bp sidbp 95 114 mm hg systolic bp sisbp 180 mm hg eligible randomization,C0043210|C0450371|C0450371|C0001779|C0750546|C0011900|C1522326|C0205224|C0020538|C1521975|C0242570|C0032042|C3274438|C0439531|C0681850|C0277814|C0012000|C0037623|G0000000|C0450371|C1442061|G0000000|C0025424|C0039155|C0037623|G0000000|C1442061|G0000000|C0025424|C1548635|C0034656
"Of the 1571 randomized patients, 1559 (99.2%) were included in the ITT and 1564 (99.6%) in safety analyses.",1571 randomized patients 1559 99 2% included itt 1564 99 6% safety analyses,G0000000|C0034656|C0030705|G0000000|C0450371|G0000000|C0332257|G0000000|G0000000|C0450371|G0000000|C0036043|C0002778
En el presente estu-dio se analizan 3 grupos de pacientes con infarto de mio-cardio anterior revascularizado con funcin ventricular deprimida (fraccin de eyeccin [FE] < 45%).,en el presente estu-dio se analizan 3 grupos de pacientes con infarto de mio-cardio anterior revascularizado con funcin ventricular deprimida fraccin de eyeccin fe < 45%,C0014908|C1416870|G0000000|G0000000|C0036919|G0000000|G0000000|G0000000|C0011198|G0000000|G0000000|G0000000|C0011198|C1826259|C0205094|G0000000|G0000000|G0000000|C0018827|G0000000|G0000000|C0011198|G0000000|C2346593|G0000000|C0450371
"This study was an investigation into 3 groups of patients who had a revascularized anterior wall AMI and depressed left ventricular function (i.e., ejection fraction <45%).",study investigation 3 patients revascularized anterior wall ami depressed left ventricular function ejection fraction <45%,C0557651|C0220825|G0000000|C0030705|G0000000|C0205094|C0677535|G0000000|C0344315|C0205091|C0018827|C0031843|C0302131|C1264633|C0450371
The study population consisted of 27 consecutive patients (age 59  12 years; 81% males) with the first ST-segment elevation acute anterior myocardial infarction due to occlusion of the proximal left anterior descending artery (LAD) who had undergone successful primary stented PCI.,study population consisted 27 consecutive patients age 59 12 81% males st-segment elevation acute anterior myocardial infarction occlusion proximal left anterior descending artery lad undergone successful primary stented pci,C0557651|C0032659|C0332529|C0450371|C1707491|C0030705|C0001779|C0450371|C0450371|C0450371|C0086582|C0429029|C0439775|C0205178|C0205094|C0027061|C0021308|C0011382|C0205107|C0205091|C0205094|C0205386|C0003842|G0000000|G0000000|C0597535|C0205225|C0038257|C4049621
"Therefore, we designed a randomized study to test the safety and efficacy of intracoronary injection of autologous bone marrow-derived mononuclear cells (BMNCs) in patients with large acute anterior myocardial infarction and late presentation who were treated with successful primary PCI.",designed randomized study test safety efficacy intracoronary injection autologous bone marrow-derived mononuclear cells bmncs patients acute anterior myocardial infarction late presentation treated successful primary pci,C1707689|C0034656|C0557651|C0022885|C0036043|C1280519|C0595454|C0021485|C0439859|C0262950|C0086590|C1513475|C0007634|G0000000|C0030705|C0205178|C0205094|C0027061|C0021308|C0205087|C0449450|C1522326|C0597535|C0205225|C4049621
"Furthermore, the present study is the first direct comparison of antihypertensive medication on large and small artery endothelial function in the same population of patients.",study direct comparison antihypertensive medication artery endothelial function population patients,C0557651|C0439851|C1707455|C0003364|C0013227|C0003842|C0014257|C0031843|C0032659|C0030705
The aim of the present study was therefore twofold: first to describe the relation between blood flow velocity and brachial artery FMD and second to compare the effect of antihypertensive therapy with an angiotensin-converting enzyme (ACE) inhibitor and a beta-blocker on brachial artery as well as small artery endothelium-mediated relaxation.,aim study twofold relation blood flow velocity brachial artery fmd compare antihypertensive therapy angiotensin-converting enzyme ace inhibitor beta-blocker brachial artery artery endothelium-mediated relaxation,C1947946|C0557651|G0000000|C0080103|C0005767|C0806140|C0439830|C0445456|C0003842|C0238288|C1707455|C0003364|C0039798|C0003018|C0014442|C1452534|C1999216|C0001645|C0445456|C0003842|C0003842|C0014257|C0035028
Previously untreated hypertensive patients were recruited from general practitioners and the outpatient clinic.,untreated hypertensive patients recruited practitioners outpatient clinic,C0332155|C0857121|C0030705|G0000000|C1709627|C0029921|C0002424
Thirty-one previously untreated hypertensive patients were randomized in a double-blind fashion to treatment with either the angiotensin-converting enzyme (ACE) inhibitor perindopril or the beta-blocker atenolol and compared with 17 healthy normotensive controls.,thirty-one untreated hypertensive patients randomized double-blind fashion treatment angiotensin-converting enzyme ace inhibitor perindopril beta-blocker atenolol compared 17 healthy normotensive controls,C3816446|C0332155|C0857121|C0030705|C0034656|C0013072|G0000000|C0039798|C0003018|C0014442|C1452534|C1999216|C0136123|C0001645|C0004147|C1707455|C0450371|C3898900|C2712122|C0243148
"Exclusion criteria included (1) estimated fetal weight of > 4,000 g or evidence of cephalopelvic disproportion, (2) parity of > 6, (3) previous cesarean delivery or history of uterine incision, (4) any contraindication to vaginal delivery such as placenta previa, vasa previa and active genital herpes simplex infection, (5) evidence of chorioamnionitis as determined by maternal temperature > 100.4F and the presence of either uterine tenderness or, foul-smelling amniotic fluid, or both, (6) any contraindication for prostaglandin use eg.",exclusion criteria included 1 estimated fetal weight 4 000 evidence cephalopelvic disproportion 2 parity 6 3 previous cesarean delivery history uterine incision 4 contraindication vaginal delivery placenta previa vasa previa active genital herpes simplex infection 5 evidence chorioamnionitis determined maternal temperature 100 4f presence uterine tenderness foul-smelling amniotic fluid 6 contraindication prostaglandin,C0680251|C0243161|C0332257|G0000000|C0750572|C0015965|C0005910|G0000000|C1442061|C3887511|G0000000|C0341906|G0000000|C0030563|G0000000|G0000000|C0205156|C3841297|C0011209|C0019664|C0042149|C0184898|G0000000|C0522473|C0042232|C0011209|C0032043|G0000000|C1425720|G0000000|C0205177|C0559522|C0019340|C2338991|C0009450|G0000000|C3887511|C0008495|G0000000|C2347083|C0005903|C1442061|G0000000|C0150312|C0042149|C0234233|C0037361|C0002630|C0005889|G0000000|C0522473|C0033554
"Material and Method: This study was a randomized, double-blind controlled trial conducting in pregnant women admitted at delivery room, pregnancies at > 37 weeks' gestation who had indication for labor induction with unfavorable cervix were randomly divided into a group of single dose of 50 g misoprostol orally or 25 g misoprostol vaginally.",material method study randomized double-blind controlled trial conducting pregnant women admitted delivery pregnancies 37 weeks gestation indication labor induction unfavorable cervix randomly divided single dose 50 misoprostol orally 25 misoprostol vaginally,C0520510|C0025663|C0557651|C0034656|C0013072|C2587213|C0008976|C0004927|C0549206|C0043210|C0184666|C0011209|C0032961|C0450371|C0439230|C0032961|C0392360|C0022864|C0205263|C3640815|C0007874|G0000000|C0332849|C0037179|C0178602|C0450371|C0085174|C0442027|C0450371|C0085174|G0000000
The population consisted of women in labor with a term (36 gestational weeks) singleton fetus in cephalic presentation who met the following inclusion criteria: abnormal cardiotocography or thick meconiumstained amniotic fluid (7%) during labor.,population consisted women labor term 36 gestational weeks singleton fetus cephalic presentation met inclusion criteria abnormal cardiotocography thick meconiumstained amniotic fluid 7% labor,C0032659|C0332529|C0043210|C0022864|C0233324|C0450371|C0439671|C0439230|C0481462|C0015965|C0205096|C0449450|C0268621|C0007637|C0243161|C0205161|C0007208|C1280412|G0000000|C0002630|C0005889|G0000000|C0022864
OBJECTIVE: The purpose of this study was to assess whether knowledge of ST-segment analysis was associated with a reduction in operative deliveries for nonreassuring fetal status (NRFS) or with a need for at least 1 scalp pH during labor.,objective purpose study assess knowledge st-segment analysis reduction operative deliveries nonreassuring fetal status nrfs 1 scalp ph labor,C0018017|C1285529|C0557651|C1516048|C0376554|C0429029|C0002778|C0301630|C1882154|C0011209|G0000000|C0015965|C0449438|G0000000|G0000000|C0036270|C0450407|C0022864
"The exclusion criteria were gestational age 36 weeks, normal cardiotocography without deceleration during labor, maternal infection contraindicating placement of scalp electrodes (seropositive for HIV or hepatitis B or C) cardiac malformation, severe decelerations with variability reduced immediately on entry into the delivery room, and refusal to participate.",exclusion criteria gestational age 36 weeks normal cardiotocography deceleration labor maternal infection contraindicating placement scalp electrodes seropositive hiv hepatitis cardiac malformation severe decelerations variability reduced entry delivery refusal participate,C0680251|C0243161|C0439671|C0001779|C0450371|C0439230|C0205307|C0007208|C0011100|C0022864|C2347083|C0009450|G0000000|C0441587|C0036270|C0013812|C0521143|C0019682|C0019158|C0018787|C0000768|C0205082|C0011100|C2827666|C0392756|C1705654|C0011209|G0000000|G0000000
"After obtaining the approval of the Institutional Ethics Committee (Trakya University, Edirne, Turkey) and written consent of the patients, 80 normotensive patients (ASA physical status I) undergoing elective varicocele surgery were randomly assigned to four groups of 20 patients each.",obtaining approval institutional ethics committee trakya university edirne turkey written consent patients 80 normotensive patients asa physical status undergoing elective varicocele surgery randomly assigned 20 patients,C1301820|C0205540|C0018704|C0015000|C2699414|G0000000|C0041740|G0000000|C0041400|C0043266|C1511481|C0030705|C0450371|C2712122|C0030705|C0004057|C0031809|C0449438|G0000000|C0206058|C0042341|C0038894|G0000000|C1516050|C0450371|C0030705
"Exclusion criteria were cardiac disease, contraindications to anesthetics, asthma, renal insufficiency, predicted difficulty in intubation or airway maintenance, and pregnancy.",exclusion criteria cardiac disease contraindications anesthetics asthma renal insufficiency predicted difficulty intubation airway maintenance pregnancy,C0680251|C0243161|C0018787|C0012634|C0079164|C0002930|C0004096|C0022646|C0231179|C0681842|C1299586|C0021925|C0178987|C0024501|C0032961
"The patients' age ranged between 33 and 70 years, 21% were 33-49, 37% 50-59, 42% 60-70 years of age (mean 58 years old CABG, coronary artery bypass graft; DM, diabetes mellitus; HTN, hypertension; MI, myocardial infarction; PVD, peripheral vascular disease.",patients age ranged 33 70 21% 33-49 37% 50-59 42% 60-70 age 58 cabg coronary artery bypass graft dm diabetes mellitus htn hypertension mi myocardial infarction pvd peripheral vascular disease,C0030705|C0001779|C1514721|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0450371|C0001779|C0450371|C0010055|C0018787|C0003842|C0741847|C0181074|C3250443|C0011847|G0000000|C0020538|C0020538|C3810814|C0027061|C0021308|C0085096|C0205100|C0005847|C0012634
"Male patients (age r70 years) who underwent recent MI or CABG and admitted to a phase 2 multidisciplinary cardiac rehabilitation program in the Shaare Zedek Medical Center, Jerusalem.",male patients age r70 underwent mi cabg admitted phase 2 multidisciplinary cardiac rehabilitation program shaare zedek medical center jerusalem,C0086582|C0030705|C0001779|G0000000|G0000000|C3810814|C0010055|C0184666|C0205390|G0000000|C0242479|C0018787|C0034991|C1709697|G0000000|G0000000|C0199168|C0205099|G0000000
The prevalence of lower sexual activity and reduced satisfaction in patients who have undergone myocardial infarction (MI) or patients who had bypass surgery (coronary artery bypass graft; CABG) is reported to be significantly high [1][2][3][4][5][6][7][8][9].,prevalence lower sexual activity reduced satisfaction patients undergone myocardial infarction mi patients bypass surgery coronary artery bypass graft cabg reported 123456789,C0033105|C0441994|C0036864|C0205177|C0392756|C0242428|C0030705|G0000000|C0027061|C0021308|C3810814|C0030705|C0741847|C0038894|C0018787|C0003842|C0741847|C0181074|C0010055|C0684224|G0000000
"3101 patients with suspected TIA or ischaemic stroke presenting within 24 h of symptom onset were screened at 18 centres for study enrolment, among which 288 (93% of the screened population) were excluded for failure to meet an inclusion criterion and 2417 (779%) were excluded for meeting an exclusion criterion (table 1).",3101 patients suspected tia ischaemic stroke 24 symptom onset screened 18 centres study enrolment 288 93% screened population excluded failure meet inclusion criterion 2417 779% excluded meeting exclusion criterion table 1,G0000000|C0030705|C0332147|C0007787|C0475224|C0038454|C0450371|C1457887|C0206132|C0220908|C0450371|C0205099|C0557651|C1516879|C1442061|C0450371|C0220908|C0032659|C1554077|C0231174|C1550543|C0007637|C0243161|G0000000|C1442061|C1554077|C0556656|C0680251|C0243161|C0039224|G0000000
"Between May, 2003, andDecember, 2006, patients aged 40 years or older with a minor stroke, as defi ned by a US National Institutes of Health stroke scale (NIHSS) score of 3 or less at the time of randomisation, or TIA within 24 h of onset were eligible for enrolment.",2003 anddecember 2006 patients aged 40 minor stroke defi ned national institutes health stroke scale nihss score 3 time randomisation tia 24 onset eligible enrolment,G0000000|G0000000|G0000000|C0030705|C0001779|C0450371|C0026193|C0038454|G0000000|C1518340|C3245503|C0021622|C0018684|C0038454|C0175659|C3476804|C0449820|G0000000|C0040223|C0034656|C0007787|C0450371|C0206132|C1548635|C1516879
The analysis was based on the 37 patients who completed the 3 year follow-up.,analysis based 37 patients completed 3 follow-up,C0002778|C1527178|C0450371|C0030705|C0205197|G0000000|C0589120
"Exclusion criteria were as follows: Serum creatinine >4.0 mg/dl, myocardial infarction or cerebrovascular accident in the past 12 months, known intolerance to study medication, pregnancy or females without contraception, evidence for severe hepatic disease, use of immunosuppressants or non-steroidal anti-inflammatory drugs (NSAIDs), congestive heart failure, alcohol abuse or consumption of narcotics, the presence of a malignant disease or noncompliance of the subjects.",exclusion criteria serum creatinine 4 0 mg/dl myocardial infarction cerebrovascular accident 12 months intolerance study medication pregnancy females contraception evidence severe hepatic disease immunosuppressants non-steroidal anti-inflammatory drugs nsaids congestive heart failure alcohol abuse consumption narcotics presence malignant disease noncompliance subjects,C0680251|C0243161|C0229671|C0010294|G0000000|G0000000|C0439269|C0027061|C0021308|C1880018|C0000924|C0450371|C0439231|C0231199|C0557651|C0013227|C0032961|C0015780|C0700589|C3887511|C0205082|C0205054|C0012634|C0021081|C1518422|C0003209|C0013227|C0003211|C0742742|C0018787|C0231174|C0001962|C0013146|C0009830|C0027415|C0150312|C0205282|C0012634|C0376405|C0681850
"Inclusion criteria for the trial were: Confirmed diagnosis of ADPKD, age 18-65 years, evidence for hypertension (casual BP 140/90 mm Hg and/or presence of an antihypertensive medication), and serum creatinine 4.0 mg/dl.",inclusion criteria trial confirmed diagnosis adpkd age 18-65 evidence hypertension casual bp 140/90 mm hg and/or presence antihypertensive medication serum creatinine 4 0 mg/dl,C0007637|C0243161|C0008976|C0521093|C0011900|C0085413|C0001779|C0450371|C3887511|C0020538|G0000000|C0037623|C1442061|G0000000|C0025424|G0000000|C0150312|C0003364|C0013227|C0229671|C0010294|G0000000|G0000000|C0439269
"At baseline, the rigorous and the standard BP control group did not differ with respect to age (40  2 vs 41  2 years; P = NS), gender (males/females: 9/10 vs 8/10; P = NS), duration of hypertension (7.2  2.3 vs 6.0  1.8 years; P = NS), GFR (83.1  8.6 vs 91.2  6.4 ml/min; P = NS), LVMI (94.5  4.7 vs 97.0  5.2 g/m 2 ; P = NS), and urinary albumin/creatinine ratio (56.8  23.2 vs 84.2  19.8 mg/g; P = NS).",baseline rigorous standard bp control respect age 40 2 41 2 = ns gender males/females 9/10 8/10 = ns duration hypertension 7 2 2 3 6 0 1 8 = ns gfr 83 1 8 6 91 2 6 4 ml/min = ns lvmi 94 5 4 7 97 0 5 2 g/m 2 = ns urinary albumin/creatinine ratio 56 8 23 2 84 2 19 8 mg/g = ns,C0168634|C0026837|C1442989|C0037623|C0243148|C0679133|C0001779|C0450371|G0000000|C0450371|G0000000|G0000000|C0038944|C0079399|C0086582|C0450371|C0450371|G0000000|C0038944|C0449238|C0020538|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0038944|C0017654|C0450371|G0000000|G0000000|G0000000|C0450371|G0000000|G0000000|G0000000|C0439445|G0000000|C0038944|G0000000|C0450371|G0000000|G0000000|G0000000|C0450371|G0000000|G0000000|G0000000|C0456715|G0000000|G0000000|C0038944|C0042027|C0486293|C0456603|C0450371|G0000000|C0450371|G0000000|C0450371|G0000000|C0450371|G0000000|C1300563|G0000000|C0038944
"Of the 2,560 patients screened, 353 patients were enrolled; 176 were randomly assigned to receive pravastatin and 177 were randomly assigned to receive standard AMI therapy without pravastatin (Fig 1).",2 560 patients screened 353 patients enrolled 176 randomly assigned receive pravastatin 177 randomly assigned receive standard ami therapy pravastatin fig 1,G0000000|C1442061|C0030705|C0220908|C1442061|C0030705|G0000000|C1442061|G0000000|C1516050|C1514756|C0085542|C1442061|G0000000|C1516050|C1514756|C1442989|G0000000|C0039798|C0085542|C0349966|G0000000
The AMI patients are included in the study if the serum level of TC was between 200 and 250 mg/dl and that of triglycerides did not exceed 300 mg/dl.,ami patients included study serum level tc 200 250 mg/dl triglycerides exceed 300 mg/dl,G0000000|C0030705|C0332257|C0557651|C0229671|C0441889|C0039411|C1442061|C1442061|C0439269|C0041004|G0000000|C1442061|C0439269
"Between May 2000 and December 2003, 2,560 patients with AMI were screened, and finally 353 patients were enrolled in the OACIS-LIPID study at 14 hospitals in Japan (see Appendix 1).",2000 december 2003 2 560 patients ami screened finally 353 patients enrolled oacis-lipid study 14 hospitals japan appendix 1,G0000000|C3830550|G0000000|G0000000|C1442061|C0030705|G0000000|C0220908|G0000000|C1442061|C0030705|G0000000|C0023779|C0557651|C0450371|C0019994|C0022341|C0003617|G0000000
Methods and Results The study group comprised 353 patients with AMI who had plasma total cholesterol levels of 200-250 mg/dl and triglyceride levels <300 mg/dl.,methods study comprised 353 patients ami plasma total cholesterol levels 200-250 mg/dl triglyceride levels <300 mg/dl,C0025663|C0557651|C2700400|C1442061|C0030705|G0000000|C0032105|C0439175|C0008377|C0441889|C1442061|C0439269|C0041004|C0441889|C1442061|C0439269
"Considering the number of patients who were excluded, we set the number at 175 patients for each group.",patients excluded set 175 patients,C0030705|C1554077|C0036849|C1442061|C0030705
Thirteen women were excluded because they requested and underwent cesarean deliveries without medical indications or had epidural analgesia during the course of labor.,thirteen women excluded requested underwent cesarean deliveries medical indications epidural analgesia labor,C3715149|C0043210|C1554077|C1272683|G0000000|C3841297|C0011209|C0199168|C0392360|C0228134|C0002766|C0022864
OBJECTIVE: To compare the efficacy and safety of ti-trated oral misoprostol and vaginal misoprostol for labor induction.,objective compare efficacy safety ti-trated oral misoprostol vaginal misoprostol labor induction,C0018017|C1707455|C1280519|C0036043|C0039247|C0442027|C0085174|C0042232|C0085174|C0022864|C0205263
Women assigned to the vaginal misoprostol group received 25 mcg every 4 hours until attaining a more favorable cervix (Bishop score greater than or equal to 7) or adequate uterine activity (greater than or equal to three contractions in 10 minutes) or entering active labor.,women assigned vaginal misoprostol received 25 mcg 4 hours attaining favorable cervix bishop score equal 7 adequate uterine activity equal contractions 10 minutes entering active labor,C0043210|C1516050|C0042232|C0085174|C1514756|C0450371|C0439211|G0000000|C0439227|G0000000|C3640814|C0007874|C1551458|C0449820|C0205163|G0000000|C0205410|C0042149|C0205177|C0205163|C1140999|C0450371|C0439232|C1522196|C0205177|C0022864
A total of 220 women were enrolled in the study.,total 220 women enrolled study,C0439175|C1442061|C0043210|G0000000|C0557651
"We excluded patients with residual myocardial ischemia, severe ventricular arrhythmias, atrio-ventricular block, valvular disease requiring surgery, pericarditis, and severe renal dysfunction (i.e.",excluded patients residual myocardial ischemia severe ventricular arrhythmias atrio-ventricular block valvular disease requiring surgery pericarditis severe renal dysfunction,C1554077|C0030705|C1609982|C0027061|C0022116|C0205082|C0018827|C0003811|C0018827|C0028778|C0184252|C0012634|G0000000|C0038894|C0031046|C0205082|C0022646|C0031847
"Aims To investigate the effects of exercise training (ET) on left ventricular (LV) volumes, cardiopulmonary functional capacity and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in postinfarction patients with moderate LV dysfunction.",aims investigate effects exercise training left ventricular lv volumes cardiopulmonary functional capacity n-terminal pro-brain natriuretic peptide nt-probnp levels postinfarction patients moderate lv dysfunction,C1947946|C1292732|C1280500|C0015259|C0040607|C0205091|C0018827|C0023128|C0449468|C0553534|C0205245|C1516240|C0369718|C0033382|C0597421|C0030956|C0669479|C0441889|G0000000|C0030705|C0205081|C0023128|C0031847
Eighty-one consecutive patients immediately after acute ST elevation MI were screened for inclusion into the study.,eighty-one consecutive patients acute st elevation mi screened inclusion study,C3816958|C1707491|C0030705|C0205178|C0036056|C0439775|C3810814|C0220908|C0007637|C0557651
"The inclusion criteria were coronary artery stenosis documented by angiograhpy or previous coronary artery bypass grafting, classes I-III angina pectoris, classified according to the Canadian Cardiovascular Society [14].",inclusion criteria coronary artery stenosis documented angiograhpy previous coronary artery bypass grafting classes i-iii angina pectoris classified canadian cardiovascular society 14,C0007637|C0243161|C0018787|C0003842|C0678234|C1301725|G0000000|C0205156|C0018787|C0003842|C0741847|C0332835|C0456387|C0021966|C0002962|G0000000|C0008902|C0238884|C0007226|C0037455|C0450371
"In stable coronary artery disease, endothelial dysfunction plays a major role in the pathogenesis of exercise-induced angina pectoris [3].",stable coronary artery disease endothelial dysfunction plays major role pathogenesis exercise-induced angina pectoris 3,C0205360|C0018787|C0003842|C0012634|C0014257|C0031847|C0032214|C0205082|C0035820|C0543483|C0239313|C0002962|G0000000|G0000000
"Methods: A randomised, controlled study was performed in Sweden between 2004 and 2006 in thirty-seven patients (five women) with stable coronary artery disease (CAD), age 63.6  6.9 years, randomised to either high frequency exercise or control group.",methods randomised controlled study performed sweden 2004 2006 thirty-seven patients women stable coronary artery disease cad age 63 6 6 9 randomised frequency exercise control,C0025663|G0000000|C2587213|C0557651|C0884358|C0038995|G0000000|G0000000|C3816446|C0030705|C0043210|C0205360|C0018787|C0003842|C0012634|C3813548|C0001779|C0450371|G0000000|G0000000|G0000000|G0000000|C0376249|C0015259|C0243148
"Thirty-seven patients with stable CAD and coronary angiographic changes indicating an elective PCI were recruited from the waiting list for PCI-patients with stable CAD at the cardiology department at SU/Sahlgrenska, Gothenburg, Sweden.",thirty-seven patients stable cad coronary angiographic indicating elective pci recruited waiting list pci-patients stable cad cardiology department su/sahlgrenska gothenburg sweden,C3816446|C0030705|C0205360|C3813548|C0018787|C0002978|G0000000|C0206058|C4049621|G0000000|C1610166|C0745732|C4049621|C0205360|C3813548|C0007189|C1704729|C0038642|G0000000|C0038995
"Objective: The objective of this 3-year, randomized, multicenter, double-blind, placebo-controlled study was to compare true GFR decline (measured by yearly 51 Cr-EDTA blood clearance) in nondiabetic, non-nephrotic adult hypertensive patients with estimated creatinine clearance of 20 to 60 mL/min  1.73 m 2 , when randomized to a CCB (amlodipine, 5-10 mg/d) or an ACEI (enalapril, 5-20 mg/d).",objective objective 3-year randomized multicenter double-blind placebo-controlled study compare true gfr decline measured yearly 51 cr-edta blood clearance nondiabetic non-nephrotic adult hypertensive patients estimated creatinine clearance 20 60 ml/min 1 73 2 randomized ccb amlodipine 5-10 mg/d acei enalapril 5-20 mg/d,C0018017|C0018017|C0439234|C0034656|C0439743|C0013072|C1706408|C0557651|C1707455|C0205238|C0017654|G0000000|C0444706|C0332181|C0450371|C0201975|C0005767|C0449297|G0000000|C1518422|C0001675|C0857121|C0030705|C0750572|C0010294|C0449297|C0450371|C0450371|C0439445|G0000000|C0450371|G0000000|C0034656|C0006684|C0051696|C0450371|C0439422|G0000000|C0014025|C0450371|C0439422
"Nondiabetic adult patients, aged 18 to 80 years, with estimated creatinine clearance of 20 to 60 mL/min  1.73 m 2 (Cockcroft-Gault), were selected for study inclusion.",nondiabetic adult patients aged 18 80 estimated creatinine clearance 20 60 ml/min 1 73 2 cockcroft-gault selected study inclusion,G0000000|C0001675|C0030705|C0001779|C0450371|C0450371|C0750572|C0010294|C0449297|C0450371|C0450371|C0439445|G0000000|C0450371|G0000000|G0000000|C1707391|C0557651|C0007637
"Exclusion criteria included nephrotic proteinuria, secondary or malignant hypertension (diastolic BP [DBP] >120 mm Hg), a major cardiovascular event within 3 months, angina pectoris, congestive heart disease (New York Heart Association class II-IV), uncontrolled arrhythmias, II-III degree atrioventricular block, need for steroids, nonsteroidal anti-inflammatory or cytotoxic drugs, women of childbearing potential not using appropriate contraception, or any disease that could limit the ability of the patient to comply with the protocol requirements.",exclusion criteria included nephrotic proteinuria secondary malignant hypertension diastolic bp dbp 120 mm hg major cardiovascular event 3 months angina pectoris congestive heart disease york heart association class ii-iv uncontrolled arrhythmias ii-iii degree atrioventricular block steroids nonsteroidal anti-inflammatory cytotoxic drugs women childbearing potential contraception disease limit ability patient comply protocol requirements,C0680251|C0243161|C0332257|G0000000|C0033687|C0027627|C0205282|C0020538|C0012000|C0037623|C0536221|C1442061|G0000000|C0025424|C0205082|C0007226|C0441471|G0000000|C0439231|C0002962|G0000000|C0742742|C0018787|C0012634|G0000000|C0018787|C0004083|C0456387|C0022326|C0205318|C0003811|C0439070|C0441889|G0000000|C0028778|C0038317|G0000000|C0003209|C0677881|C0013227|C0043210|G0000000|C3245505|C0700589|C0012634|C0439801|C0085732|C0030705|C0725694|C0442711|C1514873
"Patients with 3 or more classic risk factors (systolic blood pressure N140 mm Hg, total serum cholesterol N4.5 mmol/L, body mass index N25 kg/m 2 , physical activity 4 hours per week, diabetes, male sex, or a family history of IHD b60 years) were considered HR if they did not have CHF or IHD.",patients 3 classic risk factors systolic blood pressure n140 mm hg total serum cholesterol n4 5 mmol/l body mass n25 kg/m 2 physical activity 4 hours week diabetes male sex family history ihd b60 considered hr chf ihd,C0030705|G0000000|C0439658|C0035647|C1521761|C0039155|C0005767|C0033095|G0000000|G0000000|C0025424|C0439175|C0229671|C0008377|C0445085|G0000000|C1532563|C0242821|C0577559|G0000000|C1532718|G0000000|C0031809|C0205177|G0000000|C0439227|C0332174|C0011847|C0086582|C0009253|C0015576|C0019664|C0151744|G0000000|C0750591|G0000000|C0018802|C0151744
"Of the 770 participants, 91 (12%) had CHF, 446 (58%) IHD, and 233 (30%) HR; 380 patients were randomly allocated to CCR versus 390 to UC.",770 participants 91 12% chf 446 58% ihd 233 30% hr 380 patients randomly allocated ccr versus 390 uc,C1442061|C0679646|C0450371|C0450371|C0018802|C1442061|C0450371|C0151744|C1442061|C0450371|G0000000|C1442061|C0030705|G0000000|G0000000|C1955905|G0000000|C1442061|G0000000
"The reasons for nonparticipation in the trial are listed in Figure 1; mental and social problems were defined as conditions with an HR of inadequate participation (eg, dementia, alcohol abuse), and severe illness was defined as terminal illness or comorbidity with an HR of death within 1 year (eg, terminal cancer).",reasons nonparticipation trial listed figure 1 mental social defined conditions hr inadequate participation dementia alcohol abuse severe illness defined terminal illness comorbidity hr death 1 terminal cancer,C0392360|G0000000|C0008976|C0745732|G0000000|G0000000|C0229992|C0728831|C1704788|C0012634|G0000000|C0205412|C0679823|C0011265|C0001962|C0013146|C0205082|C0221423|C1704788|C0205088|C0221423|C0009488|G0000000|C0011065|G0000000|C0205088|C0006826
We compared the effect of antihypertensive treatment with a calcium-channel-blocker-based regimen and an angiotensin-converting-enzyme-inhibitor-based regimen on the retinal microvasculature.,compared antihypertensive treatment calcium-channel-blocker-based regimen angiotensin-converting-enzyme-inhibitor-based regimen retinal microvasculature,C1707455|C0003364|C0039798|C0006684|C0040808|C0003015|C0040808|C0035298|C0243079
"Despite the extensive data regarding the effects of hypertension and other cardiovascular risk factors on the Twenty-five patients (17 men, age range 24-71 years) with untreated hypertension (previously untreated or antihypertensive treatment discontinued for at least 1 year) were recruited from the Peart-Rose Hypertension and Cardiovascular Disease Prevention Clinic at St Mary's Hospital NHS Trust.",extensive data effects hypertension cardiovascular risk factors twenty-five patients 17 age range 24-71 untreated hypertension untreated antihypertensive treatment discontinued 1 recruited peart-rose hypertension cardiovascular disease prevention clinic st marys hospital nhs trust,C0205231|C1511726|C1280500|C0020538|C0007226|C0035647|C1521761|C3715062|C0030705|C0450371|C0001779|C1514721|C0450371|C0332155|C0020538|C0332155|C0003364|C0039798|C1444662|G0000000|G0000000|C0035853|C0020538|C0007226|C0012634|C0199176|C0002424|C0036056|G0000000|C0019994|C0796085|C0237935
"Individuals were not eligible for the study if they had accelerated hypertension, secondary hypertension, diabetes mellitus, familial hypercholesterolaemia, heart failure or any other significant concomitant disease.",individuals eligible study accelerated hypertension secondary hypertension diabetes mellitus familial hypercholesterolaemia heart failure concomitant disease,C0027361|C1548635|C0557651|C0521110|C0020538|C0027627|C0020538|C0011847|G0000000|C0015576|C0020443|C0018787|C0231174|C0521115|C0012634
"We, therefore, hypothesized that antihypertensive treatment would cause regression of microvascular changes in hypertension and we also compared the effect of a calcium-channel-blocker (CCB)-based regimen and an angiotensin-converting-enzyme-inhibitor (ACEI)-based regimen on the retinal microvasculature.",hypothesized antihypertensive treatment regression microvascular hypertension compared calcium-channel-blocker ccb -based regimen angiotensin-converting-enzyme-inhibitor acei -based regimen retinal microvasculature,G0000000|C0003364|C0039798|C0684320|C0443258|C0020538|C1707455|C0006684|C0006684|C1527178|C0040808|C0003015|G0000000|C1527178|C0040808|C0035298|C0243079
Methods and Results Thirty-four male CAD patients (>65 years old) were randomly assigned to an intervention group (n=18) or a control group (n=16).,methods thirty-four male cad patients 65 randomly assigned intervention n=18 control n=16,C0025663|C3816446|C0086582|C3813548|C0030705|C0450371|G0000000|C1516050|C0886296|C0369718|C0243148|C0369718
"Patients with ongoing congestive heart failure, liver dysfunction (aspartate aminotransferase 40 IU/L), renal dysfunction (creatinine 2.0 mg/dl), or systemic diseases, including malignancy and collagen disease, were excluded.",patients ongoing congestive heart failure liver dysfunction aspartate aminotransferase 40 iu/l renal dysfunction creatinine 2 0 mg/dl systemic diseases including malignancy collagen disease excluded,C0030705|C0549178|C0742742|C0018787|C0231174|C0023884|C0031847|C0085845|C0002594|C0450371|C0439457|C0022646|C0031847|C0010294|G0000000|G0000000|C0439269|C0205373|C0012634|C0332257|C0006826|C0009325|C0012634|C1554077
"Exclusion criteria included patients with known allergy to gabapentin, a history of drug or alcohol abuse, chronic pain or daily intake of analgesics or corticosteroids, diabetes or impaired kidney function and anticipated difficult intubation.",exclusion criteria included patients allergy gabapentin history drug alcohol abuse chronic pain daily intake analgesics corticosteroids diabetes impaired kidney function anticipated difficult intubation,C0680251|C0243161|C0332257|C0030705|C0002111|C0060926|C0019664|C0013227|C0001962|C0013146|C0205191|C0030193|C0332173|C1512806|C0002771|C0001617|C0011847|C0221099|C0022646|C0031843|C3840775|C0332218|C0021925
"The patients were considered eligible for the trial, if the age was ,75 years, there was an electrocardiogram (ECG) evidence of STEMI, elevated troponin levels, and thrombolytic therapy given within 12 h after the onset of symptoms, no need for urgent PCI immediately after thrombolysis, no cardiogenic shock, no rescue PCI due to chest pain, haemodynamic instability, or lack of resolution of ST-segment elevations after thrombolysis, no need for coronary artery bypass graft surgery, no refusal of the patient to participate, and no severe coexisting condition that interfered with the ability of the patient to comply with the protocol.",patients considered eligible trial age 75 electrocardiogram ecg evidence stemi elevated troponin levels thrombolytic therapy 12 onset symptoms urgent pci thrombolysis cardiogenic shock rescue pci chest pain haemodynamic instability lack resolution st-segment elevations thrombolysis coronary artery bypass graft surgery refusal patient participate severe coexisting condition interfered ability patient comply protocol,C0030705|C0750591|C1548635|C0008976|C0001779|C0450371|C0013798|C1623258|C3887511|C3538872|C0205250|C0041199|C0441889|C0016018|C0039798|C0450371|C0206132|C0683368|C0439609|C4049621|C0520997|C1749797|C0036974|G0000000|C4049621|C0817096|C0030193|C0019010|C1444783|C0332268|C1514893|C0429029|C0702240|C0520997|C0018787|C0003842|C0741847|C0181074|C0038894|G0000000|C0030705|G0000000|C0205082|G0000000|C0012634|C0521102|C0085732|C0030705|C0725694|C0442711
"This randomized, double-blind, multicenter study assessed the long-term efficacy and safety of the direct renin inhibitor aliskiren in comparison with the diuretic hydrochlorothiazide in patients with essential hypertension.",randomized double-blind multicenter study assessed long-term efficacy safety direct renin inhibitor aliskiren comparison diuretic hydrochlorothiazide patients essential hypertension,C0034656|C0013072|C0439743|C0557651|C1516048|C0443252|C1280519|C0036043|C0439851|C0035094|C1999216|C1120110|C1707455|C0012798|C0020261|C0030705|C0205224|C0020538
The primary objectives of this study were (1) to compare the long-term efficacy of an aliskiren-based regimen (with optional addition of amlodipine 5 or 10 mg to aliskiren 300 mg) with that of a hydrochlorothiazide-based regimen (with optional addition of,primary objectives study 1 compare long-term efficacy aliskiren-based regimen optional addition amlodipine 5 10 aliskiren 300 hydrochlorothiazide-based regimen optional addition,C0205225|C0018017|C0557651|G0000000|C1707455|C0443252|C1280519|C1120110|C0040808|C1518600|C0332287|C0051696|G0000000|C0450371|C1120110|C1442061|C0020261|C0040808|C1518600|C0332287
Patients eligible for inclusion were outpatients aged 18 years with essential hypertension (mean sitting diastolic BP [msDBP] 90 mm Hg and 110 mm Hg at the single-blind placebo run-in visit).,patients eligible inclusion outpatients aged 18 essential hypertension sitting diastolic bp msdbp 90 mm hg 110 mm hg single-blind placebo run-in visit,C0030705|C1548635|C0007637|C0029921|C0001779|C0450371|C0205224|C0020538|C0277814|C0012000|C0037623|G0000000|C0450371|G0000000|C0025424|C1442061|G0000000|C0025424|C0242570|C0032042|C3274438|C0545082
Patients with a history of severe cardiovascular or cerebrovascular disease or other severe lifethreatening medical conditions were excluded.,patients history severe cardiovascular cerebrovascular disease severe lifethreatening medical conditions excluded,C0030705|C0019664|C0205082|C0007226|C1880018|C0012634|C0205082|C1517874|C0199168|C0012634|C1554077
"Women with pathologically confirmed, HER-2-positive, locally advanced or metastatic breast cancer were enrolled on the study if they provided written informed consent.",women pathologically confirmed her-2-positive locally advanced metastatic breast cancer enrolled study provided written informed consent,C0043210|G0000000|C0521093|C0439178|C1517927|C0205179|C0036525|C0006141|C0006826|G0000000|C0557651|C1999230|C0043266|C1522154|C1511481
"Patients were required to have a Karnofsky performance status of 60% or greater; a life expectancy of greater than 3 months; and adequate hematologic, renal, hepatic, and cardiac function that was sonographically confirmed by a left ventricular ejection fraction (LVEF) of 50% or greater.",patients required karnofsky performance status 60% life expectancy 3 months adequate hematologic renal hepatic cardiac function sonographically confirmed left ventricular ejection fraction lvef 50%,C0030705|C1514873|C0206065|C0597198|C0449438|C0450371|C0376558|C0679138|G0000000|C0439231|C0205410|C0018943|C0022646|C0205054|C0018787|C0031843|G0000000|C0521093|C0205091|C0018827|C0302131|C1264633|C0428772|C0450371
We evaluated only healthy patients aged 20-60 years.,evaluated healthy patients aged 20-60,C0220825|C3898900|C0030705|C0001779|C0450371
"Fifty-six adult patients aged 20-60 years, and scheduled for elective surgery requiring orotracheal intubation and general anesthesia, were enrolled in the study.",fifty-six adult patients aged 20-60 scheduled elective surgery requiring orotracheal intubation anesthesia enrolled study,C3816723|C0001675|C0030705|C0001779|C0450371|C0086960|C0206058|C0038894|G0000000|G0000000|C0021925|C0002903|G0000000|C0557651
Sixty-one consecutive women presenting to the labor ward on scheduled days of the week were recruited to the study.,sixty-one consecutive women labor ward scheduled days week recruited study,C3816724|C1707491|C0043210|C0022864|C1305702|C0086960|C0439228|C0332174|G0000000|C0557651
The aim of the present study was to compare the safety and efficacy of oral misoprostol with PGE2 gel in women with PROM at term and an unfavorable Bishop score.,aim study compare safety efficacy oral misoprostol pge2 gel women prom term unfavorable bishop score,C1947946|C0557651|C1707455|C0036043|C1280519|C0442027|C0085174|G0000000|C0017243|C0043210|C0015944|C0233324|C3640815|C1551458|C0449820
Women with a live singleton fetus at term (37-42 weeks of gestation) in cephalic presentation and a reactive nonstress test (NST) presenting with PROM and a Bishop score of 5 or less before the onset of labor were included in the study.,women live singleton fetus term 37-42 weeks gestation cephalic presentation reactive nonstress test nst prom bishop score 5 onset labor included study,C0043210|C1548795|C0481462|C0015965|C0233324|C0450371|C0439230|C0032961|C0205096|C0449450|C0205332|G0000000|C0022885|C1831742|C0015944|C1551458|C0449820|G0000000|C0206132|C0022864|C0332257|C0557651
"Inclusion criteria were age between 40 and 65 years old, STEMI according to the WHO definition, PCI ,12 h from the onset of symptoms, one vessel disease with an open infarct related artery amenable to cell therapy.",inclusion criteria age 40 65 stemi definition pci 12 onset symptoms vessel disease infarct artery amenable cell therapy,C0007637|C0243161|C0001779|C0450371|C0450371|C3538872|C1550452|C4049621|C0450371|C0206132|C0683368|C0005847|C0012634|C0021308|C0003842|C3900053|C0007634|C0039798
"In recent years, a variety of clinical trials have explored the hypothesis that BMMNC transplantation may enhance the recovery of LV function after AMI.",variety clinical trials explored hypothesis bmmnc transplantation enhance recovery lv function ami,C1883525|C0205210|C0008976|G0000000|C1512571|G0000000|C0040732|C2349975|C0237820|C0023128|C0031843|G0000000
The final preparation of the injected cells contained 5 + 1.2  10 7 mononuclear BMMNC and the control group was made using repeated-measures ANOVA.,final preparation injected cells contained 5 + 1 2 10 7 mononuclear bmmnc control repeated-measures anova,C0205088|C1521827|C1720154|C0007634|C0332256|G0000000|G0000000|G0000000|G0000000|C0450371|G0000000|C1513475|G0000000|C0243148|C0205341|G0000000
"General exclusion criteria were previous MI, cardiomyopathy, atrial fibrillation or flutter, previous heart surgery, severe valvular heart disease, disease of the haematopoietic system, NYHA functional class IV heart failure at baseline, severe renal, lung and liver disease or cancer, significant coronary lesion in one or more major coronary vessels, intracardiac thrombus, and bone marrow disease.",exclusion criteria previous mi cardiomyopathy atrial fibrillation flutter previous heart surgery severe valvular heart disease disease haematopoietic system nyha functional class iv heart failure baseline severe renal lung liver disease cancer coronary lesion major coronary vessels intracardiac thrombus bone marrow disease,C0680251|C0243161|C0205156|C3810814|C0878544|C0018792|C0232197|C0016385|C0205156|C0018787|C0038894|C0205082|C0184252|C0018787|C0012634|C0012634|C0018957|C0449913|G0000000|C0205245|C0456387|C0022326|C0018787|C0231174|C0168634|C0205082|C0022646|C0024109|C0023884|C0012634|C0006826|C0018787|C0221198|C0205082|C0018787|C0005847|C0729936|C0087086|C0262950|C0086590|C0012634
The aim of this study was to compare the anti-hypertensive efficacy and renal and cardiac haemodynamic effects of bisoprolol with those of losartan over a 1-year time period in patients with essential hypertension.,aim study compare anti-hypertensive efficacy renal cardiac haemodynamic effects bisoprolol losartan 1-year time period patients essential hypertension,C1947946|C0557651|C1707455|C0003364|C1280519|C0022646|C0018787|C0019010|C1280500|C0053799|C0126174|C0439234|C0040223|C0439531|C0030705|C0205224|C0020538
"Inclusion criteria were a diagnosis of essential hypertension (ESH stage 1 or 2 hypertension) established by history and physical examination, together with the absence of clinical findings that would be suggestive of a secondary form of hypertension, according to ESH guidelines.",inclusion criteria diagnosis essential hypertension esh stage 1 2 hypertension established history physical examination absence clinical findings suggestive secondary form hypertension esh guidelines,C0007637|C0243161|C0011900|C0205224|C0020538|C1520135|C0205390|G0000000|G0000000|C0020538|C0443211|C0019664|C0031809|G0000000|C0332197|C0205210|C2607943|C0332299|C0027627|C0348078|C0020538|C1520135|C0162791
"Seventy-two patients (40 males, 32 females; aged from 29 to 63 years; mean -SD age 52 -12 years) with recently diagnosed essential hypertension were assessed for eligibility and enrolled in the trial.",seventy-two patients 40 males 32 females aged 29 63 -sd age 52 -12 diagnosed essential hypertension assessed eligibility enrolled trial,C3816957|C0030705|C0450371|C0086582|C0450371|C0015780|C0001779|C0450371|C0450371|C2699239|C0001779|C0450371|C0450371|C0011900|C0205224|C0020538|C1516048|C0013893|G0000000|C0008976
"Postmenopausal women with HER2-positive (immunohistochemistry [IHC] 3 by DAKO HercepTest [DAKO, Carpinteria, CA] or another US Food and Drug Administration-approved IHC test, and/or fluorescence in situ hybridization positive with  two-fold amplification; confirmed by central testing) and hormone receptor-positive (ER positive and/or PgR positive; determined locally as defined by institutional criteria) MBC were eligible.",postmenopausal women her2-positive immunohistochemistry ihc 3 dako herceptest dako carpinteria food drug administration-approved ihc test and/or fluorescence situ hybridization positive two-fold amplification confirmed central testing hormone receptor-positive er positive and/or pgr positive determined locally defined institutional criteria mbc eligible,C0232970|C0043210|C0439178|C0021044|C0021044|G0000000|G0000000|C1512416|G0000000|G0000000|C0016452|C0013227|C0001554|C0021044|C0022885|G0000000|C0016315|G0000000|C0020202|C0439178|C0205448|C1517480|C0521093|C0205099|C0039593|C0019932|C0597357|C3810541|C0439178|G0000000|G0000000|C0439178|G0000000|C1517927|C1704788|C0018704|C0243161|C0065839|C1548635
"The patients had stable (n = 36) or   unstable angina (n = 4), and none had a prior myocardial infarction.",patients stable = 36 unstable angina = 4 prior myocardial infarction,C0030705|C0205360|G0000000|C0450371|C0443343|C0002962|G0000000|G0000000|C0332152|C0027061|C0021308
"Forty patients (aged 59.2  9.5 years, 7 women) were consecutively enrolled after successful PCI with stent implantation and randomized into 2 groups.",forty patients aged 59 2 9 5 7 women consecutively enrolled successful pci stent implantation randomized 2,C3816449|C0030705|C0001779|C0450371|G0000000|G0000000|G0000000|G0000000|C0043210|G0000000|G0000000|C0597535|C4049621|C0038257|C0021107|C0034656|G0000000
"Exclusion criteria included a history of myocardial infarction (MI) or CABG, significant valvular heart disease, age over 80 years, inability to give informed consent, inability to participate in regular training due to residency, work situation or comorbidity, any known chronic inflammatory disease other than atherosclerosis, or planned surgery within the next 6 months.",exclusion criteria included history myocardial infarction mi cabg valvular heart disease age 80 inability informed consent inability participate regular training residency situation comorbidity chronic inflammatory disease atherosclerosis planned surgery 6 months,C0680251|C0243161|C0332257|C0019664|C0027061|C0021308|C3810814|C0010055|C0184252|C0018787|C0012634|C0001779|C0450371|G0000000|C1522154|C1511481|G0000000|G0000000|C0205272|C0040607|C0035182|G0000000|C0009488|C0205191|C0333348|C0012634|C0003850|C1301732|C0038894|G0000000|C0439231
To investigate the effect of intracoronary injection of autologous mononuclear bone marrow stem cells (BMSCs) in patients with ST-elevation myocardial infarction (STEMI) on left ventricular (LV) systolic and diastolic function using standard echocardiography and 2-dimensional systolic strain.,investigate intracoronary injection autologous mononuclear bone marrow stem cells bmscs patients st-elevation myocardial infarction stemi left ventricular lv systolic diastolic function standard echocardiography 2-dimensional systolic strain,C1292732|C0595454|C0021485|C0439859|C1513475|C0262950|C0086590|C0242767|C0007634|G0000000|C0030705|C0520886|C0027061|C0021308|C3538872|C0205091|C0018827|C0023128|C0039155|C0012000|C0031843|C1442989|C0013516|C1704750|C0039155|C0080194
"In the present study, we focused on detailed analysis of LV systolic and diastolic function using transthoracic echocardiography and speckle tracking imaging during a 6-month A total of 60 patients with a first anterior wall STEMI (18 women and 42 men, age 56  9 years, range 34 to 72) and a baseline LVEF 40%, were included in the present study.",study focused detailed analysis lv systolic diastolic function transthoracic echocardiography speckle tracking imaging 6-month total 60 patients anterior wall stemi 18 women 42 age 56 9 range 34 72 baseline lvef 40% included study,C0557651|C0205234|C1522508|C0002778|C0023128|C0039155|C0012000|C0031843|C0205503|C0013516|C0439691|C0546881|C0011923|C0332177|C0439175|C0450371|C0030705|C0205094|C0677535|C3538872|C0450371|C0043210|C0450371|C0001779|C0450371|G0000000|C1514721|C0450371|C0450371|C0168634|C0428772|C0450371|C0332257|C0557651
Objective: To carry out an echocardiographic analysis of the systolic function of patients with acute myocardial infarction after autologous mononuclear bone marrow cell transplantation (AMBMCT) as performed via the intracoronary and intravenous routes.,objective carry echocardiographic analysis systolic function patients acute myocardial infarction autologous mononuclear bone marrow cell transplantation ambmct performed intracoronary intravenous routes,C0018017|C0206243|C0013516|C0002778|C0039155|C0031843|C0030705|C0205178|C0027061|C0021308|C0439859|C1513475|C0262950|C0086590|C0007634|C0040732|G0000000|C0884358|C0595454|C0348016|C0449444
"Therefore, in order to reach that, we planned to recruit about 50-60 patients in each group within 2 years.",reach planned recruit 50-60 patients 2,C2584321|C1301732|G0000000|C0450371|C0030705|G0000000
"The inclusion criteria were: first AMI of anterior wall with ST elevation within 12 h from symptom onset, age between 35 and 70, and the absence of critical stenosis in other than left anterior descending (LAD), which was infarct-related artery (IRA).",inclusion criteria ami anterior wall st elevation 12 symptom onset age 35 70 absence critical stenosis left anterior descending lad infarct-related artery ira,C0007637|C0243161|G0000000|C0205094|C0677535|C0036056|C0439775|C0450371|C1457887|C0206132|C0001779|C0450371|C0450371|C0332197|C1511545|C0678234|C0205091|C0205094|C0205386|G0000000|C0021308|C0003842|C1512960
"Additional objectives were to examine the effect of this treatment on autonomic control [heart rate variability (HRV)], baroreflex sensitivity (BRS), arrhythmias, and exercise tolerance [cardiopulmonary exercise testing (CPET)] at 12-month follow-up.",additional objectives examine treatment autonomic control heart rate variability hrv baroreflex sensitivity brs arrhythmias exercise tolerance cardiopulmonary exercise testing cpet 12-month follow-up,C1524062|C0018017|G0000000|C0039798|C0004388|C0243148|C0018787|C0871208|C2827666|C0010343|C0206162|C0020517|G0000000|C0003811|C0015259|C0013220|C0553534|C0015259|C0039593|C0055954|C0450371|C0589120
"Enrolled patients underwent a series of pre-treatment baseline tests, involving a patient interview (detailed medical history, current medication, NYHA, and CCS classification), physical assessment, routine clinical laboratory tests, electrocardiogram (ECG), 24 h ECG Holter recording, autonomic control, echocardiography, and rest perfusion scintigraphy GATED-SPECT.",enrolled patients underwent series pre-treatment baseline tests involving patient interview detailed medical history current medication nyha ccs classification physical assessment routine clinical laboratory tests electrocardiogram ecg 24 ecg holter recording autonomic control echocardiography rest perfusion scintigraphy gated-spect,G0000000|C0030705|G0000000|C0205549|C2709094|C0168634|C0022885|C1314939|C0030705|C0021822|C1522508|C0199168|C0019664|C0521116|C0013227|G0000000|C3272108|C0008902|C0031809|C1261322|C0205547|C0205210|C0022877|C0022885|C0013798|C1623258|C0450371|C1623258|G0000000|G0000000|C0004388|C0243148|C0013516|C0035253|C0031001|C0034606|C0040399
The primary aim of our study was to examine whether intracoronary injection of autologous mononuclear BMC results in an improvement in global LV function assessed by 2D-echocardiography and resting and stress nuclear scintigraphy.,primary aim study examine intracoronary injection autologous mononuclear bmc improvement global lv function assessed 2d-echocardiography resting stress nuclear scintigraphy,C0205225|C1947946|C0557651|G0000000|C0595454|C0021485|C0439859|C1513475|C0065839|C2986411|C0205246|C0023128|C0031843|C1516048|C0043316|C0035253|C0038435|C0521447|C0034606
"Inclusion criteria were: age 18 -80 years, the presence of ST elevation MI of the anterior wall (positive ECG, troponin level, and symptoms, according to the WHO criteria), PCI treatment 2 -6 h after the onset of symptoms, successful PCI with was performed using the autoregressive method.",inclusion criteria age 18 -80 presence st elevation mi anterior wall positive ecg troponin level symptoms criteria pci treatment 2 -6 onset symptoms successful pci performed autoregressive method,C0007637|C0243161|C0001779|C0450371|C0450371|C0150312|C0036056|C0439775|C3810814|C0205094|C0677535|C0439178|C1623258|C0041199|C0441889|C0683368|C0243161|C4049621|C0039798|G0000000|G0000000|C0206132|C0683368|C0597535|C4049621|C0884358|G0000000|C0025663
"Metabolic syndrome is associated with intravascular inflammation, as determined by increased levels of inflammatory biomarkers and an increased risk of ischemic atherothrom-botic events.",metabolic syndrome intravascular inflammation determined increased levels inflammatory biomarkers increased risk ischemic atherothrom-botic events,C0311400|C0039082|C0442123|C0021368|G0000000|C0205217|C0441889|C0333348|C0005516|C0205217|C0035647|C0475224|G0000000|C0441471
"Diagnostic criteria for metabolic syndrome included having 3 of the 5 National Cholesterol Education Program criteria for metabolic syndrome: triglycerides 150 mg/dL, systolic blood pressure 130 mmHg and diastolic blood pressure >85 mmHg, fasting blood glucose 110 mg/dL, waist circumference >101.6 cm (40 in) for men and >88.9 cm (35 in) for women, and highdensity lipoprotein cholesterol <40 mg/dL for men and <50 mg/dL for women.",diagnostic criteria metabolic syndrome included 3 5 national cholesterol education program criteria metabolic syndrome triglycerides 150 mg/dl systolic blood pressure 130 mmhg diastolic blood pressure 85 mmhg fasting blood glucose 110 mg/dl waist circumference 101 6 cm 40 88 9 cm 35 women highdensity lipoprotein cholesterol <40 mg/dl <50 mg/dl women,C0011900|C0243161|C0311400|C0039082|C0332257|G0000000|G0000000|C3245503|C0008377|C0013621|C1709697|C0243161|C0311400|C0039082|C0041004|C1442061|C0439269|C0039155|C0005767|C0033095|C1442061|C0439475|C0012000|C0005767|C0033095|C0450371|C0439475|C0015663|C0005767|C0017725|C1442061|C0439269|C0230097|C0332520|C1442061|G0000000|G0000000|C0450371|C0450371|G0000000|G0000000|C0450371|C0043210|G0000000|C0023820|C0008377|C0450371|C0439269|C0450371|C0439269|C0043210
"Subjects were eligible for enrollment if they were 18 years of age with metabolic syndrome, had been on stable medications for 6 weeks prior to entry, had experienced an atherothrombotic vascular event or cardiovascular intervention 6 months earlier, and had an hs-CRP level between 2 mg/L and 10 mg/L at screening.",subjects eligible enrollment 18 age metabolic syndrome stable medications 6 weeks prior entry experienced atherothrombotic vascular event cardiovascular intervention 6 months earlier hs-crp level 2 mg/l 10 mg/l screening,C0681850|C1548635|C1516879|C0450371|C0001779|C0311400|C0039082|C0205360|C0013227|G0000000|C0439230|C0332152|C1705654|C0237607|G0000000|C0005847|C0441471|C0007226|C0886296|G0000000|C0439231|C1279919|C3890735|C0441889|G0000000|C0439268|C0450371|C0439268|C0220908
Patients must have received prior anthracycline-and taxane-based regimens in either the adjuvant or metastatic setting.,patients received prior anthracycline-and taxane-based regimens adjuvant metastatic setting,C0030705|C1514756|C0332152|C0003234|C0215136|C2945654|C0001551|C0036525|C0542559
Eligible patients were women  18 years of age with histologically or cytologically confirmed BC.,eligible patients women 18 age histologically cytologically confirmed bc,C1548635|C0030705|C0043210|C0450371|C0001779|C0205462|G0000000|C0521093|C0006041
Eligible patients had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) or bone-only disease.,eligible patients measurable lesion response evaluation criteria solid tumors recist bone-only disease,C1548635|C0030705|C1513040|C0221198|C0871261|C0220825|C0243161|C0205208|C0027651|C1709926|C0262950|C0012634
"Patients must have metastatic disease that progressed on their most recent treatment regimen, which must have contained trastuzumab.",patients metastatic disease progressed treatment regimen contained trastuzumab,C0030705|C0036525|C0012634|C1272688|C0039798|C0040808|C0332256|C0728747
"Exclusion criteria were systolic blood pressure 160 or 95 mm Hg or diastolic 105 mm Hg; clinical conditions other than cardiomyopathy that could increase plasma levels of inflammatory markers such as sepsis, autoimmune disease, or HIV positivity; significant liver disease (defined as liver transaminase levels 2 times the upper limit of normal); history of peptic ulcer disease; history of psychiatric disorders; impaired renal function (defined as urea and/or creatinine 1.5 times the upper limit of normal); and any clinical condition that, according to the investigators, precluded inclusion in the study such as ischemic heart disease or malignancy.",exclusion criteria systolic blood pressure 160 95 mm hg diastolic 105 mm hg clinical conditions cardiomyopathy increase plasma levels inflammatory markers sepsis autoimmune disease hiv positivity liver disease defined liver transaminase levels 2 times upper limit normal history peptic ulcer disease history psychiatric disorders impaired renal function defined urea and/or creatinine 1 5 times upper limit normal clinical condition investigators precluded inclusion study ischemic heart disease malignancy,C0680251|C0243161|C0039155|C0005767|C0033095|C1442061|C0450371|G0000000|C0025424|C0012000|C1442061|G0000000|C0025424|C0205210|C0012634|C0878544|C0442805|C0032105|C0441889|C0333348|C0005516|C0036690|C0443146|C0012634|C0019682|C0439178|C0023884|C0012634|C1704788|C0023884|C0002594|C0441889|G0000000|C0040223|C1282910|C0439801|C0205307|C0019664|C0443277|C0041582|C0012634|C0019664|C0205487|C0012634|C0221099|C0022646|C0031843|C1704788|C0041942|G0000000|C0010294|G0000000|G0000000|C0040223|C1282910|C0439801|C0205307|C0205210|C0012634|C0035173|G0000000|C0007637|C0557651|C0475224|C0018787|C0012634|C0006826
"Inclusion criteria were symptoms of congestive heart failure that developed in the last month of pregnancy or during the first month postpartum, no other identifiable cause for heart failure, and LVEF 35% by transthoracic echocardiography.",inclusion criteria symptoms congestive heart failure developed month pregnancy month postpartum identifiable heart failure lvef 35% transthoracic echocardiography,C0007637|C0243161|C0683368|C0742742|C0018787|C0231174|G0000000|C0332177|C0032961|C0332177|C0086839|C0205396|C0018787|C0231174|C0428772|C0450371|C0205503|C0013516
Ninety-three patients with suspected PPCM were screened to recruit 20 consecutive patients with confirmed PPCM who were HIV negative and presented within 1 month postpartum.,ninety-three patients suspected ppcm screened recruit 20 consecutive patients confirmed ppcm hiv negative 1 month postpartum,C3816959|C0030705|C0332147|C3828544|C0220908|G0000000|C0450371|C1707491|C0030705|C0521093|C3828544|C0019682|C0205160|G0000000|C0332177|C0086839
A total of one-hundred and fifty-six patients were randomized and all completed the follow-up; seventy-eight subjects were assigned to each group ( Figure  1).,total one-hundred fifty-six patients randomized completed follow-up seventy-eight subjects assigned figure 1,C0439175|C0205447|C3816723|C0030705|C0034656|C0205197|C0589120|C3816957|C0681850|C1516050|G0000000|G0000000
Patients were eligible for the enrolment if they had ACS with ST-elevation (rest chest pain less than 12 hours before admission and  1 mm ST-segment elevation in 2 or more contiguous leads or new left bundle branch block Serum was prepared immediately after blood sampling and stored frozen at -70C until laboratory assessment.,patients eligible enrolment acs st-elevation rest chest pain 12 hours admission 1 mm st-segment elevation 2 contiguous leads left bundle branch block serum prepared blood sampling stored frozen -70c laboratory assessment,C0030705|C1548635|C1516879|G0000000|C0520886|C0035253|C0817096|C0030193|C0450371|C0439227|C0184666|G0000000|G0000000|C0429029|C0439775|G0000000|C0205283|C0023175|C0205091|G0000000|C1253959|C0028778|C0229671|C4082130|C0005767|C0441621|C1698986|C0016701|G0000000|C0022877|C1261322
"Laboring women aged 18 years or older with a singleton high-risk pregnancy, a fetus in cephalic presentation, a gestational age greater than 36 weeks, and an indication for internal electronic fetal monitoring were eligible.",laboring women aged 18 singleton high-risk pregnancy fetus cephalic presentation gestational age 36 weeks indication internal electronic fetal monitoring eligible,C0022864|C0043210|C0001779|C0450371|C0481462|C0332167|C0032961|C0015965|C0205096|C0449450|C0439671|C0001779|C0450371|C0439230|C0392360|C0205102|C0013850|C0015965|C0150369|C1548635
"High-risk pregnancies are complicated by preexisting maternal disease, complicated obstetric history, hypertensive disorders, intrauterine growth restriction, ruptured membranes for more than 24 hours, a postdate gestational age, failure to progress, need for pain relief, meconium-stained amniotic fluid, or nonreassuring fetal heart rate at intermittent auscultation by a midwife.",high-risk pregnancies complicated preexisting maternal disease complicated obstetric history hypertensive disorders intrauterine growth restriction ruptured membranes 24 hours postdate gestational age failure progress pain relief meconium-stained amniotic fluid nonreassuring fetal heart rate intermittent auscultation midwife,C0332167|C0032961|C0231242|C2347662|C2347083|C0012634|C0231242|C0205484|C0019664|C0857121|C0012634|C0694756|C0018270|C0443288|C0443294|C0025255|C0450371|C0439227|C0032993|C0439671|C0001779|C0231174|C1272688|C0030193|C0564405|C1112318|C0002630|C0005889|G0000000|C0015965|C0018787|C0871208|C0205267|C0004339|C0026083
"Women with a singleton pregnancy at 37 weeks' gestation requiring induction of labour because of either obstetric or medical complication, Bishop's score 6, intact membranes, cephalic presentation and reactive non-stress test, were included in the study.",women singleton pregnancy 37 weeks gestation requiring induction labour obstetric medical complication bishops score 6 intact membranes cephalic presentation reactive non-stress test included study,C0043210|C0481462|C0032961|C0450371|C0439230|C0032961|G0000000|C0205263|C0022864|C0205484|C0199168|C0009566|C0649610|C0449820|G0000000|C0205266|C0025255|C0205096|C0449450|C0205332|C1518422|C0022885|C0332257|C0557651
This prospective double blind study was undertaken to compare the safety and efficacy of oral vs vaginal misoprostol in equivalent doses (50 mg) for induction of labour.,prospective double blind study undertaken compare safety efficacy oral vaginal misoprostol equivalent doses 50 induction labour,C0023981|C0205173|C0150108|C0557651|G0000000|C1707455|C0036043|C1280519|C0442027|C0042232|C0085174|C0205163|C0178602|C0450371|C0205263|C0022864
"Pregnant women with a contraindication to vaginal birth, previous uterine surgery, abnormal fetal heart rate pattern, ruptured membranes, vaginal bleeding and women with known hypersensitivity to misoprostol or prostaglandin analogues were excluded.",pregnant women contraindication vaginal birth previous uterine surgery abnormal fetal heart rate pattern ruptured membranes vaginal bleeding women hypersensitivity misoprostol prostaglandin analogues excluded,C0549206|C0043210|C0522473|C0042232|C0005615|C0205156|C0042149|C0038894|C0205161|C0015965|C0018787|C0871208|C0449774|C0443294|C0025255|C0042232|C0019080|C0043210|C0020517|C0085174|C0033554|C0243071|C1554077
A total of 134 women were enrolled in the study.,total 134 women enrolled study,C0439175|C1442061|C0043210|G0000000|C0557651
Peripheral Arterial disease (CASPAR) study design.,peripheral arterial disease caspar study design,C0205100|C0003842|C0012634|G0000000|C0557651|C1707689
"Patients undergoing primary isolated CABG, with or without cardiopulmonary bypass, were eligible for inclusion in the study.",patients undergoing primary isolated cabg cardiopulmonary bypass eligible inclusion study,C0030705|G0000000|C0205225|C0205409|C0010055|C0553534|C0741847|C1548635|C0007637|C0557651
All patients referred for isolated surgical coronary revascularization from December 2007 to December 2008 with at least 1 SVG at Fuwai Hospital were screened according to the inclusion criteria.,patients referred isolated surgical coronary revascularization december 2007 december 2008 1 svg fuwai hospital screened inclusion criteria,C0030705|C0205543|C0205409|C0543467|C0018787|C0581603|C3830550|G0000000|C3830550|G0000000|G0000000|C0729538|G0000000|C0019994|C0220908|C0007637|C0243161
Prevalence of graft occlusion is high after CABG.,prevalence graft occlusion cabg,C0033105|C0181074|C0011382|C0010055
"Screening criteria were: age 18 -75 years, a successful percutaneous coronary intervention (PCI) with bare metal stent implantation performed on the culprit lesion during the 24 h after the onset of symptoms, and LVEF ,50% assessed by echocardiography.",screening criteria age 18 -75 successful percutaneous coronary intervention pci bare metal stent implantation performed culprit lesion 24 onset symptoms lvef 50% assessed echocardiography,C0220908|C0243161|C0001779|C0450371|C0450371|C0597535|C0522523|C0018787|C0886296|C4049621|G0000000|C0025552|C0038257|C0021107|C0884358|G0000000|C0221198|C0450371|C0206132|C0683368|C0428772|C0450371|C1516048|C0013516
The mean delay between BMC preparation and intracoronary injection was   A total of 122 patients with successfully reperfused STEMI by PCI and stent implantation within 24 h of the onset of chest pain gave written informed consent and was enrolled in the study.,delay bmc preparation intracoronary injection total 122 patients reperfused stemi pci stent implantation 24 onset chest pain written informed consent enrolled study,C0205421|C0065839|C1521827|C0595454|C0021485|C0439175|C1442061|C0030705|G0000000|C3538872|C4049621|C0038257|C0021107|C0450371|C0206132|C0817096|C0030193|C0043266|C1522154|C1511481|G0000000|C0557651
"Overall, the mean age was 56 + 9 years, 85% of the patients were men, median time from onset of symptoms to reperfusion was 3.3 h (IQR 2.3 -4.5), and 90% had thrombolysis in myocardial infarction flow grade 3 after primary PCI.",age 56 + 9 85% patients median time onset symptoms reperfusion 3 3 iqr 2 3 -4 5 90% thrombolysis myocardial infarction flow grade 3 primary pci,C0001779|C0450371|G0000000|G0000000|C0450371|C0030705|C0549183|C0040223|C0206132|C0683368|C0035124|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|G0000000|C0450371|C0520997|C0027061|C0021308|C0806140|C0441800|G0000000|C0205225|C4049621
A total of 200 patients were enrolled in the study and underwent baseline MRI at a median time of 3 days after primary PCI [interquartile range (IQR) 2-4].,total 200 patients enrolled study underwent baseline mri median time 3 days primary pci interquartile range iqr 2-4,C0439175|C1442061|C0030705|G0000000|C0557651|G0000000|C0168634|C0024485|C0549183|C0040223|G0000000|C0439228|C0205225|C4049621|G0000000|C1514721|G0000000|G0000000
Unselected bone marrow mononuclear cells have been tested in several randomized controlled trials [5][6][7][8][9] to investigate the effect of cell administration on clinical end-points and left ventricular function.,unselected bone marrow mononuclear cells tested randomized controlled trials 56789 investigate cell administration clinical end-points left ventricular function,G0000000|C0262950|C0086590|C1513475|C0007634|C0392366|C0034656|C2587213|C0008976|G0000000|C1292732|C0007634|C0001554|C0205210|C2349179|C0205091|C0018827|C0031843
"Furthermore, patients were required to have at least one measurable tumor lesion (patients with bone only disease were eligible).",patients required measurable tumor lesion patients bone disease eligible,C0030705|C1514873|C1513040|C0027651|C0221198|C0030705|C0262950|C0012634|C1548635
Main exclusion criteria were clinical or radiological signs of CNS metastasis; inflammatory breast cancer; other concurrent or previous malignant disease; uncontrolled cardiac diseases; prior anti-HER2 therapy apart from trastuzumab in the adjuvant setting.,main exclusion criteria clinical radiological signs cns metastasis inflammatory breast cancer concurrent previous malignant disease uncontrolled cardiac diseases prior anti-her2 therapy trastuzumab adjuvant setting,C0205225|C0680251|C0243161|C0205210|C0034599|C0220912|C3714787|C0027627|C0333348|C0006141|C0006826|C0205420|C0205156|C0205282|C0012634|C0205318|C0018787|C0012634|C0332152|G0000000|C0039798|C0728747|C0001551|C0542559
"For postmenopausal women with ER and/or PgR positive tumors, aromatase inhibitors are effective and well established agents both in the adjuvant and in the metastatic situation.",postmenopausal women er and/or pgr positive tumors aromatase inhibitors effective established agents adjuvant metastatic situation,C0232970|C0043210|C3810541|G0000000|G0000000|C0439178|C0027651|C0003805|C0243077|C1280519|C0443211|C0450442|C0001551|C0036525|G0000000
"Inclusion criteria were women aged 18 years or older with a term, singleton pregnancy who had obstetric or medical indication for labor induction (pre-eclampsia, postdate or post-term pregnancy, IUGR, and GDM).",inclusion criteria women aged 18 term singleton pregnancy obstetric medical indication labor induction pre-eclampsia postdate post-term pregnancy iugr gdm,C0007637|C0243161|C0043210|C0001779|C0450371|C0233324|C0481462|C0032961|C0205484|C0199168|C0392360|C0022864|C0205263|C0032914|C0032993|C1398117|C0032961|C0015934|C0085207
"Statistical analyses were performed using the t test,  A total of 70 women were recruited to the study.",statistical analyses performed test total 70 women recruited study,C0038215|C0002778|C0884358|C0022885|C0439175|C0450371|C0043210|G0000000|C0557651
Methods: A randomized double-blind trial of women with term single-ton pregnancies with indications for labor induction.,methods randomized double-blind trial women term single-ton pregnancies indications labor induction,C0025663|C0034656|C0013072|C0008976|C0043210|C0233324|C0037179|C0032961|C0392360|C0022864|C0205263
Objective: This study evaluated the effects of a home-based rehabilitation program for Chinese patients with myocardial infarction in terms of health-related quality of life and psychological status.,objective study evaluated effects home-based rehabilitation program chinese patients myocardial infarction terms health-related quality life psychological status,C0018017|C0557651|C0220825|C1280500|C0442519|C0034991|C1709697|C0008120|C0030705|C0027061|C0021308|C0233324|C0018684|C0332306|C0376558|C0205486|C0449438
"Exclusion criteria comprised a known history of major psychiatric illness, preexisting mobility problems, unstable angina, severe complications such as uncontrolled arrhythmias or heart failure, and other conditions that could be aggravated by exercise, such as a resting systolic blood pressure (BP) >200 mm Hg or a resting diastolic BP >110 mm Hg.",exclusion criteria comprised history major psychiatric illness preexisting mobility unstable angina severe complications uncontrolled arrhythmias heart failure conditions aggravated exercise resting systolic blood pressure bp 200 mm hg resting diastolic bp 110 mm hg,C0680251|C0243161|C2700400|C0019664|C0205082|C0205487|C0221423|C2347662|C0425245|C0443343|C0002962|C0205082|C0009566|C0205318|C0003811|C0018787|C0231174|C0012634|C0436331|C0015259|C0035253|C0039155|C0005767|C0033095|C0037623|C1442061|G0000000|C0025424|C0035253|C0012000|C0037623|C1442061|G0000000|C0025424
"Exclusion criteria were inability to perform their activities of daily living (such as feeding themselves, bathing, dressing, grooming, work, homemaking, and leisure), enrolment in another research project or in a heart failure clinic where serial follow-up creates a bias and contraindication to exercise testing.",exclusion criteria inability perform activities daily living feeding bathing dressing grooming homemaking leisure enrolment project heart failure clinic serial follow-up creates bias contraindication exercise testing,C0680251|C0243161|G0000000|C0884358|C0441655|C0332173|C0376558|C0204695|C0150141|C0013119|C0018249|G0000000|C0086542|C1516879|C1709701|C0018787|C0231174|C0002424|C0031082|C0589120|C1706214|C0242568|C0522473|C0015259|C0039593
"Finally, subjects with serious and unstable mental incapacities or major depression were excluded.",finally subjects unstable mental incapacities major depression excluded,G0000000|C0681850|C0443343|C0229992|G0000000|C0205082|C0011570|C1554077
Subjects with a previous history of stroke could be included if they had no residual effects related to their stroke.,subjects previous history stroke included residual effects stroke,C0681850|C0205156|C0019664|C0038454|C0332257|C1609982|C1280500|C0038454
Other inclusion criteria were willingness to travel to the cardiac rehabilitation centre every 3 months to meet the clinical nurse specialist and able to read and speak French.,inclusion criteria willingness travel cardiac rehabilitation centre 3 months meet clinical nurse specialist read speak french,C0007637|C0243161|C0600109|C0040802|C0018787|C0034991|C0205099|G0000000|C0439231|C1550543|C0205210|C0028661|C0087009|C0034754|C0234856|C0376246
"Exclusion criteria (recorded) were physical frailty, mental confusion, serious co-existing disease, communication difficulty, previous cardiac rehabilitation and discharged to hospice or another hospital.",exclusion criteria recorded physical frailty mental confusion co-existing disease communication difficulty previous cardiac rehabilitation discharged hospice hospital,C0680251|C0243161|C0034869|C0031809|C0424594|C0229992|C0009676|C3245499|C0012634|C0009452|C1299586|C0205156|C0018787|C0034991|C0030685|C0019947|C0019994
"The entry criteria were admission to hospital with a principal primary diagnosis of acute MI (two of the three standard criteria 'typical history', electrocardiographic features and cardiac enzymes), discharged home within 28 days, local resident and able to give informed consentdwith no age or gender restrictions.",entry criteria admission hospital principal primary diagnosis acute mi standard criteria typical history electrocardiographic features cardiac enzymes discharged 28 days local resident informed consentdwith age gender restrictions,C1705654|C0243161|C0184666|C0019994|C0205225|C0205225|C0011900|C0205178|C3810814|C1442989|C0243161|C3538928|C0019664|C0013798|C1521970|C0018787|C0014442|C0030685|C0450371|C0439228|C0205276|C1320928|C1522154|G0000000|C0001779|C0079399|C0443288
BACKGROUND: We carried out this study to compare the efficacy of oral gabapentin and clonidine premedication for controlling the pressor responses to laryngoscopy and tracheal intubation.,background carried study compare efficacy oral gabapentin clonidine premedication controlling pressor responses laryngoscopy tracheal intubation,C1706907|C0206243|C0557651|C1707455|C1280519|C0442027|C0060926|C0009014|C0033045|C2239193|C0237795|C0871261|C0023072|C0040578|C0021925
"The other inclusion criteria covered patients without receiving any drugs that could influence hemodynamic and autonomic function, patients with no difficult airways or obesity (body weight > 100 kg), no allergy or contraindications to anaesthetics or any drug used, no hypovolemia, no electrocardiographic abnormalities, no congestive heart failure, no diabetes mellitus, no hypertension, no coronary artery, respiratory, renal, cerebral diseases, and no pregnancy.",inclusion criteria covered patients receiving drugs influence hemodynamic autonomic function patients difficult airways obesity body weight 100 allergy contraindications anaesthetics drug hypovolemia electrocardiographic abnormalities congestive heart failure diabetes mellitus hypertension coronary artery respiratory renal cerebral diseases pregnancy,C0007637|C0243161|C0439844|C0030705|C1514756|C0013227|C4054723|C0019010|C0004388|C0031843|C0030705|C0332218|C0178987|C0028754|C0242821|C0005910|C1442061|C0002111|C0079164|C0002930|C0013227|C0546884|C0013798|C0000768|C0742742|C0018787|C0231174|C0011847|G0000000|C0020538|C0018787|C0003842|C0521346|C0022646|G0000000|C0012634|C0032961
"After obtaining Institutional Ethics Committee approval and written informed consent from all the patients, ninety-six ASA I and II consequent patients, aged 18-65 years, scheduled for elective surgery under general anaesthesia requiring tracheal intubation, were included in this study.",obtaining institutional ethics committee approval written informed consent patients ninety-six asa ii consequent patients aged 18-65 scheduled elective surgery anaesthesia requiring tracheal intubation included study,C1301820|C0018704|C0015000|C2699414|C0205540|C0043266|C1522154|C1511481|C0030705|C3816959|C0004057|G0000000|C3845876|C0030705|C0001779|C0450371|C0086960|C0206058|C0038894|C0002903|G0000000|C0040578|C0021925|C0332257|C0557651
"Between October 1, 2009 andNovember 30, 2011, the study population was selected according to the following criteria: consecutive outpatients of either sex, age 40-80 years, with stage I hypertension (systolic blood pressure [SBP] 140 mm Hg and <160 mm Hg and/or diastolic blood pressure [DBP] 90 mm Hg and <100 mm Hg), in sinus rhythm, but with 2 electrocardiogram (ECG)-documented episodes of symptomatic AF in the previous 6 months, each lasting >60 minutes but <7 days and terminating spontaneously.",october 1 2009 andnovember 30 2011 study population selected criteria consecutive outpatients sex age 40-80 stage hypertension systolic blood pressure sbp 140 mm hg <160 mm hg and/or diastolic blood pressure dbp 90 mm hg <100 mm hg sinus rhythm 2 electrocardiogram ecg -documented episodes symptomatic af previous 6 months lasting 60 minutes <7 days terminating spontaneously,C3828732|G0000000|G0000000|G0000000|C0450371|G0000000|C0557651|C0032659|C1707391|C0243161|C1707491|C0029921|C0009253|C0001779|C0450371|C0205390|C0020538|C0039155|C0005767|C0033095|G0000000|C1442061|G0000000|C0025424|C1442061|G0000000|C0025424|G0000000|C0012000|C0005767|C0033095|C0536221|C0450371|G0000000|C0025424|C1442061|G0000000|C0025424|C0016169|C0871269|G0000000|C0013798|C1623258|C1301725|C0332189|C0231220|C0344434|C0205156|G0000000|C0439231|C1517741|C0450371|C0439232|G0000000|C0439228|C0011065|G0000000
Hypothesis: Telmisartan may be more effective than amlodipine in preventing AF recurrence in hypertensive patients with paroxysmal AF and normal or increased left atrial dimension (LAD).,hypothesis telmisartan effective amlodipine preventing af recurrence hypertensive patients paroxysmal af normal increased left atrial dimension lad,C1512571|C0248719|C1280519|C0051696|C0309872|C0344434|C0034897|C0857121|C0030705|C0205311|C0344434|C0205307|C0205217|C0205091|C0018792|C0439534|G0000000
"Palpitations were not taken into consideration, nor were patients' subjective appraisals.",palpitations consideration patients subjective appraisals,C0030252|C0518609|C0030705|C0439655|G0000000
"From December 2006 to October 2009, 300 consecutive patients undergoing isolated CABG for stable coronary artery disease who received at least one saphenous vein graft (SVG) were enrolled.",december 2006 october 2009 300 consecutive patients undergoing isolated cabg stable coronary artery disease received saphenous vein graft svg enrolled,C3830550|G0000000|C3828732|G0000000|C1442061|C1707491|C0030705|G0000000|C0205409|C0010055|C0205360|C0018787|C0003842|C0012634|C1514756|G0000000|C0042449|C0181074|C0729538|G0000000
"To our knowledge, this study is the first to compare the efficacy of a RAS vs a non-RAS antihypertensive agent on arterial stiffness in postmenopausal women with hypertension.",knowledge study compare efficacy ras non-ras antihypertensive agent arterial stiffness postmenopausal women hypertension,C0376554|C0557651|C1707455|C1280519|C0034678|C1518422|C0003364|C0450442|C0003842|C0427008|C0232970|C0043210|C0020538
"Postmenopausal women (aged 50-75 years) with mild to moderate hypertension (SBP !140 mm Hg, DBP <110 mm Hg, and pulse pressure [PP] !50 mm Hg) were eligible for enrollment.",postmenopausal women aged 50-75 mild moderate hypertension sbp 140 mm hg dbp <110 mm hg pulse pressure 50 mm hg eligible enrollment,C0232970|C0043210|C0001779|C0450371|C2945599|C0205081|C0020538|G0000000|C1442061|G0000000|C0025424|C0536221|C1442061|G0000000|C0025424|C0232117|C0033095|C0450371|G0000000|C0025424|C1548635|C1516879
Exclusion criteria included BP above the safety limit of SBP !180 mm Hg and  or DBP !110 mm Hg before or at any point during the study.,exclusion criteria included bp safety limit sbp 180 mm hg dbp 110 mm hg study,C0680251|C0243161|C0332257|C0037623|C0036043|C0439801|G0000000|C1442061|G0000000|C0025424|C0536221|C1442061|G0000000|C0025424|C0557651
This ran-domized controlled study investigated the difference between an angiotensin receptor blocker and a calcium channel blocker in reducing arterial stiffness.,ran-domized controlled study investigated difference angiotensin receptor blocker calcium channel blocker reducing arterial stiffness,G0000000|C2587213|C0557651|C1292732|C1705241|C0003018|C0597357|G0000000|C0006675|C0439799|G0000000|C0392756|C0003842|C0427008
"Patients were eligible if they had a history of anterior MI, by history, electrocardiography, and cardiac enzymes during the past month.",patients eligible history anterior mi history electrocardiography cardiac enzymes month,C0030705|C1548635|C0019664|C0205094|C3810814|C0019664|C0013798|C0018787|C0014442|C0332177
